



4th Schizophrenia International Research Society Conference

*Fostering Collaboration in
Schizophrenia Research*

**FLORENCE, ITALY
05 - 09 APRIL 2014**



This meeting is jointly sponsored by the
Vanderbilt University School of Medicine and
the Schizophrenia International Research Society





4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



Opening Letter

Dear Attendees,

It is our great pleasure to welcome you to the 4th Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The third congress in 2012 was a major success for the field attracting more than 1600 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia. In addition to the Biennial Congress, the Society will host the second regional meeting in Buenos Aires, Argentina in December of 2014.

Under the outstanding leadership of Program Committee Chairs, Anissa Abi-Dargham and Jonathan Rabinowitz, we have an exciting scientific program planned for the 4th Biennial Conference. The Program Committee selected thirty-five outstanding symposia session in addition to seven evening workshops out of ninety-two submissions. Special sessions including the Family Forum, Italian Research and Family Day and the Pharmaceutical Pipeline session have been added to the conference schedule. The Program Committee also selected forty-eight superior oral presentations from more than 1000 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers

John Kane, M.D., President
René Kahn, M.D., Ph.D., President-Elect
Robin Murray, M.D., Past-President
Lynn E. DeLisi, M.D., Secretary
Anthony Grace, Ph.D., Treasurer
Anissa Abi-Dargham, M.D., Program Committee Chair
Jonathan Rabinowitz, Ph.D., Program Committee Chair

Table of Contents


General Information	Page 2
Saturday, 05 April	Page 24
Sunday, 06 April	Page 28
Monday, 07 April	Page 38
Tuesday, 08 April	Page 48
Wednesday, 09 April	Page 64
Sunday Posters	Page 70
Monday Posters	Page 96
Tuesday Posters	Page 122
Index of Presenters and Authors	Page 148
Notes	Page 159



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



Disclosures

Disclosures for 2014 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org.
A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research society appreciates the generous support of the Society from our 2013-2014 Supporting Corporations.

Gold



Silver



Pioneering science delivers vital medicines™



Educational Grants:

The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

Otsuka America Pharmaceutical, Inc.

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (Lynn DeLisi, PI) (Grant ED: R13MH082446).

Additional Supporters:

The Bowman Family Foundation

General Information

OFFICERS



John Kane
M.D.
President



René Kahn
M.D., Ph.D.
President-Elect



Lynn E. DeLisi
M.D.
Secretary



Anthony Grace
Ph.D.
Treasurer

BOARD OF DIRECTORS (2013-2014)

Jean Addington	Canada
Celso Arango	Spain
Geraldo Busatto	Brazil
John McGrath	Australia
Stephen Marder	USA
Jun Soo Kwon	Korea
Patrick McGorry	Australia
Herbert Meltzer	USA
Cynthia Shannon-Weickert	Australia
Xin Yu	China
Alison Yung	Australia

INCOMING OFFICERS:

René Kahn	The Netherlands, <i>President</i>
Patrick McGorry	Australia, <i>President-Elect</i>
Cynthia Shannon-Weickert	Australia, <i>Secretary</i>
Til Wykes	United Kingdom, <i>Treasurer</i>
John Kane	USA, <i>Past-President</i>



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



INTERNATIONAL ADVISORY COUNCIL

Mary Cannon Ireland
William Carpenter USA
David Castle Australia
Eric Chen China
Siow Ann Chong Singapore
Christina Dalman Sweden
Paola Dazzan United Kingdom
Robin Emsley South Africa
Peter Falkai Germany
Wolfgang Fleischhaker Australia
Wagner Gattaz Brazil
Birte Glenthøj Denmark
Michael Green USA
Kyung Sue Hong Korea
Matti Huttunen Finland
Richard Keefe USA
Mario Maj Italy
Philip McGuire United Kingdom

Paulo Menezes Brazil
Preben Mortensen Denmark
Dieter Naber Germany
Michael Owen United Kingdom
Christos Pantelis Australia
Sibylle Schwab Germany
Cynthia Shannon-Weickert Australia
Iris Sommer The Netherlands
Masatoshi Takeda Japan
Carol Tamminga USA
Rangaswamy Thara India
Si Tianmei China
Jim van Os The Netherlands
Dawn Velligan USA
Antonio Vita Italy
John Waddington Ireland
Mark Weiser Israel
Til Wykes United Kingdom

TRAVEL AWARD SELECTION COMMITTEE

Lynn DeLisi USA, CHAIR
Robin Emsley South Africa
Dieter Naber Germany
Larry Seidman USA
Sibylle Schwab Australia
Cynthia Shannon-Weickert Australia

2014 PROGRAM COMMITTEE



Anissa Abi-Dargham
USA
CHAIR



Jonathan Rabinowitz
Israel
CO-CHAIR

2014 Meetings Committees

CONGRATULATIONS TO THE 2014 TRAVEL FELLOWS


Olukayode Abayomi Nigeria
Davide Amato Germany
Candace Bailey USA
Byron Bitanirwe Switzerland
Lynniece Bowen USA
Shimon Burshtein Israel
Alexis Cullen United Kingdom
Montserrat Fuste United Kingdom
Ana Herrmann Brazil
Babak Khodaie Iran
Sanja Kilian South Africa
Qortni Lang USA
Elizabeth Manning Australia
Raffael Massuda Brazil
Roy Mathew India

Yuya Mizuno Japan
Milawaty Nurjono Singapore
Sarosh Sadiq Pakistan
Tamara Sheinbaum Spain
Venkataram Shivakumar India
Nicholas Simon USA
Anneliese Spiteri-Staines Australia
Sirijit Suttajit Thailand
Rafael Tapias USA
Yi Wang China
Sunali Wadehra USA
Rebekah Wigton United Kingdom
Sergey Yagoda Russia
Yulia Zaytseva Russia

2014 PROGRAM COMMITTEE

Celso Arango Spain
Michael Davidson Israel
Marc A. De Hert Belgium
André Aleman The Netherlands
Alessandro Bertolino Italy
Anthony David United Kingdom
Paola Dazzan United Kingdom
Silvana Galderisi Italy
Rohan Ganguli Canada
Birte Glenthøj Denmark
Michael Green USA
Eileen Joyce United Kingdom
Pablo Gejman USA
Melissa Green Australia
Carsten Rygaard Hjorthøj Denmark
Donald Linszen The Netherlands
James MacCabe United Kingdom
Anil Malhotra USA
Robert McCarley USA
Vera Morgan Australia

Dolores Malaspina USA
Stephen Marder USA
John McGrath Australia
Igor Nenadic Germany
Merete Nordentoft Denmark
Maxine Patel United Kingdom
Dan Rujescu Germany
Patricio O'Donnell USA
Marco Michael Picchioni United Kingdom
Avi Reichenberg United Kingdom
Nina Schooler USA
Martha Shenton USA
Iris Sommer The Netherlands
Daniel Umbricht Switzerland
Sophia Vinogradov USA
Neeltje E.M. Van Haren The Netherlands
Thomas Weickert Australia
Mark Weiser Israel
Robert Zipursky Canada



Continuing Medical Education

ACCME

The 4th Biennial Schizophrenia International Research Society Conference is jointly sponsored by the Vanderbilt University School of Medicine and SIRS. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vanderbilt University School of Medicine and the SIRS. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of *33 AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be a \$50.00 USD charge for scientific registrants to obtain CME credits.

To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.SchizophreniaConference.org.

EACCME

The 4th Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Italian Ministry of Health Credits:

The 4th Biennial Schizophrenia Research Conference has been accredited at the Italian Ministry of Health with ID Number 110-86354 for the following specialties: physicians (Psychiatry, Neurology, Pediatric Neuropsychiatry, Psychotherapy), Technicians for Psychiatric Rehabilitation, Psychology. For more information and for the evaluation form, please inquire at the Registration Desk.

Conference Evaluation:

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.SchizophreniaConference.org. All evaluations must be completed by 9 May, 2014.

Videotaping Sessions:

Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

COURSE OBJECTIVES

After participating in the CME Activity, Clinicians should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia
- The status of genetic findings, and how they can be incorporated into strategies for managing patients with schizophrenia
- The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
- The implications of basic neuroscience findings for managing patients with schizophrenia

After participating in the CME Activity, Researchers should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia
- Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
- Differences in schizophrenia research across diverse cultures and geographic areas
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
- Methods to advance the clinical application of genetic research in schizophrenia

Disclosures:

It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2014 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

General Information

REGISTRATION

Registration for the 4th Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.


DATE	TIME
Saturday, 05 April	11:00 AM – 7:30 PM
Sunday, 06 April	8:00 AM – 6:30 PM
Monday, 07 April	8:00 AM – 7:00 PM
Tuesday, 08 April	8:00 AM – 8:30 PM
Wednesday, 09 April	8:00 AM – 4:00 PM



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



REGISTRATION TYPES

Delegate: Scientific Attendee

Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research.

A letter from the student's immediate supervisor verifying his/her student status and relevant field will be required for registration.

Accompanying Guest: Non-scientific attendee who only attends social functions.

REGISTRATION TIME FRAMES

Regular: Register August 2013 – 12 March 2014

Late: Register 13 March 2014 – onsite

REGISTRATION FEES

Category	Up to 12 March 2014	13 March or later
SIRS 2013 and 2014 Member	400.00€	450.00€
SIRS 2014 New Member	440.00€	490.00€
SIRS 2013 and 2014 Student Member	150.00€	190.00€
SIRS 2014 New Student Member	190.00€	240.00€
Non-Member Delegate	650.00€	700.00€
Non-Member Student	230.00€	280.00€
Accompanying Other	200.00€	200.00€

ABSTRACTS

Abstracts for all presentations are available online at www.SchizophreniaConference.org.

Abstracts will be published electronically by *Schizophrenia Research* and will be available as an electronic flipbook and as a PDF document.

OPENING RECEPTION TICKET

60,00 €

Saturday, 05 April 07:00 PM - 09:00 PM

HONORIFIC AWARDS

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society's Honoric Award Winners.

OUTSTANDING BASIC RESEARCH



Akira Sawa, M.D., Ph.D.

Dr. Sawa is a psychiatrist and neuroscientist. He is currently the Director of Johns Hopkins Schizophrenia Center and a Professor of Psychiatry, Mental Health, Neuroscience, and Institute of Genetic Medicine at Johns Hopkins Schools of Medicine and Public Health. The Johns Hopkins Schizophrenia Center aims better care and cure for schizophrenia and adult-onset major mental illness by organizing academic efforts on patient care, research, professional education, and public outreach in a good balanced manner.

He also led NIH designated P50 Silvio O. Conte center grant at Johns Hopkins, which takes a multifaceted translational approach on the development and maturation of the cerebral cortex in association with the pathological trajectory of schizophrenia.

In addition to these administrative leaderships, Dr. Sawa also runs his own research program on mental illness (Molecular Psychiatry Program at Johns Hopkins). The overall emphasis of Dr. Sawa's academic activity is on how new discoveries can be efficiently delivered to the clinical setting and patient care from the global health viewpoint.

OUTSTANDING CLINICAL/COMMUNITY RESEARCH



Michael Foster Green, Ph.D.

Dr. Green is a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior at the Geffen School of Medicine at UCLA. He is Director of the Treatment Unit of the VA Desert Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Green obtained his B.A. in psychobiology at Oberlin College, his doctorate in neuropsychology at Cornell University, and his postdoctoral training in neuropsychology at UCLA. He is an associate editor for *Schizophrenia Bulletin*, on the editorial boards of several journals, including *Cognitive Neuropsychiatry* and *Schizophrenia Research*, and has authored over

250 journal articles. He has received numerous grants from the National Institute of Mental Health, the VA, and private foundations.

His laboratory (greenlab.npih.ucla.edu) has explored the relationship between cognitive impairments in schizophrenia and activities of daily living, as well as the neural mechanisms of cognitive and social cognitive dysfunction. Ongoing studies are evaluating social cognitive retraining and novel pharmacological interventions to improve cognitive impairment. He has written two books: *Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness* (1998), and *Schizophrenia Revealed: From Neurons to Social Interactions* (2001). Dr. Green has had leadership roles in several NIMH treatment development initiatives: he was Co-PI of the MATRICS Initiative, PI of the MATRICS-Psychometric and Standardization Study, and PI of the MATRICS-CT Validation of Intermediate Measures Study. He is a Fellow in the American College of Neuropsychopharmacology, a member of the work group for Psychotic Disorders for the 11th edition of the International Classification of Diseases (ICD), and past-president of the Society for Research in Psychopathology.




4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM

FLORENCE, ITALY
05 - 09 APRIL 2014



RIISING STAR



Oliver Howes, BM, BCh, MA, MRCPsych, PhD, DM

Oliver Howes is Group Head/ Reader at the Institute of Psychiatry, London, and the MRC CSC Psychiatric Imaging Group, Imperial College, Hammersmith Hospital. His clinical work is as Consultant Psychiatrist at The Maudsley Hospital where, amongst other things, he runs a service for refractory psychoses.

His research interests centre on the causes and treatment of psychosis. His recent work has focussed on characterising the dopaminergic system in the psychotic prodrome, the effects of antipsychotic drugs on the endocrine system, & the causes of cognitive impairment in schizophrenia. This work has been recognised through a number of awards including the European Psychiatric

Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), Royal College of Psychiatrists research prize (2005), the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007) and awards at the International Conference of Schizophrenia Research (2006), the European College of Neuropsychopharmacology (2008). He was made an honorary associate of the European College of Neuropsychopharmacology in 2006.

Other career highlights include a stint as junior potato scrubber on a farm.

DISTINGUISHED SERVICE AWARDS



LYNN E. DELISI, M.D.

Lynn E. Delisi, MD, is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she is editor-in-chief and co-founder of the Elsevier journal, *Schizophrenia Research*. She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and The International Society of Psychiatric Genetics (ISPG). She is also an active fellow of the American College of Neuropsychopharmacology. Her undergraduate degree is in zoology from The University of Wisconsin, Madison, Wisconsin. She obtained her M.D. degree from the Medical College

of Pennsylvania and went on from there to do 3 years of general practice work with the migrant Chile farmers of Northern New Mexico. She completed a residency in psychiatry at Saint Elizabeth's Hospital, Washington DC, and then went on to complete a post-doctoral fellow and then remain as a full-time staff research psychiatrist in the NIMH intramural research program, at both St. Elizabeth's Hospital and in Bethesda, Maryland. In 1987, she left NIMH to assume a professorship at The State University of New York at Stony Brook where she set up several research programs on the longitudinal biological outcome of schizophrenia, emphasizing both brain imaging and genetic studies. During this time, she was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to be used in molecular genetic studies. From 2001 through 2008, she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people at high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia.

She has edited and authored over 300 books and manuscripts and aside from editing her own journal, serves on the editorial board of several other journals. Her book, *100 Questions and Answers about Schizophrenia: Painful Minds*, about to be revised in a 3rd edition, has been circulated widely among families of people with schizophrenia and medical students internationally and has been translated into Japanese and Spanish, as well as other languages besides English. In her non-professional life she contributes to her local community of Lincoln, Massachusetts as a member of its Planning Board, and as an amateur photographer, and spends time with her partner, 2 adult children and 4 grandchildren.



HENRY A. NASRALLAH, M.D.

Dr. Henry Nasrallah is an internationally recognized neuropsychiatrist, educator and researcher. He received his BS and MD degrees at the American University of Beirut (AUB) whose Board of Trustees is located in New York. Following his psychiatric residency at the University of Rochester and post-residency neuroscience research fellowship at NIH, he served as a faculty member at the University of California at San Diego and the University of Iowa before assuming the chair of the Ohio State University Department of Psychiatry for twelve years. In 2003, following a research sabbatical, he joined the University of Cincinnati College of Medicine as Associate Dean for Faculty Development

and Professor of Psychiatry and Neuroscience, and also served as Vice - Chair for Education and training in the Department of Psychiatry and behavioral neuroscience, overseeing 3 residencies, 4 fellowships, medical students education and the Neuroscience PhD Graduate Program. In October 2013, he joined Saint Louis University as the Sydney W. Souers Endowed Chair and Professor of Neurology and Psychiatry.

Dr. Nasrallah's main research focus is the neurobiology and psychopharmacology of schizophrenia and related psychoses. He has published over 380 scientific articles, 440 abstracts, 135 editorials as well as 12 books. He is Editor-In-Chief of two peer-reviewed journals (*Schizophrenia Research* and *Current Psychiatry*) and is the co-founder, with Lynn Delisi, of the Schizophrenia International Research Society (SIRS) whose biannual meetings are now attended by over 1400 international researchers. He is board-certified in adult psychiatry. He is a Fellow of the American College of Neuropsychopharmacology [ACNP], Fellow of the American College of Psychiatrists (ACP), distinguished life Fellow of the American Psychiatric Association (APA), past President of the Cincinnati Psychiatric Society (CPS) and past president of the American Academy of Clinical Psychiatrists (AACP), and has served as the President of the Ohio Psychiatric Physicians Association / Education and Research Foundation (OPPA-ERF). He was elected President of the University of Cincinnati College of Medicine Faculty [comprised of over 1500 faculty members]. He twice received the NAMI Exemplary Psychiatrist Award and was recognized as the U.S. Teacher of the Year by The Psychiatric Times. He also received the Golden Apple Teaching Excellence Award from the psychiatric residents at several universities. He received the highest research honor at Ohio State (Distinguished Scholar Award). He has received over 85 research grants from federal, industry and private foundations, and is listed in all editions of the book "Best Doctors in America".




4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM

FLORENCE, ITALY
05 - 09 APRIL 2014



AWARD COMMITTEE MEMBERS

Philip Harvey	USA, <i>Chair</i>	Anthony David	United Kingdom
John Waddington	Ireland, <i>Co-Chair</i>	Tilo T.J. Kircher	Germany
Alessandro Bertolino	Italy	Maxine Patel	United Kingdom
Donald Linszen	The Netherlands	Nina Schooler	USA
Mary Cannon	Ireland	Nadia Solowij	Australia

POSTER AWARDS

Cognitive Neuropsychiatry, Schizophrenia Bulletin, Schizophrenia Research will award poster prizes during the Closing Session on Wednesday, 09 April at 4:00 PM. The SIRS Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

Scientific Sessions

NEW INVESTIGATOR ORIENTATION

Saturday, 05 April, 3:45 PM – 5:45 PM

Auditorium

All attendees are welcome to attend. Travel Awardees are required to attend.

3:45 - 4:45

How To Successfully Publish Papers Panel

Peter Buckley, Will Carpenter, Lynn DeLisi

4:45 - 5:45

How To Successfully Obtain Funding Support Panel

Robert McCarley (in USA) and Jim van Os (in Europe)

KEYNOTE LECTURE



Saturday, 05 April, 6:00 PM – 7:00 PM
Auditorium

Road to Damascus: A Scientific Journey


Huda Akil, Ph.D., is the Gardner Quarten Distinguished University Professor of Neuroscience and Psychiatry and the co-Director of the Molecular & Behavioral Neuroscience Institute (MBNI) at the University of Michigan. Dr. Akil together with Dr. Stanley J. Watson and their colleagues have made seminal contributions to the understanding of the brain biology of emotions, including pain, anxiety, depression and substance abuse. She and her collaborators provided the first physiological evidence for a role of endorphins in the brain, and showed that endorphins are activated by stress and cause pain inhibition.

Dr. Akil's current research investigates the genetic, molecular and neural mechanisms underlying stress, addiction and mood disorders. Along with Dr. Watson, she is the Michigan Site Director of the Pritzker Consortium, which is engaged in large-scale studies to discover new genes and proteins that cause vulnerability to major depression and bipolar illness. She is the author of over 500 original scientific papers, and has been recognized as one of the most highly cited neuroscientists by the ISI Citation Index.

Dr. Akil's scientific contributions have been recognized with numerous honors and awards. These include the Pacesetter Award from the National Institute on Drug Abuse in 1993 and the Pasarow Award (with S.J. Watson) for Neuroscience Research in 1994. In 1998, she received the Sachar Award from Columbia University, and the Bristol Myers Squibb Unrestricted Research Funds Award. She is also the recipient of the Society for Neuroscience Mika Salpeter Lifetime Achievement Award and the NARSAD Patricia Goldman-Rakic Prize for Cognitive Neuroscience (2007), the Koch Award from the American College of Neuropsychopharmacology (2010). She has shared with Dr. Stanley Watson the Thomas William Salmon Award in 2010, and the Institute of Medicine Sarnat Award in 2012. In 2013, she received Association of American Medical Colleges (AAMC) Award for Distinguished Research in the Biomedical Sciences.

In 1994, Dr. Akil was elected to the membership of the Institute of Medicine (IOM) of the National Academy of Science. She was elected as a Fellow of the American Association for the Advancement of Science in 2000. In 2004, she was elected to the American Academy of Arts and Sciences. In 2011, she was elected to the National Academy of Sciences.

Dr. Akil service includes membership of numerous boards and scientific councils. She has served on several national and international organizations to promote scientific and brain health awareness nationally and globally. She is the past President of the American College of Neuropsychopharmacology (1998) and the past President of the Society for Neuroscience (2004) the largest neuroscience organization in the world. She has co-chaired the Neuroscience Steering Committee for Biomarkers Development at the Foundation for the National Institute of Health; she has served two terms on the Council of the Institute of Medicine of the US National Academy of Sciences, and currently serves on the National Research Council (NRC) review board.



PLENARY SESSIONS

There will be four plenary sessions covering topics including new approaches on schizophrenia research, drug development, an update on therapeutics, and the clinical challenges of comorbid disorders.

**Sunday, 06 April
Auditorium**

8:30 AM – 12:00 PM

Impact of Genomics and Connectomics Approaches on Schizophrenia Research

Chairs: Lynn DeLisi and René Kahn

Genomics Panel

Pat Sullivan, University of North Carolina, Chapel Hill, USA

Jonathan Sebat, Cold Spring Harbor Laboratory, USA

Tiina Paunio, National Public Health Institute, Finland

Francis McMahon, National Institute of Mental Health, USA

Connectomics Panel

Ed Bullmore, University of Cambridge, United Kingdom

Deanna Barch, Washington University, USA

Holly Moore, Columbia University, USA

**Monday, 07 April
Auditorium**

8:30 AM – 12:00 PM

Behavioral and Imaging Translational Paradigms in Drug Development

Chair: Holly Moore

*Novel Drug Targets and Translating Results from Animal Models into Humans:
Insights Using the MAM Development Model*

Anthony Grace

Negative Symptoms in Schizophrenia as a Target for Translation Research

Jim Gold

A Central Role of the Dopamine D2 Receptor in the Modulation of Motivation

Pierre Trifilieff

*Translating Social Cognition and Social Neuroscience for
Schizophrenia Research*

Michael Green

*Translational Paradigms for Social Cognition in Rodents and
Non-Human Primates*

Karen Bales

*Neural Substrates of Abnormal Predictions and Rewards: Clinical and
Preclinical fMRI Studies of Incentives and Surprises in Psychiatric Illness*

Graham Murray

**Tuesday, 08 April
Auditorium**

8:30 AM – 12:00 PM

Update on Therapeutics: Improving the Clinical Yield

Chairs: John Kane and Richard Keefe

Sharpening the Signal in Cognitive Enhancement Trials

Richard Keefe

*Preclinical and Clinical Evaluation of PDE10A Inhibition as
a Treatment for Schizophrenia*

Chris Schmidt

*The Development of Pomaglumetad Methionil as a Glutamate-based
Pharmacotherapy for Schizophrenia: Lesson Learned*


Bruce Kinon

Challenges and Potential Solutions in Negative Symptom Trials

Daniel Umbricht

*Power of Collaborations and Big Data in Advancing Drug Development:
NewMeds and Beyond*

Jonathan Rabinowitz



Wednesday, 09 April
Auditorium
8:30 AM – 12:00 PM

The Clinical Challenges of Comorbidity with Addiction and Somatic Disease

Chairs: Nick Stefanis and Mary Cannon (Substance Abuse)

Chairs: Robin Murray and John McGrath (Physical Disease)

*Dopaminergic Dysfunction in Schizophrenia Comorbid with
Substance Dependence*

Anissa Abi-Dargham

Why is Treatment of People with Cannabis-Induced Psychosis so Unsuccessful?

Robin Murray

Methamphetamine Use and Schizophrenia:

A Population-Based Cohort Study in California

Russell Callaghan

*Family-Based Study Examining Moderation of Familial Correlation
in Psychotic Experiences by the Environment*

Jim van Os

Obesity and Cardiovascular Disease in Schizophrenia

Christoph Correll

Epidemiological Studies of Somatic Co-Morbidity in Schizophrenia

Preben Mortensen

*Understanding the Widening Gap in Schizophrenia Mortality
through Electronic Medical Record Databases.*

Rob Stewart

IMPACTing Lifestyle Choice and Cardiovascular Risk in Psychosis

Fiona Gaughran

SPECIAL SESSIONS

Special sessions have been included in the conference program:

• *The Italian Research and Family Day*

Saturday, 05 April, 10:00 AM – 5:15 PM, Sala Verde

The day will be in English and is open and free to all attendees at the SIRS meeting and the general public (Italian and non- Italian alike). Those with experience of psychosis and their relatives are very welcome.


• *Voices in My Head: Dom's Story*

A video and discussion session about Dom's schizophrenia diagnosis at age 10.

Sunday, 06 April 1:00 PM - 2:00 PM

Monday, 07 April 1:00 PM - 2:00 PM


Tuesday, 08 April 1:00 PM - 2:00 PM



SYMPOSIA SESSIONS

The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session.

Symposia are scheduled:	Sunday, 06 April	2:00 PM – 4:00 PM 4:15 PM – 6:15 PM
	Monday, 07 April	2:00 PM – 4:00 PM 4:15 PM – 6:15 PM
	Tuesday, 08 April	2:00 PM – 4:00 PM
	Wednesday, 09 April	1:30 PM – 3:30 PM



WORKSHOPS

Six workshops have been scheduled on Tuesday evening from 6:30 PM – 8:30 PM. The title and location of each workshop is indicated in the program. The presentations within each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presentation within each workshop.

ORAL PRESENTATIONS

Six concurrent oral presentation sessions are scheduled on Tuesday, 08 April from 4:15 PM – 6:15 PM. Within the concurrent sessions, there are 8 individual presentations. Oral sessions scheduled:

Advances in Imaging in Schizophrenia I
Chair: Sophia Vinogradov

Advances in Imaging in Schizophrenia II
Chair: Alessandro Bertolino

Biomarkers
Chair: Cynthia Shannon-Weickert

Therapeutics
Chair: Robert Zipursky

Genetics and Epidemiology
Chair: Dan Rujescu

High Risk Research
Chair: Nina Schooler

POSTERS

Three poster sessions have been scheduled. Presenters should put their poster up by 9:30 AM and remove the poster at 5:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 PM. E-Posters are available for viewing online at www.SchizophreniaConference.org.

Sunday, 06 April	Poster Session I 12:00 PM – 2:00 PM
Monday, 07 April	Poster Session II 12:00 PM – 2:00 PM
Tuesday, 08 April	Poster Session III 12:00 PM – 2:00 PM

COMPUTER ACCESS

Complimentary wireless internet is available in the conference center. To access the wireless internet, input “SIRSCongress” as the username and “SIRS2014” as the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees who wish not to bring a laptop. The Computer Center will be open the following hours:

Saturday, 05 April	9:00 AM – 7:00 PM
Sunday, 06 April	7:30 AM – 6:30 PM
Monday, 07 April	7:30 AM – 6:30 PM
Tuesday, 08 April	7:30 AM – 6:30 PM
Wednesday, 09 April	7:30 AM – 4:30 PM

SPEAKER READY ROOM

A speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:


Saturday, 05 April	8:00 AM – 7:00 PM
Sunday, 06 April	7:30 AM – 7:00 PM
Monday, 07 April	7:30 AM – 7:00 PM
Tuesday, 08 April	7:30 AM – 8:00 PM
Wednesday, 09 April	7:30 AM – 3:30 PM

REFRESHMENT BREAKS


All registered individuals are invited. Coffee and light pastries are available Sunday through Wednesday mornings at 8:00 AM. The morning break will be located in the Passi Perduti, located outside the Auditorium. Afternoon coffee/tea breaks will be available Saturday – Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS


Buffet lunch will be served Sunday through Tuesday from 12:00 PM – 2:00 PM in the Cavaniglia, Lower Floor during the poster sessions. Buffet lunch will be served on Wednesday from 12:00 PM – 1:30 PM in the Passi Perduti, located outside the Auditorium.




Floor Plan




Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia. This is a short 3 to 5 minute walk from the Palazzo de Congressi.




Concurrent Symposia, Oral Presentations and Special Sessions will be held on the Lower Level, Ground Level, First Level, Second Level of the Palazzo degli Affari.



The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.




Palazzo Congressi - Villa Vittoria AUDITORIUM




Keynote, Plenary Sessions and some Special Sessions, Symposia and Oral Presentations will be held in the Auditorium.

Palazzo Congressi - Villa Vittoria

First Floor



Second Floor



The Speaker Ready Room (Sala 103) and other small meeting rooms and committee meetings will be in the Villa Vittoria Building on the 1st Floor. The Villa Vittoria building is connected to the Auditorium.

The Sala Verde room is on the 2nd floor of the Villa Vittoria building. The Italian Research and Family Day, Symposia and Oral Presentations will be held in the Sala Verde.

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium										3:45 PM 5:45 PM New Investigator Orientation	6:00 PM 7:00 PM Keynote Address: Huda Akil			
Passi Perduti									3:30 PM 4:45 PM Coffee Available	6:00 PM 6:30 PM Coffee Break				
Palaffari Lawn														7:00 PM 9:00 PM Welcome Reception
Sala Verde								10:00 AM 5:15 PM Italian Research and Family Day						
Palazzo Affari Entrance									11:00 AM 7:30 PM Registration					
Sala 103									8:00 AM 7:00 PM Speaker Ready Room					
Limonaia										9:00 AM 7:00 PM Computer Center				

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia


Workshop

Poster Session

Plenary

Oral Presentation

Coffee Break

FINAL PROGRAM**FLORENCE, ITALY****05 - 09 APRIL 2014****Saturday, 05 April****REGISTRATION****11:00 AM - 7:00 PM****Location:** Palazzo Affari Entrance**Scientific Sessions****SCIENTIFIC SESSIONS – THE ITALIAN RESEARCH AND FAMILY DAY 10:00 AM - 5:15 PM****Location:** Sala Verde**ABSTRACT:**

This satellite meeting builds on a very successful similar day at the last SIRS meeting. It provides the opportunity to all attendees, and to all those interested in mental illness, to hear the best of Italian Research into Schizophrenia, both from those Italian research scientists now working in other countries and those carrying out research in major Italian Centres.

We will hear of how the incidence of schizophrenia appears surprisingly low in different centres in Italy, of the relative importance in Italy and elsewhere of risk factors for schizophrenia such as child abuse, immigration and drug abuse (including novel internet drugs). We will also hear how imaging can predict outcome of psychosis and how it reflects genetic predisposition.

The afternoon will include sessions on the ways in which relatives are involved in care of people with psychosis in Italy. The day will close with a panel of very distinguished clinicians from across the globe discussing the merits and demerits of the care offered to people with schizophrenia in their respective countries.

The day will be in English and is open and free to all attendees at the SIRS meeting and the general public (Italian and non- Italian alike). Those with experience of psychosis and their relatives are very welcome.


**THE CONTRIBUTION OF THE ITALIAN DIASPORA
TO RESEARCH ON PSYCHOSIS****10:00 AM - 11:15 AM****Chairs:** Robin Murray and Jim van Os**COFFEE BREAK****11:15 AM - 11:45 AM****THE STATE OF THE ART: ITALIAN RESEARCH ON PSYCHOSIS – I****11:45 AM - 12:30 PM****Chairs:** John McGrath and Anita Reicher-Rossler**LUNCH****12:30 PM - 1:45 PM**



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



Saturday 05 April

THE STATE OF THE ART: ITALIAN RESEARCH ON PSYCHOSIS – II 1:45 PM - 2:45 PM
Chairs: Mirella Ruggeri and Robin Murray

COFFEE BREAK 2:45 PM - 3:15 PM

THE VIEW OF FAMILIES AND PATIENTS 3:15 PM - 4:00 PM
Chairs: Silvana Galderisi and Jean-Paul Selten

**IS IT BETTER TO HAVE SCHIZOPHRENIA IN ITALY, UK, USA,
AUSTRALIA OR BRAZIL?** 4:05 PM - 5:15 PM
Chairs: Lynn Delisi and John Kane

SPECIAL SESSION – New Investigator Orientation 3:45 PM - 5:45 PM
Location: Auditorium
Travel Awardees are required to attend

HOW TO SUCCESSFULLY PUBLISH PAPERS 3:45 PM - 4:45 PM
Peter Buckley, Lynn DeLisi

HOW TO SUCCESSFULLY OBTAIN FUNDING SUPPORT 4:45 PM - 5:45 PM
Robert McCarley (in USA) and Jim van Os (in Europe)

**KEYNOTE LECTURE - The Road from Damascus:
A Scientific Journey** 6:00 PM - 7:00 PM

Location: Auditorium
Akil Huda, Ph.D.

In this talk, Dr. Akil will share her transition from Syria to the USA to become a scientist, witnessing the discovery of Endorphins, her current interests in neuroscience, and lessons she learned along the way about how to keep her love of science alive.



Saturday 05 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM
Auditorium	8:30AM-12:00PM				Impact of Genomics and Connectomics Approaches on Schizophrenia Research				2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Palazzo Affari Ground Level									Negative Symptoms and Social Cognition in Schizophrenia: Neural Circuitry, Functional Outcomes and Treatment Innovation		Coffee Break	PHARMA PIPELINE SESSION
Palazzo Affari 1st Level									2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Palazzo Affari 2nd Level									Developmental Stress in Schizophrenia: Epidemiology & Possible Mechanisms		ICOSR Session: The Advances in Structural and Functional Brain Imaging on Schizophrenia and Other Psychotic Disorders	
Palazzo Affari Lower Level									2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Palazzo Affari Lower Level									No Smoke Without Fire: Could Tobacco Smoking Have a Causal Role in Psychosis?		Using Neuroimaging to Predict Outcomes in Subjects at High Risk	
Palazzo Affari Lower Level									2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Palazzo Affari Lower Level									Oligodendrocytes as a Target for Treatment in Schizophrenia		When Does the Trouble Start? Obesity, Diabetes Risks and Metabolic Disturbances in Young People with Psychosis	
Palazzo Affari Lower Level									2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Palazzo Affari Lower Level									New Vistas in Dopamine Receptor Research: Implications for Novel Therapies in Schizophrenia		Should We Continue to do Placebo-controlled Medication Trials in Schizophrenia? An Ethico-clinical Debate	
Sala Verde					1:00PM 2:00PM				2:00PM-4:00PM		4:00PM 4:15PM	4:15PM-6:15PM
Sala Verde					Voices in my Head: Dom's Story				Suicide and Psychosis: The Context and Meaning of Early Risk		Coffee Break	The Long Search for an Inflammatory Component in Schizophrenia
Cavaniglia					12:00PM-2:00PM				Poster Session I and Lunch			
Palazzo Affari Entrance					8:00AM-6:30PM				Registration			
Sala 103					7:30AM-7:00PM				Speaker Ready Room			
Limonaia					7:30AM-6:30PM				Computer Center			
Passi Perduti					8:00AM-11:00AM				Coffee Available			
Legend:	Keynote	Special Session	Speaker Ready	Registration	Computer Center	Symposia	Workshop	Poster Session	Plenary	Oral Presentation	Coffee Break	

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia

Workshop

Poster Session

Plenary


Oral Presentation

Coffee Break

FINAL PROGRAM

FLORENCE, ITALY

05 - 09 APRIL 2014



Sunday, 06 April

REGISTRATION

Location: Palazzo Affari Entrance

8:00 AM - 6:30 PM

COFFEE/PASTRIES

Location: Passi Perduti

8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION – IMPACT OF GENOMICS AND CONNECTOMICS APPROACHES ON SCHIZOPHRENIA RESEARCH

Location: Auditorium

Chairpersons: Lynn DeLisi and René Kahn

8:30 AM - 12:00 PM


OVERALL ABSTRACT

Wikipedia defines “Omics” as an informal suffix that implies “the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism or organisms.” Thus, “genomics” describes all that is known about the multiple aspects of the genetic architecture of an organism or its disorders and “connectomics” describes the complex cerebral architecture that is uniquely human and can develop in deviant ways in schizophrenia. In this session we thus aim to review the most up-to-date knowledge in the fields of both genomics and connectomics as they relate to improving our understanding about schizophrenia. Research findings are accumulating so rapidly now that even the latest published literature cannot keep up with the pace of progress in these fields.

In the genomics session, Dr. Patrick Sullivan will cover the latest Genome-Wide Association Study (GWAS) findings of common alleles with increased risk for schizophrenia from the large international collaborative effort, The Psychiatric Genomics Consortium (PGC). He will be followed by Dr. Jonathan Sebat who will discuss how rare genetic variants, such as Copy Number Variants (CNV's) can play a role in risk for schizophrenia. This will be followed by a discussion of environmental-gene interaction as led by Dr. Tiina Paunio. All panelists will then discuss the field of Next-Generation Sequencing and how it will be effective in finding genes for schizophrenia. We will end this session with a discussion of controversial ethical issues that the field of psychiatric genetics is now faced with, including commercial direct-to-consumer genome testing availability. This will be led by Dr. Francis McMahon, president of The International Society of Psychiatric Genetics. General audience participation will be encouraged.

The second half of this plenary will be devoted to “Connectomics” in the human brain and how connectivity is influenced by genetics. It will include Drs. Ed Bullmore and Deanna Barch. All of these researchers have developed innovative methods for viewing how the brain communicates and functions through its connectivity and how genes influence the variation that exists in human brain connections. Some of the latter variation may be relevant to neurodevelopmental disorders, such as schizophrenia. They will then lead a panel discussion session with audience participation to conclude this session.

Sunday 06 April



PRESENTERS

Genomics Panel

Pat Sullivan, University of North Carolina, Chapel Hill, USA
Jonathan Sebat, Cold Spring Harbor Laboratory, USA
Tiina Paunio, National Public Health Institute, Finland
Francis McMahon, National Institute of Mental Health, USA

Connectomics

Ed Bullmore, University of Cambridge, United Kingdom
Deanna Barch, Washington University, USA
Holly Moore, Columbia University, USA

COFFEE BREAK

Location: Palazzo Entrance

10:15 AM - 10:30 AM

TRAVEL FELLOW AND MENTOR LUNCH

Location: Scherma, Fortezza de Basso

12:00 PM - 2:00 PM

POSTER SESSION I AND LUNCH

Location: Cavaniglia

Buffet lunch will be served daily at the poster sessions
Please see page 70 for a complete listing of posters.

12:00 PM - 2:00 PM

SPECIAL SESSION - VOICES IN MY HEAD: DOM'S STORY

Location: Sala Verde

1:00 PM - 2:00 PM

CONCURRENT SYMPOSIA

DEVELOPMENTAL STRESS IN SCHIZOPHRENIA: EPIDEMIOLOGY AND POSSIBLE MECHANISMS

2:00 PM - 4:00 PM

Location: Affari, Ground Level

Chair: James Koenig

Co-Chair: Preben Bo Mortensen

Epidemiological Evidence for a Role of Developmental Stress in Schizophrenia
Preben Bo Mortensen

Transient Neuroinflammation is a Key Mechanism Mediating the Neuropathological Interactions between Prenatal Immune Challenge and Peripubertal Stress
Urs Meyer

Epigenetic Profiling of Prenatal Stress and Long-Term Psychopathological Implications
Marco A. Riva

Adolescent Stress-Induced Epigenetic Control of Neuronal Networks
Akira Sawa

Discussant: James Koenig

NEGATIVE SYMPTOMS AND SOCIAL COGNITION IN SCHIZOPHRENIA: NEURAL CIRCUITRY, FUNCTIONAL OUTCOMES, AND TREATMENT INNOVATION

2:00 PM - 4:00 PM

Location: Auditorium

Chair: Aristotle Voineskos

Behavioral and Neural System Effects of Computerized Social Cognitive Training Exercises in Schizophrenia
Sophia Vinogradov

Network Topology in Deficit Schizophrenia, Nondeficit Schizophrenia, and Bipolar Disorder: From Circuits to Functional Outcome
Aristotle Voineskos

Neuroscientific Explorations of Two Levels of Social Cognition in Schizophrenia
Michael Green

The Neural Circuitry of Social Impairments in Schizophrenia Spectrum Disorders
Robert W. Buchanan

Identification of Neuroimaging Biomarkers for Negative Symptoms in Schizophrenia
Anil K. Malhotra

Discussant: Celso Arango



**NEW VISTAS IN DOPAMINE RECEPTOR RESEARCH:
IMPLICATIONS FOR NOVEL THERAPIES IN SCHIZOPHRENIA**

2:00 PM - 4:00 PM

Location: Affari, Lower Level

Chair: Larry J. Siever

Mutant Mouse Models to Explore D1-Glutamate Interactions and Cortical vs Subcortical D1 Dopamine Receptor Function: Schizophrenia-Related Phenotypic Effects

John L. Waddington

Chemical, Molecular, and Cellular Factors Influencing the Discovery and Development of Dopamine D1 Agonists

Richard B. Mailman

Dopamine Receptors as Targets for Cognitive Deficits in Schizophrenia: Lessons from Animal Models

Patricio O'Donnell

The D1 Receptor and Cognition and Trial of a Novel D1 Agonist in the Schizophrenia Spectrum

Larry J. Siever

Modulation of Dopamine using a D2/D3 Agonist in Patients with Bipolar Disorder: Effects on Cognition and Reward Processing

Katherine Burdick

Discussant: René S. Kahn

**NO SMOKE WITHOUT FIRE: COULD TOBACCO
SMOKING HAVE A CAUSAL ROLE IN PSYCHOSIS?**

2:00 PM - 4:00 PM

Location: Affari, First Level

Chair: James H. MacCabe

Co-Chair: Robin M. Murray

Tobacco Use and Psychotic Experiences in UK Teenagers - Evidence from the ALSPAC Longitudinal Study

Suzanne H. Gage

Systematic Review and Meta-analysis on Associations between Tobacco Smoking and Both the Diagnosis and the Clinical Symptoms of Psychosis?

Pedro Gurillo Muñoz

Another Good Reason to Stop Smoking:

A Case-Control Study of the Association between Tobacco Use and First Episode Psychosis

Marta Di Forti

Cigarette Smoking is Equally Strongly Associated with Psychotic-like Experiences as Cannabis Use

Marco P.M. Boks

Discussant: John J. McGrath

**OLIGODENDROCYTES AS A TARGET FOR TREATMENT
IN SCHIZOPHRENIA**

2:00 PM - 4:00 PM

Location: Affari, Second Level

Chair: Johann Steiner

Co-Chair: Natalya Uranova

Ultrastructural Abnormalities and Deficit of Oligodendrocytes in Schizophrenia: Clinical-pathological Correlates

Natalya Uranova

Oligodendrocyte-targeted Proteomics: Insights about Schizophrenia

Daniel Martins-de-Souza

Animal Experiment Data Regarding the Effect of Antipsychotic Drugs on Oligodendrocyte Turnover

Lan Xiao

A Systems Biology Approach toward Understanding Schizophrenia

Vahram Haroutunian

Discussant: Andrea Schmitt

**SUICIDE AND PSYCHOSIS:
THE CONTEXT AND MEANING OF EARLY RISK**

2:00 PM - 4:00 PM

Location: Sala Verde

Chair: Stephen Wood

Suicide-related Behaviour in Young People: Rates, Risk Factors and Intervention

Jo Robinson

Psychotic Experiences as a Predictor of the Natural Course of Suicidal Ideation: A Swedish Cohort Study

Ian Kelleher

Depression and Suicidality in First Episode Psychosis: Subordination and Shame

Rachel Upthegrove

The Long-term Risk of Suicide Following First Onset Psychosis and Potential Early Risk Factors


Rina Dutta

Discussant: Stephen Wood

COFFEE BREAK

4:00 PM - 4:15 PM

Location: Passi Perduti – Adjacent to the Auditorium; Palazzo Affari Foyers; Sala Verde



CONCURRENT SYMPOSIA

PHARMACEUTICAL PIPELINE SESSION

4:15 PM - 6:15 PM

Location: Auditorium

Chair: John Kane

Efficacy and Safety of Adjunctive Bitopertin versus Placebo in Subjects with Persistent Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics - Update from the Searchlyte Programme
Dragana Bugarski-Kirola

Randomized, Double-blind, Active-controlled, Phase 2/3 Study to Determine the Short-term (6-week) and Long-term (6 month) Cognitive and Anti-psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone
Jonathan Rabinowitz

ITI-007, a New Approach to the Treatment of Schizophrenia
Kimberly E. Vanover

Results of a Phase 2B Clinical Trial of TC-5619, a Selective Alpha 7 Neuronal Nicotinic Receptor (NMR) Agonist, in the Adjunctive Treatment of Negative Symptoms and Cognitive Dysfunction in Schizophrenia
David Hosford

Dopamine-1 Receptor Stimulation in Schizophrenia: a Randomized, Clinical Trial
Ragy Girgis

Early Clinical Results of the Phosphodiesterase 10 Inhibitor OMS643762 in Development for the Treatment of Schizophrenia and Huntington's Disease
Albert Yu

Efficacy and Safety of Novel Dopamine Serotonin Stabilizer RP 5063 in Acute Schizophrenia and Schizoaffective Disorder
Marc Cantillon

**ICOSR SYMPOSIUM: THE ADVANCES IN STRUCTURAL AND
FUNCTIONAL BRAIN IMAGING IN SCHIZOPHRENIA AND
OTHER PSYCHOTIC DISORDERS**

4:15 PM - 6:15 PM

Location: Affari, Ground Level

Chair: S. Charles Schulz

Guiding Neuromodulation with Neuroimaging
Kelvin Lim

Structural and Functional Neuroimaging Findings in the BSNIP Psychosis Consortium
Godfrey D. Pearlson

New Neuroscience Based Cognitive Paradigms for Biomarker Research in Schizophrenia
Deanna M. Barch

Dynamics of Intrinsic Connectivity Networks in Schizophrenia
Vince Calhoun

Discussant: S. Charles Schulz

**SHOULD WE CONTINUE TO DO PLACEBO-CONTROLLED MEDICATION
TRIALS IN SCHIZOPHRENIA? AN ETHICO-CLINICAL DEBATE**

4:15 PM - 6:15 PM

Location: Affari, Lower Level

Chair: Anthony S. David


The Use of Placebo in Randomized Controlled Trials in Schizophrenia: A Regulator's View
Luca Pani

The Ethics of Placebo-Controlled Trials in Schizophrenia: A View Informed by Working with Industry
Robert R. Conley

Placebo Controlled Trials in Patients Suffering from Schizophrenia: Methodological Issues with an Indirect Effect on Ethical Considerations
W. Wolfgang Fleischhacker

Ethics of Placebo Use in Schizophrenia Trials
Paul S. Appelbaum

Discussant: William T. Carpenter



**THE LONG SEARCH FOR AN INFLAMMATORY COMPONENT
IN SCHIZOPHRENIA**

4:15 PM - 6:15 PM

Location: Sala Verde
Chair: Sabine Bahn
Co-Chair: Iris Sommer

Meta-analyses on Double-blind RCTs Adding Drugs with Anti-inflammatory Properties to Antipsychotic Medication
Iris Sommer

Serum Biomarkers for Psychiatric Disorders
Sabine Bahn

The Microbiome - The Missing Link in the Pathogenesis of Schizophrenia
Robert Yolken

Infections, Inflammatory Markers and Schizophrenia
Faith Dickerson

Neuroinflammation in Temporal Cortex of Patients with Recent Onset Schizophrenia
Bart van Berckel

Discussant: Cynthia Shannon-Weickert

**USING NEUROIMAGING TO PREDICT OUTCOMES IN
SUBJECTS AT HIGH RISK**

4:15 PM - 6:15 PM

Location: Affari, First Level
Chair: Philip McGuire
Co-Chair: Tyrone Cannon

Identifying Biomarkers of Risk for and Progression to Psychosis Using High-Risk Strategies
Tyrone Cannon

Relationship between Brain Glutamate Concentrations and Functional Outcome in Individuals at Ultra High Risk of Psychosis
Alice Egerton

Clinical and Imaging Prediction of Schizophrenia in People at High Familial Risk
Stephen Lawrie

Outcome in Subjects at Ultra High Risk of Psychosis: Relationship to Dopaminergic Function
Oliver Howes

Discussant: Ed Bullmore

**WHEN DOES THE TROUBLE START? OBESITY, DIABETES RISKS
AND METABOLIC DISTURBANCES IN YOUNG PEOPLE WITH PSYCHOSIS**

4:15 PM - 6:15 PM

Location: Affari, Second Level
Chair: Cherrie Galletly

Risk Factors for Death and Disability in Young People with Psychosis
Cherrie Galletly

Weight Gain and Metabolic Changes after Six Months of Treatment with Second-generation Antipsychotics in Antipsychotic-naïve Pediatric and Adult Patients
Celso Arango

Dysglycemic Signals in Children and Adolescents Treated with Antipsychotics for the First Time
Christoph Correll

Results from the NIMH-funded Metabolic Effects of Antipsychotics in Children (MEAC) Study
John W. Newcomer

Discussant: Benno G. Schimmelmann



	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30AM-12:00PM Behavioral and Imaging Translational Paradigms in Drug Development						2:00PM-4:00PM Debate: Attenuated Psychosis Syndrome is a Needed Diagnostic Category	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Translational Studies Isolating Cognitive Dysfunction and Amotivation in Schizophrenia	6:15PM-7:15PM SIRS Business Meeting & Awards Presentation			
Palazzo Affari Ground Level								2:00PM-4:00PM Exposure to Infection/Inflamma- tion during Brain Development and Risk for Psychotic Disorders	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Is the Associative Striatum a Locus of Vulnerability for Transition to Psychosis ?				
Palazzo Affari 1st Level								2:00PM-4:00PM The Biology of Social Defeat	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Reward Processing, Cognition & Perception during Adolescent Brain Development and Vulnerability for psychosis				
Palazzo Affari 2nd Level								2:00PM-4:00PM Schizophrenia Interneuron Phatology: Lost in Migration	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Cannabis, Skunk and Spice: The Evolving Risk of Psychosis				
Palazzo Affari Lower Level								2:00PM-4:00PM Novel Treatment Options for Impaired Cognition in Schizophrenia: Combining Different Modes of Cognitive Remediation	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Potential Role of NMDA-receptor Antibodies in Schizophrenia: Overlap and Distinction from NMDA-receptor Encephalitis				
Sala Verde						1:00PM 2:00PM Voices in my Head: Dom's Story		2:00PM-4:00PM Violence and Schizophrenia: Risk Factors and Mediators	4:00PM 4:15PM Coffee Break	4:15PM-6:15PM Relapse - Risk and Prevention				
Cavaniglia						12:00PM-2:00PM Poster Session II and Lunch								
Palazzo Affari Entrance						8:00AM-7:00PM Registration								
Sala 103						7:30AM-7:00PM Speaker Ready Room								
Limonaia						7:30AM-6:30PM Computer Center								
Passi Perduti			8:00AM-11:00AM Coffee Available											
Legend:	Keynote	Special Session	Speaker Ready	Registration	Computer Center	Symposia	Workshop	Poster Session	Plenary	Oral Presentation	Coffee Break			

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia

Workshop

Poster Session

Plenary

Oral Presentation

Coffee Break

FINAL PROGRAM**FLORENCE, ITALY****05 - 09 APRIL 2014****Monday, 07 April****REGISTRATION****8:00 AM - 7:00 PM****Location:** Palazzo Affari Entrance**COFFEE/PASTRIES****8:00 AM - 11:00 AM****Location:** Passi Perduti – Adjacent to the Auditorium**Scientific Sessions****PLENARY SESSION****8:30 AM - 12:00 PM****Behavioral and Imaging Translational Paradigms in Drug Development****Location:** Auditorium**Chairpersons:** Holly Moore and Barbara Sahakian**ABSTRACT**

Many would agree that we are currently in the “Decade of Neuroconnectomics”. Advances in genetic, electrical and biochemical engineering have made it possible to map and measure function in specific circuits in animal models with levels of selectivity and precision never before achieved. Complementing this revolution are advances in brain stimulation and imaging methods that allow us to map interactions between anatomically defined regions of the human brain, and, further, examine how these maps change with psychiatric disease. But, as we embark on this journey into new territories opened by these new technologies, it is valuable to review what we already think we know from the previous century of neuroanatomical and electrophysiological studies of the brain circuits most commonly implicated in psychiatric disorders. The goal of this talk will be to take iconic cortico-basal ganglia and limbic circuits known to mediate appetitive motivation, fear, memory and decision-making and use the structural and functional connectivity to review “motifs of connectivity” within these systems.

PRESENTERS*Novel Drug Targets and Translating Results from Animal Models into Humans:**Insights Using the MAM Development Model*

Anthony Grace, University of Pittsburgh, USA

Negative Symptoms in Schizophrenia as a Target for Translation Research

Jim Gold, Maryland Psychiatric Research Center, USA

A Central Role of the Dopamine D2 Receptor in the Modulation of Motivation

Pierre Trifillief, University of Bordeaux, France

Translating Social Cognition and Social Neuroscience for Schizophrenia Research

Michael Green, University of California, Los Angeles, USA

Translational Paradigms for Social Cognition in Rodents and Non-Human Primates

Karen Bales, University of California, Davis, USA

Neural Substrate of Abnormal Predictions and Rewards: Clinical and Preclinical fMRI studies of Incentives and Surprises in Psychiatric Illness

Graham Murray, California National Primate Research Center, USA

Monday 07 April



POSTER SESSION II AND LUNCH

Location: Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

Please see page 96 for a complete listing of posters.

12:00 PM - 2:00 PM

Special Session - Voices in My Head: Dom's Story

Location: Sala Verde

1:00 PM - 2:00 PM

Coffee Available

Locations: Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

1:45 PM - 2:15 PM

CONCURRENT SYMPOSIA

**DEBATE: ATTENUATED PSYCHOSIS SYNDROME IS A
NEEDED DIAGNOSTIC CATEGORY**

Location: Auditorium

Chair: Robin M. Murray

2:00 PM - 4:00 PM

Attenuated Psychosis Syndrome = Common Mental Disorder with Subthreshold Psychosis

Jim van Os

The Psychosis High Risk State: Is It Valid?

Paolo Fusar-Poli

Debate: Attenuated Psychosis Syndrome Is a Needed Diagnostic Category

David J. Castle

Debate: Attenuated Psychosis Syndrome: A New Diagnostic Class Is Needed

William T. Carpenter

Discussant: Robin M. Murray

**EXPOSURE TO INFECTION/INFLAMMATION DURING
BRAIN DEVELOPMENT AND RISK FOR PSYCHOTIC DISORDERS**

2:00 PM - 4:00 PM

Location: Affari, Ground Level

Chair: Christina Dalman

Early-life Exposure to Epstein Barr Virus, Childhood IQ and the Risk of Psychotic Experiences in the ALSPAC Birth Cohort

Golam Khandaker

Serologically Documented Maternal Influenza and Bipolar Disorder in Adult Offspring

Alan Brown

Fetal and Childhood Infections and Later Risk of Developing Psychoses; in Search of Possible Underlying Mechanisms by Combining Different Research Disciplines

Åsa Blomström

Early Infection/Inflammation and Later Development of Psychoses: An Overview of the Research Area

Christina Dalman

Manganese-Enhanced Magnetic Resonance Imaging Reveals Increased Hallucination-Like brain Activity in a Mouse Model of a Schizophrenia Risk Factor

Paul H. Patterson

Discussant: Robert Yolken

**NOVEL TREATMENT OPTIONS FOR IMPAIRED COGNITION
IN SCHIZOPHRENIA: COMBINING DIFFERENT MODES OF
COGNITIVE REMEDIATION**

2:00 PM - 4:00 PM

Location: Affari, Lower Level

Chair: Peter Falkai

Co-Chair: William Honer

Combining Exercise and Cognitive Remediation

Peter Falkai

Yoga Exercise for Cognitive Impairment in Psychotic Disorders

Eric Yu Hai Chen

Understanding of Musical Impairment May Facilitate the Development of Insight for Cognitive Remediation

Ken Sawada

Combining Cognitive and Social Cognitive Training for Individuals with Schizophrenia

Sophia Vinogradov

Discussant: William Honer



SCHIZOPHRENIA INTERNEURON PATHOLOGY: LOST IN MIGRATION 2:00 PM - 4:00 PM

Location: Affari, Second Level
Chair: Cindy Shannon-Weickert

Increased White Matter Neuron Density Is Related to High Neuroinflammation in People with Schizophrenia
Cindy Shannon-Weickert

Subcortical White Matter Neurons in Autism, Schizophrenia and Depression
Schahram Akbarian

Oxidative Stress in Parvalbumin Interneurons in a Developmental Rodent Model of Schizophrenia
Patricio O'Donnell

*Patterns of Neuronal Migration from the Early Postnatal Subventricular Zone:
Potential Relevance for Schizophrenia*
Dragos Inta

Discussant: Bitu Moghaddam

THE BIOLOGY OF SOCIAL DEFEAT

2:00 PM - 4:00 PM

Location: Affari, First Level
Chair: Jean-Paul Selten
Co-Chair: Andreas Meyer-Lindenberg

*Abnormalities of Neural Social Stress Processing and
Exposure to Environmental Risk Factors for Schizophrenia*
Andreas Meyer-Lindenberg

Exaggerated Dopamine Release in Immigrants during Social Stress: A Risk Mechanism for Psychosis
Romina Mizrahi

ΔfosB in the Prefrontal Cortex, Susceptibility to Social Stress and Antipsychotic Treatment
Vincent Vialou

*Social Exclusion and Sensitization of the Dopamine System: A [123I]IBZM-SPECT Study in Young Adults
with Serious Hearing Impairment*
Martin Gevonden

Discussant: Oliver Howes

VIOLENCE AND SCHIZOPHRENIA: RISK FACTORS AND MEDIATORS 2:00 PM - 4:00 PM

Location: Sala Verde
Chair: Seena Fazel

Risk Factors for Violence in Psychosis: Findings from a Meta-analysis
Seena Fazel

Delusions and Violence
Jeffrey Swanson

*Systematic Review of the Prevalence and Risk Factors for Interpersonal Violence
in Acute Psychiatric Units*
Giovanni De Girolamo


Preventing Violence in Schizophrenia
Olav Nielssen

Discussant: John J. McGrath

COFFEE BREAK

4:00 PM - 4:15 PM

Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde



CONCURRENT SYMPOSIA

**CANNABIS, SKUNK AND SPICE: THE EVOLVING RISK
OF PSYCHOSIS**

Location: Affari, Second Level
Chair: Marta Di Forti

How Sinsemilla (Skunk) Use has Reshaped the Association between Cannabis and Psychosis
Marta Di Forti

*Spicing Thing Up - What Can We Learn from Synthetic Cannabinoids about the Link
between Cannabinoids and Psychosis*
Deepak Cyril D'Souza

*Epigenetic and Transcriptional Changes Associated with the Development of the Schizoaffective-like
Phenotype Induced by Adolescent Exposure to THC in Rats*
Tiziana Rubino

"The Good, the Bad, the Ugly": Experimental Human Studies of CBD, THC, and THCV
Amir Englund

Discussant: Robin M. Murray

**IS THE ASSOCIATIVE STRIATUM A LOCUS OF VULNERABILITY FOR
TRANSITION TO PSYCHOSIS?**

Location: Affari, Ground Level
Chair: Anissa Abi-Dargham

Developmental and Dietary Sensitivity of Dopamine in Dorsal Striatum
Bita Moghaddam

Abnormalities of Frontostriatal Circuits in the Psychosis Prodrome
Tiziano Colibazzi

*Striatal GABAergic and Glutamatergic Dysregulations as Potential Predictors of Conversion to Psychosis
in Individuals at Ultra-High Risk*
Camilo de la Fuente-Sandoval

Is the Associative Striatum a Locus of Vulnerability for Transition to Psychosis?
Oliver Howes

Discussant: Anissa Abi-Dargham

4:15 PM - 6:15 PM

**POTENTIAL ROLE OF NMDA-RECEPTOR ANTIBODIES
IN SCHIZOPHRENIA:
OVERLAP AND DISTINCTION FROM NMDA-RECEPTOR ENCEPHALITIS**

Location: Affari, Lower Level
Chair: Johann Steiner
Co-Chair: Hannelore Ehrenreich

*Increased Prevalence of Diverse N-methyl-D-aspartate Glutamate Receptor Antibodies in Patients with
an Initial Diagnosis of Schizophrenia*
Johann Steiner

NMDA Receptor Antibodies in First Episode Psychosis: Prevalence and Clinical Phenotype
Belinda Lennox

*Anti-NMDA-receptor Antibody Detected in Limbic Encephalitis, Schizophrenia and
Narcolepsy with Psychotic Symptoms*
Takashi Kanbayashi

*Neuropsychiatric Disease Relevance of Circulating Anti-NMDA Receptor Autoantibodies Depends on Blood
Brain Barrier Integrity*
Hannelore Ehrenreich

Discussant: Souhel Najjar

RELAPSE - RISK AND PREVENTION

Location: Sala Verde
Chair: Robert Zipursky
Co-Chair: Robin Emsley

Can the Ongoing Use of Placebo in Relapse-Prevention Clinical Trials in Schizophrenia be Justified?
Robin Emsley

Are There Clinically Useful Predictors and Early Warning Signs for Relapse in Schizophrenia?
Wolfgang Gaebel

Patterns of Response and the Neurobiology of Relapse in Schizophrenia
Ofer Agid

*Risk of Symptom Recurrence with Medication Discontinuation in First-Episode Psychosis:
A Systematic Review*
Robert Zipursky

Discussant: S. Charles Schulz

4:15 PM - 6:15 PM

4:15 PM - 6:15 PM



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



REWARD PROCESSING, COGNITION AND PERCEPTION DURING ADOLESCENT BRAIN DEVELOPMENT AND VULNERABILITY FOR PSYCHOSIS

Location: Affari, First Level
Chair: Richard S.E. Keefe
Co-Chair: Bitu Moghaddam

4:15 PM - 6:15 PM

Neuronal Processing Differences in the Prefrontal Cortex of Adolescents and Adults during Motivated Behavior
Bitu Moghaddam

Dorsolateral Prefrontal Cortex Drives Mesolimbic Dopaminergic Regions During Motivated Behavior: Insights from Dynamic Causal Modeling and fMRI in At-risk Adolescents
R. Alison Adcock

The Binocular Depth Inversion Illusion Test - A Basic Measure of Perceptual Integration
F. Markus Leweke

Abnormalities in Reward Processing in Offspring of Schizophrenia Patients: Frontal-Striatal Abnormalities as a High-risk Phenotype
René S. Kahn

Discussant: Philip McGuire

TRANSLATIONAL STUDIES ISOLATING COGNITIVE DYSFUNCTION AND AMOTIVATION IN SCHIZOPHRENIA AND RELATED DISORDERS

Location: Auditorium
Chair: Mark A. Geyer
Co-Chair: Jared W. Young

4:15 PM - 6:15 PM

Effort, Motivation and Reward Learning in Schizophrenia: Relationships to Amotivation and Functional Impairment
Deanna M. Barch

Adapting Effort-Based Decision-making Paradigms for Schizophrenia: What Works and What Doesn't
Michael Green

Dissecting Motivation in Animal Models of Dopamine Dysfunction
Eleanor H. Simpson

Isolating Poor Attention, Reward Learning, and Motivation in the Sp4 Hypomorphic Mouse Model of Schizophrenia: GLYT1 Inhibitors Treat Only Inattention
Jared W. Young

Discussant: Athina Markou

Coffee Available

Location: Passi Perduti – Adjacent to the Auditorium


6:00 PM - 6:30 PM

SIRS Business Meeting and Award Presentations

Location: Auditorium

6:15 PM - 7:15 PM

Monday 07 April



Monday 07 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30AM-12:00PM Update on Therapeutics: Improving the Clinical Yield						2:00PM-4:00PM Modeling Schizophrenia Using Patient Derived Cells but Which Ones?	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM Therapeutics	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM Recent Advances in Cognitive Behaviour Therapy for Psychotic Treatment Resistant Group		
Palazzo Affari Ground Level								2:00PM-4:00PM Childhood Trauma as Risk Factor in Psychotic Disorders-in Search of Mechanisms	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM Biomarkers	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM Biological and Psychopathological Dimensions of Psychotic Disorders: The Road Forward to Deconstruction?		
Palazzo Affari 1st Level								2:00PM-4:00PM At Risk Mental State Treatment Update	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM Advances in Imaging in Schizophrenia I	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM Neuroadaptations to Chronic Antipsychotic Treatment in Preclinical Models		
Palazzo Affari 2nd Level								2:00PM-4:00PM The Cannabinoid Dichotomy in Schizophrenia: From Risk Factor to Therapy	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM Advances in Imaging in Schizophrenia II	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM Neurostimulation for Psychotic Symptoms		
Palazzo Affari Lower Level								2:00PM-4:00PM What is the Long Term Outcomes of schizophrenia?	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM High Risk Research	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM Next Steps with GWAS and Gene Sequencing: Functional Mutations, Gene by Gene Interactions & Pathway Analysis		
Sala Verde						1:00PM-2:00PM Voices in my Head: Don's Story		2:00PM-4:00PM Understanding Pathways to Care as a Means of Advancing Early Intervention	4:00PM-4:15PM Coffee Break	4:15PM-6:15PM Genetics and Epidemiology	6:00PM-6:30PM Coffee Break	6:30PM-8:30PM 20 Years of Research on the 22q11.2 Deletion Syndrome & Schizophrenia: What have we Learned so far?		
Cavaniglia					12:00PM-2:00PM Poster Session II and Lunch									
Palazzo Affari Entrance							8:00AM-8:30PM Registration							
Sala 103							7:30AM-8:00PM Speaker Ready Room							
Limonata							7:30AM-4:30PM Computer Center							
Passi Perduti			8:00AM-11:00AM Coffee Available				1:45PM-2:15PM Coffee Break							

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia


Workshop

Poster Session

Plenary

Oral Presentation

Coffee Break

FINAL PROGRAM**FLORENCE, ITALY****05 - 09 APRIL 2014****Tuesday, 08 April****REGISTRATION****8:00 AM - 8:30 PM****Location:** Palazzo Affari Entrance**COFFEE/PASTRIES****8:00 AM - 11:00 AM****Location:** Passi Perduti – Adjacent to the Auditorium**Scientific Sessions****PLENARY SESSION – UPDATE ON THERAPEUTICS: IMPROVING THE CLINICAL YIELD****8:30 AM - 12:00 PM****Location:** Auditorium**Chairpersons:** John Kane and Richard Keefe**ABSTRACT**

New treatment development in schizophrenia remains a challenge. Despite a variety of preclinical models and translational efforts, the availability of compounds with novel mechanisms of action is limited. There are important initiatives underway to enhance our approach to diagnosis (e.g. RDoC, genomics, stem cell research) and provide a better understanding of the heterogeneity of schizophrenia in order to facilitate drug development and come closer to personalized or precision medicine. However, despite the promise that this multiyear process holds, we still face the immediate challenge of improving the lives of our current patients with better treatments.

This session will allow experts from industry and academia to discuss strategies to improve the clinical yield in current drug development efforts. A number of high profile disappointments and the increasing challenge of maintaining the engagement of large pharma companies in CNS research underscore the urgency of these efforts.

Daniel Umbricht will discuss strategies to assessing treatment effects in negative symptoms. Christopher Schmidt will review lessons learned from a PDE 10 development program and Bruce Kinon will do the same for a mGlu program. Richard Keefe will provide an overview of signal detection in trials involving cognitive enhancement. Jonathan Rabinowitz will discuss the power of industry academia collaboration to enhance therapeutics and John Kane will review overall challenges in the design and conduct of clinical trials in schizophrenia.

PRESENTERS*Sharpening the Signal in Cognitive Enhancement Trials*

Richard Keefe, Duke University, USA

Preclinical and Clinical Evaluation of PDE10A Inhibition as a Treatment for Schizophrenia

Chris Schmidt, Pfizer, USA

*The Development of Pomaglutmetad Methionil as a Glutamate-based Pharmacotherapy**for Schizophrenia: Lesson Learned*

Bruce Kinon, Eli Lilly, USA

Challenges and Potential Solutions in Negative Symptom Trials

Daniel Umbricht, La Roche, Switzerland

Power of Collaborations and Big Data in Advancing Drug Development: NewMeds and Beyond

Jonathan Rabinowitz, Bar Ilan University, Israel

Tuesday 08 April



COFFEE AVAILABLE

Location: Passi Perduti – Adjacent to the Auditorium

10:15 AM - 10:30 AM

POSTER SESSION III

Location: Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

Please see page 122 for a complete listing of posters.

SPECIAL SESSION - VOICES IN MY HEAD: DOM'S STORY

Location: Sala Verde

1:00 PM - 2:00 PM

COFFEE AVAILABLE

Location: Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

1:45 PM - 2:15 PM

CONCURRENT SYMPOSIA

AT-RISK MENTAL STATE TREATMENT UPDATE

Location: Affari, First Level

Chair: Dorien H. Nieman

Co-Chair: Mark van der Gaag

2:00 PM - 4:00 PM

Subthreshold Intervention to Reduce the Impact of Emerging Psychosis and Risk for Stage Progression:

Recent and Future Clinical Trials

Patrick McGorry

Internalised Stigma in Young People at High Risk of Developing Psychosis:

Findings from a Cognitive Therapy Trial

Anthony P. Morrison

Preventing a First Episode of Psychosis: A Meta-Analysis

Mark van der Gaag

Preventive Psychotherapy

Dorien H. Nieman

Discussant: Stephan Ruhrmann

**CHILDHOOD TRAUMA AS RISK FACTOR IN PSYCHOTIC
DISORDERS IN SEARCH OF MECHANISMS**

2:00 PM - 4:00 PM

Location: Affari, Ground Level

Chair: Ingrid Melle

History of Trauma in the Ultra High Risk for Psychosis Population: Findings from the PACE Clinic

Barnaby Nelson

Childhood Trauma Influences the Clinical Expression of Bipolar Disorders

Bruno Etain

How Does Childhood Trauma Contribute to Psychosis Onset? A Focus on the Biological Stress Response

Valeria Mondelli

BDNF Val66Met Polymorphism Modulates Associations between Childhood Abuse–Neglect and Functional and Structural Abnormalities in Psychoses

Monica Aas

Discussant: Paola Dazzan

**MODELING SCHIZOPHRENIA USING PATIENT DERIVED CELLS
BUT WHICH ONES?**

2:00 PM - 4:00 PM

Location: Auditorium

Chair: David Cotter

Co-Chair: Alan Mackay-Sim

Significant Down-regulation of EIF2 and Associated Ribosomal Proteins in ONS Cell Model of Schizophrenia

Jane A. English

Patient-derived Stem Cells and SZ: A Path to Aetiology?

Alan Mackay-Sim

Elucidating the Molecular Pathophysiology of Mental Illness with Olfactory Neuronal Cells and Induced Pluripotent Stem Cells

Akira Sawa

Modeling Predisposition to SZ Using hiPSCs

Kristen Brennand

Discussant: Paul Harrison



**THE CANNABINOID DICHOTOMY IN SCHIZOPHRENIA:
FROM RISK FACTOR TO THERAPY**

2:00 PM - 4:00 PM

Location: Affari, Second Level

Chair: Andrea Giuffrida

Co-Chair: Daniel Lodge

Endocannabinoid-enhancing Drugs Reverse Social Withdrawal in the PCP Rat Model of Schizophrenia
Andrea Giuffrida

Increasing Endocannabinoid Levels Restores Aberrant Dopamine System Function in the PCP Model of Schizophrenia
Daniel Lodge

CB1 Receptor Signaling, Prefrontal GABAergic Transmission and Adolescence
Kuei Y. Tseng

Modulation of the Endocannabinoid System as a Potential New Target in the Treatment of Schizophrenia
F. Markus Leweke

Discussant: David Morilak

**UNDERSTANDING PATHWAYS TO CARE AS A MEANS
OF ADVANCING EARLY INTERVENTION: FINDINGS
FROM AROUND THE WORLD**

2:00 PM - 4:00 PM

Location: Sala Verde

Chair: Michael T. Compton

A Comparative Study of Pathways to First-Episode Care for Psychosis in Three Ethnic Groups in Ontario, Canada: The African, Caribbean, & European Project (ACE)
Kelly K. Anderson

The Use of Social Media in Early Psychosis
Michael L. Birnbaum

Reducing Duration of Untreated Psychosis: Care Pathways to Early Intervention in Psychosis Services
Max Birchwood

Help-seeking and Pathways to Care in the Early Stages of Psychosis: Results from the FePsy Study
Anita Riecher-Rössler

Discussant: John M. Kane

WHAT IS THE LONG TERM OUTCOME OF SCHIZOPHRENIA?

2:00 PM - 4:00 PM

Location: Affari, Lower Level

Chair: Michael Davidson

Ten-Year Outcomes of Psychotic Disorders: The AESOP-10 Study
Peter B. Jones

*Outcomes of Schizophrenia from a Lifespan Perspective.
The Northern Finland 1966 Birth Cohort Study (NFBC 1966)*
Matti Isohanni

Long Term Outcome in Schizophrenia: A 6 Year Follow Up in over 1000 Patients
René S. Kahn

Nation-wide Employment Status in Patients with Schizophrenia and Bipolar Disorders
Mark Weiser

Discussant: Robin M. Murray

COFFEE AVAILABLE

3:45 PM - 4:15 PM

Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde



ORAL PRESENTATIONS

ADVANCES IN IMAGING IN SCHIZOPHRENIA I

Location: Affari, First Level

Chair: Sophia Vinogradov

4:15 PM - 6:15 PM

- 4:15 PM** *Altered Patterns of Reward Activation in a Large Cohort of Antipsychotic Naïve First Episode Schizophrenia Patients*
Mette Ødegaard Nielsen
- 4:30 PM** *Dynamic Susceptibility Contrast (DSC) MRI Can Be Useful to Automatically Classify Patients with Psychosis*
Letizia Squarcina
- 4:45 PM** *Exploring the Sensory Complexity of Hallucinatory Experiences Using Multimodal Connectivity Analysis*
Renaud Jardri
- 5:00 PM** *Functional Outcome in People at High Risk for Psychosis Predicted by Thalamic Glutamate Levels and Prefronto-striatal Activation*
Paul Allen
- 5:15 PM** *Genetic and Environmental Influences on Brain Function in Schizophrenia. An fMRI Study of the Maudsley Twin and Family Cohorts*
Marco M. Picchioni
- 5:30 PM** *In vivo Evidence of Reduced Brain Cannabinoid Receptors in Schizophrenia*
Deepak Cyril D'Souza
- 5:45 PM** *Integrating Pharmacology and Computation: Towards Understanding Mechanisms of Cognitive and Connectivity Deficits in Schizophrenia*
Alan Anticevic
- 6:00 PM** *Stress-induced Changes in Prefrontal Cortex Dopamine D2/3 Receptor Availability in Psychosis*
Dennis Hernaus

ADVANCES IN IMAGING IN SCHIZOPHRENIA II

4:15 PM - 6:15 PM

Location: Affari, Second Level

Chair: Alessandro Bertolino

- 4:15 PM** *Cortical Thickness in Individuals with Nonclinical and Clinical Psychosis*
Sanne Koops
- 4:30 PM** *Differential Diagnostic Classification of Functional Psychoses Using MRI-based Pattern Recognition*
Nikolaos Koutsouleris
- 4:45 PM** *Elevated Anterior Cingulate Cortex Glutamate Levels are Associated with Antipsychotic Treatment Resistance and Clinical Severity in Schizophrenia*
Elias Mouchlianitis
- 5:00 PM** *Emerging Evidence of Affected Anatomical Rich Club Hub Structure in Schizophrenia Patients, their Healthy Siblings and their Non-affected Young Offspring*
Martijn van den Heuvel
- 5:15 PM** *GABA and Glutamate in Schizophrenia: A 7T 1H-MRS Study*
Anouk Marsman
- 5:30 PM** *Prefrontal Abnormalities in NAA and Glutamate Levels in Persons with a Psychotic Disorder or at Risk for a Psychosis: A Large H-MRS Study*
Edith Liemburg
- 5:45 PM** *Reduced Microstructural White Matter Alterations in Psychotic Disorder; Stable or Progressive?*
Patrick A.E. Domes
- 6:00 PM** *Topological Features of Structural Brain Networks in Sub-Clinical Psychosis Revealed by Graph Theoretical Analysis of Tractography Data*
Mark Drakesmith



BIOMARKERS

Location: Affari, Ground Level
Chair: Cynthia Shannon-Weickert

4:15 PM - 6:15 PM

- 4:15 PM** *Continuity of Externalising and Internalising Psychopathology as Predictors of Psychotic-like Experiences in a Longitudinal General Population Cohort of Teenagers*
Alessandra Raudino
- 4:30 PM** *Inflammatory Response in First-episode Psychosis*
Jaana Suvisaari
- 4:45 PM** *Premorbid and Current Cognitive Function in Schizophrenia associate with Treatment Resistance and EGF 61 AA Genotype*
Vaidy Swaminathan
- 5:00 PM** *Real-time Detection of Cognitive Decline in Children at High Genetic Risk of Schizophrenia and Bipolar Disorder*
Michel Maziade
- 5:15 PM** *Risk of Diabetes in Pediatric Patients Exposed to Antipsychotics: A Nationwide 12-year Case-control Study*
René E. Kondrup (Nielsen)
- 5:30 PM** *RNA Sequencing of Choroid Plexus in Schizophrenia and Unaffected Control Subjects*
Maree J. Webster
- 5:45 PM** *The Neurobiology of Negative Symptoms and the Effect of Glycine Reuptake Inhibitors*
Daniela Alberati
- 6:00 PM** *The Role of Oligopeptidases in Schizophrenia – Translational Evidence from Human to Animal Research*
Ary Gadelha

GENETICS AND EPIDEMIOLOGY

Location: Sala Verde
Chair: Dan Rujescu

4:15 PM - 6:15 PM

- 4:15 PM** *A Population-Based Longitudinal Study of Serum Interleukin-6 and C-reactive Protein in Childhood as Predictors of Psychosis and Depression in Young Adult Life*
Golam Khandaker
- 4:30 PM** *Anticipating and Experiencing Pleasure in Schizophrenia: A New Paradigm*
Clementine Edwards
- 4:45 PM** *Common and Rare Risk Variants Implicate PAK Signaling in the Molecular Etiology of Schizophrenia*
Aiden Corvin
- 5:00 PM** *Dopamine or Glutamate: Using Genetic Copy Number Variant Pathway Analysis and Treatment Resistance to Adjudicate Schizophrenia Hypotheses*
James T.R. Walters
- 5:15 PM** *Interaction of Maternal Infection and Adolescent Cannabinoid Exposure on miRNA Regulation of Gene Expression in the Adult Entorhinal Cortex*
Sharon L. Hollins
- 5:30 PM** *Premature Death is Higher in Persons with Psychotic Disorders but not with Psychotic Experiences: A Population-based Longitudinal Study*
Nomi Werbeloff
- 5:45 PM** *The Genetic Architecture of Schizophrenia: How do CNVs and Polygenic Scores Contribute to Disease Risk?*
Sarah E. Bergen
- 6:00 PM** *The Role of Imaging Genetics in Unanticipated Schizophrenia Risk Gene Discovery: TNK1 and microRNA-137*
Steven G. Potkin



HIGH RISK RESEARCH

Location: Affari, Lower Level

Chair: Nina Schooler

4:15 PM - 6:15 PM

- 4:15 PM** *Altered Relationship between Medial Temporal Lobe Resting Cerebral Blood Flow and Striatal Dopamine Synthesis Capacity in People at Risk of Psychosis*
Paul Allen
- 4:30 PM** *Childhood Sleep Disturbance and Risk of Psychotic Experiences in a Large UK Birth Cohort*
Andrew Thompson
- 4:45 PM** *Difficulty in Making Contact with Others and Social Withdrawal as Early Signs of Psychosis in Adolescents – The Northern Finland Birth Cohort 1986*
Juha Veijola
- 5:00 PM** *High Blood Cytokine Levels are Related to Decreased Verbal Fluency and Broca's Area Volume Reduction in Schizophrenia*
Thomas Weickert
- 5:15 PM** *Is Treatment Resistant Schizophrenia a 'Type' or a 'Stage' of Psychotic Illness?*
Arsime Demjaha
- 5:30 PM** *Reward Processing in Unaffected Siblings of Schizophrenia Patients: An fMRI Study*
Max de Leeuw
- 5:45 PM** *Salience Matters: Brain Potentials Distinguish Premorbid Attention Problems among Children At-Risk for Schizophrenia*
Kristin R. Laurens
- 6:00 PM** *The Excess of Non-right-handedness in Schizophrenia is not the Result of Methodological Artifacts and Biases – A Meta-Analysis*
Marco Hirnstein

THERAPEUTICS

Location: Auditorium

Chair: Robert Zipursky

4:15 PM - 6:15 PM

- 4:15 PM** *Antipsychotic Medication and Remission of Psychotic Symptoms. Long Term Development and Characteristics*
Ditte R. Gottfredsen
- 4:30 PM** *Childhood Trauma and Psychosis in a Prospective Cohort Study: Cause, Effect and Directionality*
Ian Kelleher
- 4:45 PM** *Intention-to-harm is the Key Component Linking Childhood Traumatic Experiences to Psychosis*
Martine M. van Nierop
- 5:00 PM** *Negative Modulation of the Synaptic Vesicle Protein (SV2A): A New Pharmacological Target for Cognitive Deficit Associated with Schizophrenia*
Marc Laruelle
- 5:15 PM** *Novel Genetic Risk Variants for Clozapine-associated Neutropenia*
Sophie Legge
- 5:30 PM** *Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy*
Lex Wunderink
- 5:45 PM** *Risk of Mortality in Offspring of Mothers with Psychosis: A Western Australian Whole-of-population Cohort Study*
Sonal Shah
- 6:00 PM** *Social Support as an Effect Modifier or Mediator in the Relationship between Childhood Adversity and Psychosis?*
Charlotte Gayer-Anderson

COFFEE AVAILABLE

Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

5:45 PM - 6:30 PM



WORKSHOPS

BIOLOGICAL AND PSYCHOPATHOLOGICAL DIMENSIONS OF PSYCHOTIC DISORDERS: THE ROAD FORWARD TO DECONSTRUCTION?

6:30 PM - 8:30 PM

Location: Affari, Ground Level

Chair: Tilo Kircher

Co-Chair: Werner Strik

Thought and Language Disorders and their Neural Pathophysiology
Tilo Kircher

The Brain Systems Underlying Hallucinations and Catatonia
Werner Strik

*Altered Transfer of Momentary Mental States (ATOMS) as the Basic Unit of Psychosis Liability in Interaction
with Environment and Emotions*
Jim van Os

Neural Network Model Deconstruction of Psychosis
Sophia Frangou

Discussant: Wolfgang Gaebel

NEUROADAPTATIONS TO CHRONIC ANTIPSYCHOTIC TREATMENT IN PRECLINICAL MODELS

6:30 PM - 8:30 PM

Location: Affari, First Level

Chair: Shitij Kapur

Mechanisms of Antipsychotic Treatment Failure
Davide Amato

Impact of Chronic Antipsychotic Drug Treatment on Brain Morphology: A Cause for Concern?
Anthony C. Vernon

Clinical Insights Derived from Rodent Models of Antipsychotic-Induced Metabolic Perturbations
Margaret K. Hahn

Dopamine D2 Receptors Regulate the Anatomical Balance of Basal Ganglia Circuitry
Christoph Kellendonk

Discussant: Shitij Kapur

NEUROSTIMULATION FOR PSYCHOTIC SYMPTOMS

6:30 PM - 8:30 PM

Location: Affari, Second Level

Chair: Remko van Lutterveld

Co-Chair: Iris Sommer

*Effects of Transcranial Direct Current Stimulation on Treatment-resistant Psychotic Symptoms and Brain
Functional-connectivity in Patients with Schizophrenia*
Jerome Brunelin

From the Neurobiology of Origin and Treatment of Auditory Verbal Hallucinations
Philipp Homan

A Pilot Case Series of Magnetic Seizure Therapy in Refractory Schizophrenia
Daniel M. Blumberger

Theta-burst Repetitive Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations
Remko van Lutterveld

Discussant: Iris Sommer

NEXT STEPS WITH GWAS AND GENE SEQUENCING: FUNCTIONAL MUTATIONS, GENE BY GENE INTERACTIONS AND PATHWAY ANALYSIS

6:30 PM - 8:30 PM

Location: Affari, Lower Level

Chair: Dick McCombie


Epistasis and Empirical Pathways in Schizophrenia
Kristin K. Nicodemus

PAK Signaling as a Molecular Risk Mechanism for Psychosis
Aiden Corvin

*Using High Through-put Sequencing of the DISC1 Locus to Understand the Genetic Complexity of
Psychiatric Illness*
Pippa A. Thomson

Interpreting Gene Networks for Schizophrenia Research: Biases, Heuristics, and Controls
Jesse Gillis

Discussant: David Porteous



**RECENT ADVANCES IN COGNITIVE BEHAVIOUR THERAPY
FOR PSYCHOSIS (CBTP) FOR COMPLEX AND TREATMENT
RESISTANT GROUPS**

Location: Auditorium
Chair: Emmanuelle Peters

The MRC COMMAND Trial: Results of a Multi-centre, Randomised Controlled Trial of Cognitive Therapy to Prevent Harmful Compliance with Command Hallucinations
Max Birchwood

Computer Assisted Therapy for Auditory Hallucinations: The AVATAR Clinical Trial
Tom Craig

Cognitive Therapy for People with Schizophrenia Spectrum Disorders not Taking Antipsychotic Medication: A Randomised Controlled Trial
Anthony P. Morrison

The Results of Eye Movement Desensitisation and Reprocessing and Prolonged Exposure in Patients with Posttraumatic Stress Disorder and Chronic Psychotic Disorder
Mark van der Gaag

Discussant: Til Wykes

6:30 PM - 8:30 PM

**TWENTY YEARS OF RESEARCH ON THE 22Q11.2 DELETION
SYNDROME AND SCHIZOPHRENIA:
WHAT HAVE WE LEARNED SO FAR?**

Location: Sala Verde
Chair: Jacob A.S. Vorstman

The 22q11.2 Deletion Syndrome as a Model for Dementia Praecox
Jacob A.S. Vorstman

22q11.2 Deletion Syndrome as a Genetic Model for Schizophrenia
Anne S. Bassett

Neurocognitive Functioning in 22q11.2 Deletion Syndrome
Raquel E. Gur

Structural and Functional Neural Connectivity as a Predictor of Psychotic Symptom Expression in 22q11.2 Deletion Syndrome
Carrie E. Bearden

Insights into Schizophrenia from 22q11DS Mouse Models
Laurie R. Earls

Discussant: René Kahn

6:30 PM - 8:30 PM



	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium			8:30AM-12:00PM The Clinical Challenges of Comorbid Disorders					1:30PM-3:30PM Drug Repurposing and Emerging Adjunctive Treatments for Schizophrenia	3:45PM-4:45PM Closing Session					
Palazzo Affari Ground Level								1:30PM-3:30PM Research in Unmedicated Patients Provides Insights into the Neurobiology of Schizophrenia						
Palazzo Affari 1st Level								1:30PM-3:30PM Schizophrenia Research: The Challenge of Measurement Variability						
Palazzo Affari 2nd Level								1:30PM-3:30PM Oxytocin, Social Cognition and Schizophrenia						
Palazzo Affari Lower Level								1:30PM-3:30PM Lifespan Evolution of Neurocognitive Impairment in Schizophrenia						
Sala Verde								1:30PM-3:30PM Clinical Staging in Severe Mental Disorder: Towards Stage Specific Treatments in Psychosis						
Cavaniglia						12:00PM-1:30PM Lunch								
Palazzo Affari Entrance						8:00AM-4:00PM Registration								
Sala 103						7:30AM-3:30PM Speaker Ready Room								
Limonaia						7:30AM-4:30PM Computer Center								
Passi Perduti						8:00AM-11:00AM Coffee Available								

Legend:

Keynote

Special Session

Speaker Ready

Registration

Computer Center

Symposia

Workshop

Poster Session


Plenary

Oral Presentation

Coffee Break

FINAL PROGRAM**FLORENCE, ITALY****05 - 09 APRIL 2014****Wednesday, 09 April****REGISTRATION****8:00 AM - 4:00 PM****Location:** Palazzo Affari Entrance**COFFEE/PASTRIES****8:00 AM - 11:00 AM****Location:** Passi Perduti – Adjacent to the Auditorium**Scientific Sessions****PLENARY SESSION – THE CLINICAL CHALLENGES OF COMORBIDITY WITH ADDICTION AND SOMATIC DISEASE****8:30 AM - 12:00 PM****Location:** Auditorium**Chairs:** Nick Stefanis and Mary Cannon (Substance Abuse)**Chairs:** Robin Murray and John McGrath (Physical Disease)**ABSTRACT**

In this Plenary Session, four international experts on the field will present evidence from neuroimaging, neuropharmacology and population epidemiology perspectives highlighting how substance abuse/dependence may moderate the expression of psychosis. While neuroimaging studies have indicated that the major locus of dopaminergic dysfunction in schizophrenia is presynaptic, characterized by elevated dopamine synthesis and release capacity, Prof. Abi-Dargham (Columbia University, USA) and Prof. R. Murray (Institute of Psychiatry, UK) will tackle the apparent inconsistency that arises from recent studies showing that dopamine release in patients with schizophrenia and comorbid substance use is considerably blunted, comparable in magnitude to substance users, suggesting that oversensitivity of the D2 receptor or abnormality of the post-D2 signaling pathway may also be involved in substance use psychosis. Prof. Callaghan (University of Northern British Columbia, Canada) will present evidence from a large population-based cohort study in California that patients with methamphetamine-related conditions and cannabis use have a significantly higher risk of schizophrenia than matched control population or indeed than other substance use disorders. Finally Prof. van Os (Maastricht University, The Netherlands) will present evidence from a large family based cohort including patients, their siblings and parents, that familial correlation of psychosis varies considerably as a function of selective environmental exposures such as cannabis (but interestingly not childhood trauma) indicating the importance of selective gene-environment interactions in psychosis susceptibility.



PRESENTERS

Dopaminergic Dysfunction in Schizophrenia Comorbid with Substance Dependence
Anissa Abi-Dargham, Columbia University, USA

Why is Treatment of People with Cannabis-Induced Psychosis so Unsuccessful?
Robin Murray, Kings College, United Kingdom

Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California
Russell Callaghan, University of Northern British Columbia

Family-based Study Examining Moderation of Familial Correlation in Psychotic Experiences by the Environment
Jim van Os, University Hospital of Maastricht, The Netherlands

Obesity and Cardiovascular Disease in Schizophrenia
Christoph Correll, The Zucker Hillside Hospital, USA

Epidemiological Studies of Somatic Co-Morbidity in Schizophrenia
Preben Bo Mortensen, Aarhus University, Denmark

Understanding the Widening Gap in Schizophrenia Mortality through Electronic Medical Record Databases
Rob Stewart, Kings College, United Kingdom

IMPACTing Lifestyle Choice and Cardiovascular Risk in Psychosis
Fiona Gaughran, Kings College, United Kingdom

COFFEE AVAILABLE

Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

LUNCH

Location: Palazzo Affari Lawn, Passi Perduti (in case of inclement weather)

COFFEE AVAILABLE

Locations: Passi Perduti – Adjacent to Auditorium
Palazzo Affari Foyers
Sala Verde

10:15 AM - 10:30 AM

12:00 PM - 1:30 PM

1:30 PM - 4:00 PM

CONCURRENT SYMPOSIA

CLINICAL STAGING IN SEVERE MENTAL DISORDERS: TOWARDS STAGE SPECIFIC TREATMENTS IN PSYCHOSIS

1:30 PM - 3:30 PM

Location: Sala Verde
Chair: Marta Rapado-Castro
Co-Chair: Seetal Dodd

Duration of the Illness and Response to Treatment
Marta Rapado-Castro

Staging and Neuroprotection
Seetal Dodd

Brain Imaging Markers of Psychosis Relapse. Is There Evidence for a Psychosis Relapse Signature?
Christos Pantelis

Fatty Acid Markers of Psychosis Progression and Treatment Response
Paul Amminger

Discussant: Patrick McGorry

DRUG REPURPOSING AND EMERGING ADJUNCTIVE TREATMENTS FOR SCHIZOPHRENIA

1:30 PM - 3:30 PM

Location: Auditorium
Chair: Vicki L. Ellingrod
Co-Chair: Joshua Roffman

Positive Symptoms Respond to Add-on Aspirin in Schizophrenia Patients with High Sera CRP Levels: A Post-hoc Analysis of an RCT
Mark Weiser

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Deanna L. Kelly

The Use of Sodium Nitroprusside for the Treatment of Schizophrenia
Jaime Hallak

Effects of Folic Acid and Vitamin B12 Supplementation on Negative Symptoms and Related MRI Indices
Joshua Roffman


Discussant: Peter Buckley



4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



LIFESPAN EVOLUTION OF NEUROCOGNITIVE IMPAIRMENT IN SCHIZOPHRENIA

Location: Affari, Lower Level
Chair: Larry J. Seidman

*Cognitive Trajectory between Ages 10, 13 and 18 and Risk for Psychosis in Adulthood:
a Swedish Longitudinal Cohort Study*
James H. MacCabe

Neurocognitive Functioning in Schizophrenia at First Episode and over the First Four Years of Illness
Eileen M. Joyce

A 10 Year Longitudinal Follow-up of First Episode Patients (FEP) in the Scandinavian TIPS Study
Bjørn R. Rund

*Infant Motor Development Predicts Decline in Executive Function in Adult Schizophrenia in the Northern
Finland 1966 Birth Cohort Study*
Graham Murray

Discussant: Abraham Reichenberg

1:30 PM - 3:30 PM

OXYTOCIN, SOCIAL COGNITION, AND SCHIZOPHRENIA

Location: Affari, Second Level
Chair: Robert W. Buchanan

Preclinical Assessment of Oxytocin's Ability to Modulate Social Behavior
James Koenig

Associations between Peripheral Oxytocin Levels and Impaired Social Cognition in Schizophrenia
Gregory Strauss

Impact of Prosocial Neuropeptides on Human Brain Function and Structure: Implications for Schizophrenia
Andreas Meyer-Lindenberg

Oxytocin and Social Cognition Training
Stephen R. Marder

Discussant: Shitij Kapur

1:30 PM - 3:30 PM

RESEARCH IN UNMEDICATED PATIENT POPULATIONS: INSIGHTS INTO THE NEUROBIOLOGY OF SCHIZOPHRENIA

Location: Affari, Ground Level
Chair: Peter Uhlhaas

*Medication-Naïve, First-Episode Schizophrenia Patients Show Increased Excitability of Neural Circuits:
Insights from Magnetoencephalography (MEG)*
Peter Uhlhaas

*Reward Processing, Dopamine D2/3 Receptor Binding, and Treatment Outcome: A Longitudinal Study of
Abnormalities in the Reward Circuit in Initially Antipsychotic-Naïve First-episode Schizophrenia Patients*
Birte Glenthøj

GABA and Glutamate as Potential Therapeutic Targets in Schizophrenia
Lawrence S. Kegeles

Chronic Antipsychotic Medication Exposure Changes the Brain Structure in Macaque Monkeys
Karl-Anton Dorph-Petersen

Discussant: William T. Carpenter

1:30 PM - 3:30 PM

SCHIZOPHRENIA RESEARCH: THE CHALLENGE OF MEASUREMENT VARIABILITY

Location: Affari, First Level
Chair: Janet B.W. Williams
Co-Chair: John M. Kane

Multi-site PET Imaging: Considerations for Appropriate Standardization
Ilan Rabiner

*Standardization of Magnetic Resonance Imaging Approaches in Neuropsychiatric Illness:
Challenges and Opportunities*
Alan Anticevic

Clinician-based Assessment of Psychiatric Diagnosis and Symptom Severity
Janet B.W. Williams

Sleep EEG Studies in Schizophrenia: Methodological Considerations
Matcheri Keshavan

Discussant: René S. Kahn


1:30 PM - 3:30 PM

SUMMARY, CLOSING SESSION AND POSTER AWARDS

Location: Auditorium
Chair: René Kahn

3:45 PM - 4:45 PM

Wednesday 09 April



POSTERS, SUNDAY 06 APRIL

12:00 PM - 2:00 PM

Location: Cavaniglia

1. *Further Evidence of the Effects of Childhood Abuse in First-episode Psychosis and Subclinical Psychosis*
Silvia Alemany, Rosa Ayesa-Arriola, Bárbara Arias, Mar Fatjó-Vilas, Manuel I. Ibáñez, Generós Ortet, Benedicto Crespo-Facorro, Lourdes Fañanás
2. *Cardiometabolic Adverse Effects of Second-generation Antipsychotics in Drug Naïve Children and Adolescents in Acute Care*
Marco Armando, Luigi Mazzone, Valeria Lucarelli, Valentina Postorino, Maria Laura Pucciarini, Nella Lo Cascio, Stefano Vicari
3. *Antipsychotic induced Movement Disorders in Long-stay Psychiatric Patients: A Prospective Study*
P.R. Bakker, Izaäk W. de Groot, Jim van Os, Peter N. van Harten
4. *Two Candidate Gene-Based Association Studies of Antipsychotic-induced Movement Disorders in Long-Stay Psychiatric Patients: Prospective Studies*
P.R. Bakker, Egbert Bakker, Asmar F.Y. Al Hadithy, Najaf Amin, Cornelia M. van Duijn, Jim van Os, Peter N. van Harten
5. *Gender Differences in the Effect of Childhood Trauma Experiences on Prodromal Symptoms and Personality Disorder Traits in Young Adults at High-risk for Psychosis*
Neus Barrantes-Vidal, Tecelli Domínguez-Martínez, Paula Cristobal, Tamara Sheinbaum, Thomas R. Kwapił
6. *Childhood Trauma Mediates the Association between Ethnic Minority Status and More Severe Hallucinations in Psychotic Disorder*
Akiah A.O. Berg, Monica Aas, Ole A. Andreassen, Ingrid Melle
7. *Meta-analysis of Changes in Brain Structure in Healthy Individuals with a History of Childhood Adversity*
Maria Calem, Matthew Kempton
8. *Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-treated Patients*
Bjørn H. Ebdrup, Filip K Knop, Anna Madsen, Henrik B. Mortensen, Birgitte Søgaard, Jens J. Holst, Pal B. Szecsi, Henrik Lublin
9. *Electronic Measurement of Movement Disorders: Validity and Reliability*
Thierry Q. Mentzel, Charlie Mentzel, Ritsaert Lieveise, Hein Daanen, Peter van Harten

10. *Polypharmacy to Counteract Antipsychotic-induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis*
Yuya Mizuno, Takefumi Suzuki, Atsuo Nakagawa, Kazunari Yoshida, Masaru Mimura, W. Wolfgang Fleischhacker, Hiroyuki Uchida
11. *The Joint Effect of Social Adversity in Childhood and in Adulthood on Predicting Psychosis*
Simona A. Stilo, Marta Di Forti, Charlotte Gayer-Anderson, Kathryn Hubbard, Ulrich Reininghaus, Antonella Trotta, Stephanie Beards, Helen Fisher, Valeria Mondelli, Robin M. Murray, Craig Morgan
12. *Increased Pre-synaptic Striatal Uptake of Dopamine as a Potential Mechanism of Antipsychotic Failure*
Davide Amato
13. *DNA Methylation and GABAergic Pathology of Schizophrenia*
Helene Aparecida Fachim, Umarat Srisawat, Michael Harte, Gavin Reynolds, Caroline Dalton
14. *Prenatal Immune Activation Impairs Synaptic Development in the Absence of Overt Glial Pathology*
Sandra Giovanoli, Urs Meyer
15. *A Mouse Model of 22q11 Deletion Syndrome Exhibits Deficits in Behaviors Relevant to the Core Domains of Schizophrenia*
Zoe A. Hughes, Radka Graf, Ashley Hanks, Susan Lotarski, Alexander I. More, Stacey Sukoff Rizzo, Liam Scott, Polina Stolyar
16. *Comparison of Phencyclidine-induced Deficits in Morris Water Maze Task and its Reversal by Sertindole between Wistar and Lister Hooded Rats*
Jouni Ihalaainen, Katja Savolainen, Jarkko Hiltunen, Markus M. Forsberg
17. *Are Dopamine Partial Agonist Antipsychotics Similar? Preclinical Comparison of Aripiprazole, Bifeprunox and Cariprazine*
Béla Kiss, István Gyertyán, Zsolt Némethy, Katalin Sághy, Judit Laszy, Károly Fazekas, Sándor Kolok, Zoltán Kapui
18. *Advanced Paternal Age as a Risk Factor for Schizophrenia: A Translational Study in Humans and Rats*
Axel Krug, Dominik Seffer, Henrike Rippberger, Bruno Dietsche, Heidelore Backes, Henriette Schneider-Haßloff, Rainer Schwarting, Tilo Kircher, Markus Wöhr
19. *Peripubertal High Fat Diet Exposure Leads to a Dopamine-dependent Disruption of Sensorimotor Gating in Adulthood*
Marie A. Labouesse, Ulrike Stadlbauer, Wolfgang Langhans, Urs Meyer



20. *Spreading Depression Mimics the Behavioral Features of Schizophrenia*

Mahmoud Lotfinia

21. *Characterization of a Mouse Model of the 1q21.1 Microdeletion Syndrome*

Jacob Nielsen, K.W. Fejgin, Sotty Florence, J.B. Lauridsen, V. Nielsen, D. Clausen, P.H. Larsen, I.V. Klewe, C.T. Christoffersen, M. Didriksen

22. *The Anti-anhedonic Properties of Lurasidone in the Chronic Mild Stress Model are Associated with Synaptic and Neuroplastic Changes in the Rat Prefrontal Cortex*

Marco A. Riva, Flavia Macchi, Andrea C. Rossetti, Mariusz Papp, Raffaella Molteni

23. *Upregulation of Striatal Dopamine D2 Receptors Results in Persistent Alterations in Pre-synaptic Dopamine Function*

Eleanor H. Simpson, Sabine Krabbe, Johanna Duda, Eric Kandel, Birgit Liss, Jochen Roeper

24. *Abnormal Stress Responsivity in a Rodent Developmental Disruption Model of Schizophrenia*

Eric C. Zimmerman, Mark Bellaire, Samuel Ewing, Anthony Grace

25. *Aberrant A-I RNA Editing Profile in the Brains of Schizophrenia Patients*

Ran Barzilay, Khen Khmermesh, Tali Ben-Zur, Abraham Weizman, Erez Levanon, Daniel Offen

26. *White Blood Cell Levels are related to Poor Social Functioning and Reduced Insula, Amygdala, and Nucleus Accumbens Volumes in a Subgroup of People with Schizophrenia*

Stu G. Fillman, Rhoshel Lenroot, Jason Bruggemann, Vibeke Catts, Stanley Catts, Maryanne O'Donnell, Cynthia Shannon-Weickert, Thomas Weickert

27. *The Inflammation Paradox: A Longitudinal Study Monitoring Biomarkers of Immune Function from Before Birth to After Diagnosis in Non-affective Psychosis Cases and Matched Controls*

Renee M. Gardner, Christina Dalman, Susanne Wicks, Brian Lee, Håkan Karlsson

28. *Immune Response to Stress in Postpartum Psychosis*

Annalisa Giordano, Astrid M. Pauls, Katie M. Hazelgrove, Costanza Vecchio, Valeria Mondelli, Mitul A. Mehta, Carmine M. Pariante, Susan Pawlby, Paola Dazzan

29. *Cerebrospinal Fluid Biomarkers for Schizophrenia Revealed by a cICAT Proteomic Analyses*

Kotaro Hattori, Yuichi Goto, Sumiko Yoshida, Daimei Sasayama, Toshi Komurasaki, Shigeyuki Chaki, Yasuyuki Fujii, Takao Yoshimizu, Hiroshi Kunugi

30. *Reverse-translating Biological Markers for DISC1-Associated Behavioral Disorders to Human Patients*

Laura Hecher, Svenja Trossbach, Verian Bader, Caroline Chwiesko, Magdalena Sauvage, Carsten Korth

31. *Neutrophin Brain-derived Neurotrophic Factor (BDNF) in Psychiatric Systemic Lupus Erythematosus*

Paulo Louzada-Junior, Leticia Tamashiro, Rene Oliveira, Elizabeth Comini Frota, Eduardo Donadi, Cristina Del-Ben, Antonio Teixeira

32. *Peripheral BDNF: A Candidate Biomarker of Healthy Neural Activity during Learning Is Disrupted in Schizophrenia*

Thomas Weickert, Ashley Skilleter, Ans Vercammen, Rhoshel Lenroot, Cynthia Weickert

33. *Reduced Deactivation in Medial Prefrontal Cortex during an Inner Speech Task in Schizophrenia Patients with Auditory Verbal Hallucinations*

Leonie Bais, Ans Vercammen, Henderikus Knegtering, André Aleman

34. *Impoverished High-Frequency Oscillatory Activity in Frontal Cortex in Individuals with Schizophrenia during Implicit Sequence Learning*

Bruno Biagiatti, Leighton Hinkley, Srikantan Nagarajan, Sophia Vinogradov

35. *Affective Theory of Mind and Its Relationship with Impaired Insight in Patients with Schizophrenia: An fMRI Study*

Annerieke de Vos, Marieke Pijnenborg, Daouia Larabi, Christine Hooker, Lisette van der Meer, André Aleman

36. *Simultaneous EEG-fMRI Study of Chronic Schizophrenic Patients with Auditory Hallucinations*

Beatriz Dionisio, Gracián García, Nicolás Peñaranda, Conrado J. Calvo, Francisco Olucha, Luis Martí-Bonmatí, Julio Sanjuán

37. *Self-reflection in Schizophrenia: A Preliminary Activation-likelihood Estimation Meta-analysis*

Clara S. Humpston, Anthony S. David, Ian Ellison-Wright

38. *Language-related Lateralization Before and After Antipsychotic Treatment in Prodromal or First-episode Psychosis: An fMRI Study*


Tzung-Jeng Hwang, Chia-Ta Chan, Tai-Li Chou, Chih-Min Liu, Chen-Chung Liu, Ming H. Hsieh, Yi-Ling Chien, Hai-Gwo Hwu

39. *Endogenous Testosterone Levels Are Associated with Neural Activity in Men with Schizophrenia during a Facial Emotion Processing Task*

Ellen Ji, Cynthia Shannon-Weickert, Ans Vercammen, Ashley Skilliter, Rhoshel Lenroot, Thomas Weickert

40. *Apathy Related Resting State Connectivity in Patients with Schizophrenia*

Nicky Klaasen, Edith Liemburg, Leonie Bais, Ans Vercammen, Jozarni Dlabac-de Lange, Marte Swart, Lisette van der Meer, Esther Opmeer, André Aleman



41. *Heritability of Brain Activity during Explicit Emotion Processing: A Study in Twins*
Daniela Marvulli, Tiziana Quarto, Raffaella Romano, Marina Mancin, Annamaria Porcelli, Barbara Gelao, Paolo Taurisano, Leonardo Fazio, Silvestro Trizio, Giuseppe Blasi, Alessandro Bertolino

42. *Comparison of Large-scale Human Brain Functional and Anatomical Networks in Schizophrenia*
Brent G. Nelson, Danielle Bassett, Jazmin Camchong, S. Charles Schulz, Kelvin Lim

43. *Brain's Functional Alterations in High Performance Schizophrenic Patients*
Fabrizio Parente, Alessia Mirigliani, Marianna Frascarelli, Annalisa Giordano, Fabio Di Fabio, Antonino Buzzanca, Francesca Caramia, Mariana Gallo, Giuseppe Blasi, Maria Chiara Torti, Massimo Biondi

44. *The Interaction between Variation in DRD2 and HTR2A Genes Predicts Prefrontal Function During Working Memory*
Pierluigi Selvaggi, Raffaella Romano, Leonardo Fazio, Paolo Taurisano, Antonio Rampino, Annabella Di Giorgio, Grazia Caforio, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino

45. *Development of Novel PET Ligands (PF-04831704 and PF-06327104) for PDE10A*
Karen M. Ward, Laigao Chen, Lei Zhang, Deborah Smith, Tom Chappie, Christopher Schmidt, Sarah Grimwood, Rebecca O'Connor, Stacey Rizzo, Klaas Schildknegt

46. *White Matter Perfusion Fraction in Schizophrenia and Deficits in Processing Speed*
Susan N. Wright, Joshua Chiappelli, Katie Nugent, Florian Muellerklein, Hemalatha Sampath, Pan Jiang, Laura Rowland, Danny J.J. Wang, Kavita Thangavelu, L. Elliott Hong, Peter Kochunov

47. *Brain Activation during Self-reflection in Schizophrenia Compared to Bipolar Disorder*
Li Wen Zhang, Esther Opmeer, Henricus Ruhe, Willem Nolen, André Aleman, Lisette van der Meer

48. *The Reproducibility of 1H-MRS Glutamate Concentration Estimates at 3 Tesla, Implications for Glutamate Imaging in Schizophrenia*
Kate S. Merritt, James M. Stone, Gareth J. Barker, Christopher A. Chaddock, Philip K. McGuire, Alice Egerton

49. *An Initial Report on Metabolic Defects in Recent Onset Schizophrenia with a 7 Tesla MRI Scanner: Link to Changes in Brain Temperature and Cognition*
Sotirios Posporelis, Mark Varvaris, Anouk Marsman, Jennifer Marie Coughlin, Susanne Bonekamp, Pearl Kim, Richard Edden, David J. Schretlen, Nicola Cascella, Peter B. Barker, Akira Sawa

50. *Effects of Glutamatergic Function on Membrane Lipid Turnover and Energy Metabolism – A Combined 1H- and 31P-MR Spectroscopic Imaging Study in Healthy Individuals*
Stefan Smesny, Alexander Gussew, Natalie Joan Biesel, Heinrich Sauer, Juergen Reichenbach

51. *Suicidality and Cortical Structure in Schizophrenia - Effects on Cortical Thickness and Folding*
Bianca Besteher, Claudia Schachtzabel, Gerd Wagner, Jürgen Reichenbach, Ralf Schlösser, Heinrich Sauer, C. Christoph Schultz

52. *Does Season of Birth Influence Cortical Thickness Correlates of Psychotic Experiences? A Genetically Informative MRI Study*
Aldo Cordova-Palomera, Silvia Alemany, Carles Falcón, Nuria Bargalló, Ximena Goldberg, Benedicto Crespo-Facorro, Igor Nenadic, Lourdes Fañanás

53. *Medial Frontal Gyrus Alterations in Schizophrenia: Relationship with Duration of Illness and Executive Dysfunction*
Marianna Frascarelli, Stefania Tognin, Alessia Mirigliani, Fabrizio Parente, Buzzanca Antonino, Maria Chiara Torti, Caramia Francesca, Fabio Di Fabio, Massimo Biondi, Paolo Fusar-Poli

54. *Brain Structural Abnormalities in Postpartum Psychosis: An MRI Study*
Montserrat Fusté, Astrid Pauls, Simone Reinders, Mitul Mehta, Andy Simmons, Steve Williams, Josep Maria Haro, Carmine Pariente, Paola Dazzan

55. *Prefrontal Cortex Volume in Patients with Schizophrenia is Correlated with Verbal Memory Performance*
Clarissa S. Gama, Leticia Czepielewski, Mariana Pedrini, Juliana Sartori, Marina Londero, Sandra Polita, Juliana Duarte, Pedro Goi, Mireia Vianna-Sulzbach, Paulo Belmonte-de-Abreu, Raffael Massuda

56. *Thalamic Volume Abnormalities Associated with Negative Symptoms Predating the Onset of Psychosis*
Fabienne Harrisberger, Renata Smieskova, André Schmidt, Stefan Borgwardt

57. *Emotion Recognition and Theory of Mind Are Related to Gray Matter Volume of the Prefrontal Cortex in Schizophrenia*
Arija Maat, Neeltje E.M. van Haren, Cali Bartholomeusz, René Kahn, Wiepke Cahn

58. *Serum Levels of Innate Immune Response Markers CCL22, CXCL1 and Apolipoprotein A1 Altered in First-episode Psychosis Associate with White Matter Volume and Integrity*
Teemu J.S. Mäntylä, Outi Mantere, Tuukka T. Raji, Tuula Kieseppä, Hanna Laitinen, Jaana Leiviskä, Minna Torniainen, Outi Vaarala, Jaana Suvisaari

59. *Decreased Grey Matter Volume as the Expression of Differential Sensitivity to Environmental Risk Exposure in Psychotic Disorder*
Machteld Marcelis, Aleida Frissen, Petra Habets, Ed Gronenschild, Jim van Os

60. *White Matter Alterations and Structural Connectivity in First-episode Antipsychotic-naïve Schizophrenia Patients*
Jayachandra Mitta Raghava, Bjørn H. Ebdrup, Mette Ødegaard Nielsen, Sanne Wulff, Egill Rostrup, Birte Glenthøj

61. *Heterogeneity of Brain Structural Changes across Subgroups of Schizophrenia: Cortical Thickness and Cortical Complexity Analyses*
Igor Nenadic, Rachel Yotter, Heinrich Sauer, Christian Gaser



62. *Schizotypal Traits and Psychosis Proneness Differentially Affect Brain Structure in Healthy Persons*

Igor Nenadic, Carsten Lorenz, Kerstin Langbein, Maren Dietzek, Raka Maitra, Stefan Smesny, Heinrich Sauer, Christian Gaser

63. *Reduced Hippocampal Volume in Male but Not Female Patients with First Episode Psychosis: Relationship to Cortisol Levels and Symptoms*

Marita Pruessner, Martin Lepage, Louis Collins, Ridha Joobor, Jens C. Pruessner, Ashok K. Malla

64. *Neuroanatomical Predictors of Functional Outcome in the At-risk Mental State*

Renate L. Reniers, Ashleigh Lin, Alison Yung, Nikolaos Koutsouleris, Barnaby Nelson, Dennis Velakoulis, Christos Pantelis, Stephen Wood

65. *Classification of Twins Discordant for Schizophrenia and Healthy Twins Based on Their Structural MRI Scans*

Hugo G. Schnack, Mireille Nieuwenhuis, Neeltje E.M. van Haren, Wiepke Cahn, René Kahn, Hilleke Hulshoff Pol

66. *The Polymorphism of YWHAЕ, a Gene Encoding 14-3-3epsilon, and Orbitofrontal Sulcogyral Pattern in Schizophrenia and Healthy Subjects*

Michio Suzuki, Yumiko Nakamura, Yukako Nakamura, Branko Aleksić, Yoichiro Takayanagi, Atsushi Furuichi, Mikio Kido, Kyo Noguchi, Kozo Kaibuchi, Norio Ozaki, Tsutomu Takahashi

67. *In Vivo Characterization of the PDE10A PET tracer [18F]MNI-659*

Gilles D. Tamagnan, Olivier Barret, Caroline Papin, David Alagille, David Thomae, Ronald Baldwin, Kenneth Marek, John P. Seibyl

68. *Grey Matter Volume Alterations in Patients with Schizophrenia and Unaffected Siblings Show Region-specific Effects of Genetic Risk and Disease-related Factors*

Silvestro Trizio, Giulio Pergola, Annabella Di Giorgio, Enrico D'ambrosio, Ileana Andriola, Barbara Gelao, Daniela Marvulli, Paolo Taurisano, Leonardo Fazio, Giuseppe Blasi, Alessandro Bertolino

69. *Structural Brain Abnormalities, Psychosocial Functioning, and Genetic Vulnerability for Schizophrenia*

Wanda Truong, Michael J. Spilka, Vina Goghari

70. *Is Gray Matter Volume a Structural Endophenotype for Schizophrenia?*

Iorien van der Velde, Paula Gromann, Marte Swart, Lieuwe de Haan, Richard Bruggeman, Durk Wiersma, Lydia Krabbendam, Andre Aleman

71. *Change in Intelligence Is Associated with Progressive Gray Matter Loss in the Early Years of Schizophrenia*

Neeltje E.M. van Haren, Sander Haijma, Wiepke Cahn, René Kahn

72. *Associations between Cortical Thickness and Trait Physical and Social Anhedonia in Non-clinical College Students*

Yi Wang, Yi Deng, Germaine Fung, Wen-hua Liu, Xin-hua Wei, Xin-qing Jiang, Eric Cheung, Raymond C. K. Chan

73. *Treatment and Outcome of Youth with Early-phase Schizophrenia-spectrum Disorders and Psychosis NOS: 12-Week Results from a Naturalistic Cohort Study*

Ditte Lammers Vernal, Sandeep Kapoor, Aseel Al-Jadiri, Yehonatan Borenstein, Marta Hauser, Eva Sheridan, Irmgard Borner, Maren Carbon, Christoph Correll

74. *Increased Risk of Schizophrenia Spectrum Disorders after all Childhood Psychiatric Disorders - Nationwide Study*

Cecilie F. Maibing, Michael Eriksen Benros, Merete Nordentoft, Søren Dalsgaard, Carsten Bøcker Pedersen

75. *Coping, Psychotic Symptoms and Functioning in Adolescents with Mental Illness*

Iohanna Wigman, Nina Devlin, Ian Kelleher, Aileen Murtagh, Michelle Harley, Anne Kehoe, Carol Fitzpatrick, Mary Cannon

76. *A Randomized Trial Administering Raloxifene vs Placebo as Add-on to Antipsychotics in Post-menopausal Female Patients with Schizophrenia or Schizoaffective Disorder*

Shimon Burshtein, Michael Davidson, Mark Weiser

77. *Risk-based Monitoring for Aberrant Rating Patterns and Patient Selection Anomalies in Global Schizophrenia Trials*

David G. Daniel, Alan Kott

78. *The Novel Pharmacology of ITI-007 Is Enhanced and Extended by Its Metabolic Back Conversion from IC200131*

Robert E. Davis, Joseph Hendrick, Lei Zhang, Wei Yao, Lawrence P. Wennogle, Hongwen Zhu, Gretchen L. Snyder, Kimberly Vanover, Sharon Mates

79. *Effectiveness of Integrated Cognitive Remediation Therapy for Schizophrenia Outpatients: Early Versus Long-term Course of Illness - Results from an International RCT*

Daniel R. Müller, Valentin J. Benzing, Volker Roder

80. *Understanding Social Situations (USS): Development of a New Social Cognitive Intervention for Individuals with Psychosis*

David L. Roberts, Laura Diggins, Lori Parente, Joanna Fiszdon

81. *Randomized Trial of Clozapine vs. Risperidone in Treatment-Naïve First-Episode Schizophrenia: Preliminary Results*

Francisco Javier Sanz-Fuentenebro, Diana Taboada, Vicente Molina



82. *Failures in the Facial Emotion Recognition in Patients with Schizophrenia, Siblings, and Control Subjects*

Ricardo Saracco-Alvarez, Ana Fresan, Raul Escamilla

83. *Paliperidone ER Treatment and the Improvement of Social and Cognitive Function in Patients with Schizophrenics - A 24-Week, Single Arm, Open-Label Study*

Chuan Shi, Xin Yu, Lan Kang, Shuqiao Yao, Xirong Tang, Yifeng Xu, Daihui Peng, Jianguo Shi, Huali Lin, Xiufeng Xu, Fang Liu, Congpei Zhang, Xijin Wang

84. *The Effect of Lifestyle Interventions on Psychosocial Functioning and Well-Being in Patients with Severe Mental Illness*

A.P.M. Stiekema, Anne Looijmans, Lisette van der Meer, Marian Dethmers, Robert Schoevers, Richard Bruggeman, Eva Corpeleijn, Frederike Jörg

85. *Ability to Shift to Voluntary Attention Strategies Affects Performance on a Covert Detection Task in Schizophrenia but Not for Comparison Participants*

Elizabeth Bryant, Mohammed M. Al-Uzri, Maria Dale, Vesna Acovski, Timothy Millward, Chris Stowers, Steven S. Shimozaiki

86. *Metabolic Syndrome in Young Patients with Schizophrenia Is Associated with Poor Cognitive Performance*

Wiepke Cahn, Jessica de Nijs, Milou Pet, GROUP Investigators

87. *Attentional Bias for Self-stigmatizing Stimuli in People with Schizophrenia Experiencing Habitual Self-stigma: Evidence from the Emotional Stroop Task*

Kevin K.S. Chan, Winnie W.S. Mak

88. *Prospective Memory Impairments in Patients with First-episode Schizophrenia: A 1-year Follow-up Study*

Raymond C.K. Chan, Simon S.Y. Lui, Ya Wang, Tian-xiao Yang, Yi Wang, Eric Cheung, David Shum

89. *Validation of the "Beliefs about Voices Questionnaire - Revised" (BAVQ-R) in French Speaking Switzerland*

Logos Curtis, Adriano Zanello, Maryse Badan Ba, Sylvia Mohr, Philippe Huguelet

90. *Relationship of Kremen1 Gene Variation with Symptomatology and Cognitive Functioning in Schizophrenia*

Banu Değirmencioglu, Dua Özsoylu, Güneş Can, Çiğdem Eresen Yazıcıoğlu, Berna Binnur Akdede, Köksal Alptekin

91. *Ecologically-valid Assessment of Attention in Schizophrenia in a Virtual Environment*

George Foussias, Ishraq Siddiqui, Krysta McDonald, Eliyas Jeffay, John Zawadzki, Albert Wong, Ofer Agid, Konstantine Zakzanis, Gary Remington

92. *Limited Literacy among People with Serious Mental Illness in the US and Australia: A Natural Experiment?*

Cherrie Galletly, Alisa Lincoln, Cassandra Burton, Tammi Arford, Christopher Prener, Dennis Liu

93. *AMPA-Receptor Modulators as Cognitive Enhancers in Schizophrenia: Why Are They So Difficult to Develop?*

Hugo Geerts, Athan Spiros, Patrick Roberts

94. *C-reactive Protein Levels are Inversely Associated with Neurocognitive Performance in Acutely Admitted Patients with Psychosis*

Erik Johnsen, Farivar Fathian, Rolf Gjestad, Hugo A. Jørgensen, Rune A. Kroken, Else-Marie Løberg

95. *Are Speech Illusions in a Healthy Sample Associated with Psychometric Risk for Schizophrenia?*

Richard J. Linscott, Max Nicolson, Sarah Morton, Jaimee Maha

96. *Social Cognition Anomalies in Autism and Schizophrenia: A Direct Comparison Using the French Version of Movie for the Assessment of Social Cognition (MASC)*

Gilles Martinez, Celia Mam-Lam-Fook, Patrica Garel, Marie-Odile Krebs, Isabelle Amado

97. *Time Perception Networks and Cognitive Dysfunction in Schizophrenia: A Meta-Analysis*

Felipe Ortuño, Jose Gómez, Natalia Ojeda, Francisco Guillen-Grima, Joaquim Radúa

98. *Affective Prosody in Psychosis: Recent Evidence and Future Directions*

Susan Rossell, Tamsyn Van Rheenen, Chris Groot

99. *The Association between Thought Disorder and Memory Impairments in First-episode Psychosis*

Silay Sevilmiş Demir, Esra Aydınli, Ahmet Ayer, Berna Yalınçetin, Berna Binnur Akdede, Köksal Alptekin

100. *Neurocognition, Social Cognition and Three-year Follow-up Social Functioning in Recent Versus Non-Recent Onset Psychosis*


Claudia Simons, Agna Bartels-Velthuis, Gerdina Pijnenborg

101. *Sarcasm Detection, Symptom Severity and Functional Outcome in Schizophrenia*

Arndis Simonsen, Vibeke Bliksted, Oddbjørg Johansen, Marjun Biskopstø, Andreas Roepstorff, Daniel Campbell-Meiklejohn, Ole Mors, Riccardo Fusaroli

102. *Insight into Illness, Cognitive Reasoning and Uncooperativeness in Chronic Schizophrenia*

Cynthia Siu, Ofer Agid, Mary Waye, Carla Brambilla, Wing-Kit Choi, Gary Remington, Philip D. Harvey



103. *High Educational Performance is a Distinct Feature of Bipolar Disorder compared to Schizophrenia*

Annabel Vreeker, Lucija Abramovic, Annet van Bergen, Sanne Verkooijen, BIG Investigators, GROUP Investigators, Anil Ori, Yoon Jung, Roel Ophoff, Marco Boks

104. *Childhood Trauma and Cognitive Impairments in Patients with Schizophrenia*

Seunghye Won, Do Hoon Kim, Jiwoo Kim, Taehoon Koo

105. *Disappearance of the Unmasking Effect of Temporally Pre-Presented Lipreading Cues on Speech Recognition in People with Chronic Schizophrenia*

Chao Wu, Liang Li, Chuan-Yue Wang

106. *The Relationship of Attitudinal Beliefs to Negative Symptoms, Neurocognition, and Daily Functioning in Recent-onset Schizophrenia*

Joseph Ventura, Kenneth L. Subotnik, Arielle Ered, Denise Gretchen-Doorly, Gerhard S. Hellemann, Anja Vaskinn, Keith H. Nuechterlein

107. *Dimensions of Delusions and Self-serving Bias along the Continuum of Psychosis*

Suzanne H. So, Venus Tang, Patrick Wing-leung Leung

108. *Instruments Evaluating Emotional Blunting in Schizophrenia Patients with Negative Symptoms: A Systematic Review*

Sanja Kilian, Anneke Goosen, Robin Emsley

109. *The Basel Interview for Psychosis: Structure, Reliability and Validity*

Anita Riecher-Rössler, Tamara Ackermann, Martina Uttinger, Sarah Ittig, Susan Koranyi, Charlotte Rapp, Hilal Bugra, Jacqueline Aston, Rolf-Dieter Stieglitz, Erich Studerus

110. *Redefining Schizophrenia Subtypes and Dimensions with Structural Brain Imaging: Unsupervised and Multivariate Learning Algorithms Applied to Diagnostic Nosology in Schizophrenia*

Geoffrey C. Tan, Carissa Nadia Kuswanto, Lye Yin Poon, Min Yi Sum, Guoliang Yang, Wieslaw Nowinski, Yi Yian Sitoh, John Ashburner, Swapna Verma, Kang Sim

111. *Characterizing Schizophrenia using Semantic Judgments and Body Quotients*

Bellon Thibaut

112. *Clinical Staging in People Diagnosed with Schizophrenia or a Related Disorder*

Eva Velthorst, Amy Tedja, Carin Meijer, Lieuwe de Haan, GROUP investigators

113. *A Novel Kv3 Positive Modulator Augments Gamma Frequency Oscillations in the Mammalian Neocortex In vitro*

Faiza Ben-Mabrouk, Giuseppe Alvaro, Charles Large, Fiona Lebeau, Mark Cunningham

114. *Pleiotropic Effect of Disrupted in Schizophrenia 1 Gene: Analysis of Event-related Potentials and Brain Structure*

Vincenzo deLuca, Gianfranco Spalletta

115. *Effects of Blocking D2 Receptors on Mismatch Negativity of Antipsychotic Naïve, First Episode Schizophrenia Patients*

Signe W. During, Bob Oranje, Birte Glenthoej

116. *Increasing Glutamate Release in a Genetic Model of Cognitive Deficits*

Antonietta Lavin, Darius Becker-Krail

117. *The Effect of Cognitive Training on Event-related Potentials in Schizophrenia*

Bernhard W. Müller, Daniela Kariofillis, Christian Kärger, Jens Wiltfang, Gudrun Sartory

118. *The Effect of Different Definitions of Schizophrenia*

Janne Tidselbak Larsen, Holger Jelling Sørensen, Liselotte Petersen, Ole Mors, Preben Bo Mortensen

119. *The Psychosis Recent Onset Groningen Survey (PROGR-S): Defining Dimensions and Improving Outcome in Early Psychosis*

Edith Liemburg, Slynke Castelein, Ellen Visser, Dick Smid, Erna Van 't Hag, Frank Van Es, Anne Neeltje Scholte, Gerard Van de Willige, Richard Bruggeman, Henderikus Kneegting

120. *Help-seeking Behaviour and At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey*

Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

121. *Mental Health Literacy: Is Psychosis as Well Recognized as Depression?*

Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

122. *Association between Epilepsy and Psychotic Disorders in the Northern Finland 1966 Birth Cohort Study*


Jouko Miettunen, Tanja Nordström, Emmi Keskinen, Johanna Uusimaa, Ina Rissanen, Matti Isohanni, Erika Jääskeläinen

123. *Sex Differences in Prevalence and Comorbid Substance Use Disorders among Patients with Schizophrenia and Bipolar Disorder: A Five-year Population-based Study*

Ragnar Nesvåg, Gun Peggy Knudsen, Inger Johanne Bakken, Anne Høy, Eivind Ystrøm, Pål Surén, Anne Reneflot, Camilla Stoltenberg, Ted Reichborn-Kjennerud

124. *Delay in Routinely Neonatal Blood Screening is Associated with Increased Risk of Schizophrenia*

Merete Nordentoft, Janne Larsen, Liselotte Petersen, Holger Sørensen, Mads Hollegaard, Preben Bo Mortensen, Carsten B. Pedersen



125. *Social Class and Psychosis*

Brian O'Donoghue, Felicity Fanning, John Lyne, Laoise Renwick, Kevin Madigan, Anthony Kinsella, Abbie Lane, Niall Turner, Eadbhard O' Callaghan, Mary Clarke

126. *Mental Health Literacy: Design of and Response to an Add-on Questionnaire Study to a Population Survey*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

127. *Prevalence of At-risk Criteria of Psychosis in Children and Adolescents, and in Young Adults: Results from Two Swiss Community Samples*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

128. *Risk of Schizophrenia Spectrum and Affective Disorders Associated with Small for Gestational Age Birth and Height in Adulthood*

Yoichiro Takayanagi, Liselotte Petersen, Thomas Laursen, Nicola Cascella, Akira Sawa, Preben Bo Mortensen, William Eaton

129. *Evidence for a Shared Etiological Mechanism of Psychotic Symptoms and Obsessive Compulsive Symptoms in Patients with Psychotic Disorders and Their Siblings*

Frank Van Dael, Marije Swets, Lieuwe de Haan, Jim van Os, Inez Myin-Germeys

130. *Premature Death is Higher in Persons with Psychotic Disorders but not with Psychotic Experiences: A Population-based Longitudinal Study*

Nomi Werbeloff, Bruce Dohrenwied, Itzhak Levav, Rinat Yoffe, Ziona Haklai, Mark Weiser

131. *Use and Abuse: The Role of Community Treatment Orders in an Intensive Outreach Team*

Carol Silberberg

132. *Copy Number Variant Analysis on 401 Cases of Schizophrenia: A Search for Causal Genes Finds Disruption in the Neurogenesis Regulator Jagged 2*

Joshua R. Atkins, Jing Qin Wu, Paul A. Tooney, Rodney J. Scott, Vaughan J. Carr, Murray J. Cairns

133. *Association of a Risk Allele of ANK3 with Cognitive Performance and Cortical Thickness in Patients with First-episode Psychosis*

Clifford M. Cassidy, Lisa Buchy, Michael Bodnar, Jennifer Dell'elce, Zia Choudhry, Sarojini Sengupta, Rebecca Fox, Srividya Iyer, Ashok Malla, Martin Lepage, Ridha Joobar

134. *Impact of the Schizophrenia Candidate Gene RGS4 on Psychosis-proneness*

Marta de Castro-Català, Neus Barrantes-Vidal, Elionora Peña, Thomas R. Kwapił, Paula Cristóbal-Narváez, Araceli Rosa

135. *Analysis of Neuritin1 Gene in Schizophrenia-spectrum and Bipolar Disorders: Its Influence on Age at Onset and Cognitive Functioning*

Mar Fatjó-Vilas, Claudia Prats, Edith Pomarol-Clotet, Luisa Lázaro, Carmen Moreno, Mara Parellada, Ana María González-Pinto, Generós Ortet, Peter McKenna, Lourdes Fañanás

136. *Relation of RGS4 Gene with Schizophrenia*

Emre Gulsu, Cigdem Eresen Yazıcıoglu, Sefa Kızıldag, Banu Degirmencioglu, Serhat Taslica, Koksak Alptekin

137. *Genetic Variations in Prefrontal Dopamine: Influences on Schizotypy and Cognition*

Caroline Gurvich, Erica Neill, Tamsyn Van Rheen, Stephanie Louise, Kiyomet Bozaoglu, Susan Rossell

138. *Spatio-temporal Protein Interaction Network Dynamics of 16p11.2 Genes*

Lilia M. Jakoucheva, Nick Guan Lin, Roser Corominas, Xinping Yang, Tong Hao, David Hill, Marc Vidal

139. *PLA2 Gene Expression in First Episode Drug Naive Patients*

Daniel S. Kerr, Mauricio Serpa, Leda L. Talib, Martinus Theodorus Van de Bilt, Juliana Alcantara, Tiffany Chaim, Geraldo Busatto, Marcus Zanetti, Wagner Gattaz

140. *The Influence of AH11 Variants on the Diagnosis and Treatment Outcome in Schizophrenia*

Jung Jin Kim, Jung Seo Yi, Seung Hyun Kim, Chi Un Pae

141. *Associations between Polygenic Risk Scores for Type 2 Diabetes Mellitus and Co-morbid Diabetes in a Sample of Subjects with Schizophrenia, Schizoaffective, or Bipolar I Disorders*

Jaya Padmanabhan, Neeraj Tandon, Chiara Haller, Ian Mathew, Gualberto Ruano, Andreas Windemuth, Brett Clementz, John Sweeney, Godfrey D. Pearlson, Carol Tamminga, Matcheri Keshavan

142. *Genetic Association Studies of Schizophrenia Risk Genes with Cognitive and Neuroimaging Traits in the GENUS Consortium Collection*

Tracey Petryshen, Gabriella Blokland, GENUS Consortium

143. *Interactive Effects of FKBP5 and Childhood Trauma on Cognition in Schizophrenia*


Alessandra Raudino, Vaughan J. Carr, Murray J. Cairns, Chris Oldmeadow, Paul A. Tooney, Rodney J. Scott, Melissa J. Green

144. *Neurodevelopment Genes Are Differentially Expressed in Blood of Subjects at Ultra High Risk (UHR) to Psychosis Compared to Controls and First Episode of Psychosis (FEP) Patients*

Marcos L. Santoro, Ary Gadelha, Vanessa Ota, Graciele Cunha, Elson Asevedo, Cristiano Noto, Pedro Pan, Quirino Cordeiro, Elisa Brietzke, Rodrigo Bressan, Sintia Belangero

145. *Health-related Quality of Life Outcomes among Patients with Schizophrenia: Results from a Long-term Naturalistic Trial of Patients Switching to Lurasidone from Other Antipsychotics*

Krithika Rajagopalan, Mariam Hassan, A. George Awad, Jay Hsu, Andrei Pikalov, Antony Loebel



146. *Alexithymia and Emotion Regulation Strategies in First-degree Relatives of Schizophrenia Patients*

André Aleman, Jorien van der Velde, Paula Gromann, Marte Swart, Lieuwe de Haan, Durk Wiersma, Lydia Krabbendam, Richard Bruggeman

147. *Eye Movement Abnormalities in Adults with an At-risk Mental State for Psychosis*

Sabine Bosch, Erich Studerus, Martina Papmeyer, Anita Riecher-Rössler

148. *Social Cognition, Language, and Social Functioning in 7 Year Old Children with Familial High Risk for Developing Schizophrenia Spectrum Disorder or Bipolar Disorder. Part of the High Risk and Resilience Study - VIA 7*

Camilla Austa Jerlang Christiani, Jens Richardt Jepsen, Anne A. E. Thorup, Nicoline Hemager, Aja Greve, Ditte L. Gantriis, Ditte L. Ellersgaard, Mette Skjærbæk, Ole Mors, Kerstin J. Plessen, Merete Nordentoft

149. *Dysfunctional Emotion Regulation as a Vulnerability Marker for Psychosis: The Twinsscan China Study*

Francesca A. Cotier, Lu Hua Chen, Winifred Mark, Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Touloupoulou

150. *Hypothalamic-pituitary-adrenal Axis Dysfunction: An Early Marker of Psychosis Vulnerability?*

Alexis E. Cullen, Hannah Dickson, Ruth Roberts, Patricia Zunszain, Carmine Pariante, Kristin Laurens

151. *Neurocognitive Profiles in 7-year-old Offspring of Parents with Schizophrenia or Bipolar Disorder. Part of the High Risk and Resilience Study - VIA 7*

Nicoline Hemager, Jens Richardt Møllegaard Jepsen, Anne Amalie Elgaard Thorup, Camilla Austa Jerlang Christiani, Aja Neergaard Greve, Ditte Lou Gantriis, Ditte Vestbjerg Ellersgaard, Ole Mors, Merete Nordentoft, Kerstin J. Plessen

152. *Psychosis Risk in Adolescence: Clinical Baseline Differences between Prodromal and Familial High Risk Samples*

Daniel Ilzarbe, Gisela Sugranyes, Inmaculada Baeza, Elena De la Serna, Soledad Romero, Vanessa Sanchez-Gistau, Montserrat Dolz, Josefina Castro Fornieles

153. *Clinical and Functional Course of Youths at Ultra-high Risk for Psychosis: Outcomes of Non-converters in Japan*

Masahiro Katsura, Noriyuki Ohmuro, Chika Obara, Tatsuo Kikuchi, Yumiko Hamaie, Emi Sunakawa, Fumiaki Ito, Tetsuo Miyakoshi, Atsushi Sakuma, Hiroo Matsuoka, Kazunori Matsumoto

154. *Emotional Dysregulation, Attributional Bias, Neurocognitive Impairment in Ultra-high Risk for Psychosis and Schizophrenia: It's Association with Paranoia*

Namwook Kim, Jin Young Park, Yun Young Song, Seo Yeon Baek, Jee In Kang, Eun Lee, Suk Kyo An

155. *Prediction of Psychopathology and Functional Impairment by Positive and Negative Schizotypy in the Chapmans' Ten-year Longitudinal Study*

Thomas R. Kwapil, Georgina Gross, Paul Silvia, Neus Barrantes-Vidal

156. *Speech Illusion, Perceived Social Standing and Self-esteem in Psychosis Proneness: The TwinsScan China Study*

Cecilia N.W. Leung, Emma Li, Francesca Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothea Touloupoulou

157. *The Course of Neurocognitive Functioning in Helpseeking Individuals: Comparison of Risk for Psychosis and Bipolar Disorder Criteria*

Sibylle Metzler, Diane N. Dvorsky, Christine Wyss, Mario Müller, Nina Traber-Walker, Susanne Walitza, Anastasia Theodoridou, Wulf Rössler, Karsten Heekeren

158. *Cannabis Use and Neuropsychological Functioning in Ultra-high Risk for Developing Psychosis in Child and Adolescent Patients and Healthy Controls*

Marta Pardo, Anna Sintes, Olga Puig, Clara Espelt, Elena De la Serna, Marta Rodríguez, Marta Espadas, Marta Carulla, Inmaculada Baeza, Montserrat Dolz

159. *Functional Impairment in Children and Adolescents with Psychosis Risk Syndrome: Social and Role Functioning Compared with Controls and Relationships to Prodromal Symptoms*

Olga Puig, Inmaculada Baeza, Elena De la Serna, Anna Sintes, Clara Espelt, Jordina Tor, Gisela Sugranyes, Vanessa Sánchez-Gistau, Mireia Rosa, Marta Pardo, Montserrat Dolz

160. *Review of False Negatives with the Comprehensive Assessment of At-risk Mental State (CAARMS) Screening*

Sujatha Rao, Lay Keow Lim, Lye Yin Poon, Spencer Yuen, Santha Pariyasami, Sarah Ann Tay, Swapna Verma

161. *A Joint Latent Class Modelling Approach for the Prediction of Psychosis by Basic Symptom and Ultra-high Risk Criteria*

Stefanie J. Schmidt, Stephan Ruhrmann, Benno G. Schimmelmann, Joachim Klosterkötter, Frauke Schultze-Lutter

162. *Deficits in Fine Motor Skills in Emerging Psychosis*

Fabienne S. Soguel-dit-Piquard, Erich Studerus, Martina Papmeyer, Ittig Sarah, Uttinger Martina, Avinash Ramyeed, Susan Koranyi, Anita Riecher-Rössler

163. *What Happens in the Brain When Psychosis Proneness Subject Undergoes Psychiatric Treatment for 2 Years?*

Je-Yeon Yun, Tae Young Lee, Sung Nyun Kim, Joon Hwan Jang, Do-Hyung Kang, Jun Soo Kwon

164. *Duration of Untreated Psychosis and Negative Symptoms; A Systematic Review and Meta-analysis of Individual Patient Data*

Nynke Boonstra, Rianne Klaassen, Lex Wunderink, Sjoerd Sytema, Max Marshall, Lieuwe de Haan, Durk Wiersma



165. *Apathy but not Diminished Expression in Schizophrenia is Associated with Discounting of Monetary Rewards by Physical Effort*

Matthias N. Hartmann, Oliver M. Hager, Anna V. Reimann, Matthias Kirschner, Justin R. Chumbley, Philippe N. Tobler, Stefan Kaiser

166. *Is Quality of Life Related to Cognitive Performance or Negative Symptoms in Patients with Schizophrenia? Results from a Double-Blind, Active-Controlled, Lurasidone Continuation Study*

Philip D. Harvey, Antony Loebel, Josephine Cucchiari, Debra Phillips, Cynthia Siu

167. *Negative Symptoms: Review from a Life Course Approach*

John Paul Lyne, Mary Clarke

168. *Spanish Adaptation and Validation of the Brief Negative Syndrome Scale*

Anna Mane Santacana, Clemente Garcia-Rizo, Daniel Berge, Mari Paz Garcia-Portilla, Leticia Garcia, Gisela Sugranyes, Miguel Bernardo, Julio Bobes, Emilio Fernandez-Egea

169. *Verbal Memory, but not Working Memory as Cognitive Marker of Negative Symptoms in Patients with First Episode of Psychosis*

Gisela Mezquida, Bibiana Cabrera, Miquel Bioque, Clemente García-Rizo, Cristina Oliveira, Ana Meseguer, Miguel Bernardo

170. *Identifying Negative Symptoms in Schizophrenia and Association with Clinical Outcomes Using Natural Language Processing*

Rashmi Patel, Nishamali Jayatilke, Richard Jackson, Hitesh Shetty, Robert Stewart, Philip McGuire

171. *Dissociation of Anticipatory and Consummatory Pleasure in Schizophrenia*

Chao Yan, Qi-feng Yin, Simon S.Y. Lui, Lai-quan Zou, Fu-chun Zhou, Deng-tang Liu, Raymond C.K. Chan

172. *Alteration of the Expression Balance of hnRNP C1 and C2 Changes the Expression of Myelination- and Schizophrenia-related Genes in the Human Oligodendrocytic Cell Line*

Keiko Iwata, Hideo Matsuzaki, Takayuki Manabe, Daniel Martins-de-Souza, Nori Takei

173. *Metabotropic Glutamate Receptor 5 Dysregulation in Schizophrenia*

Kelly Newell, Natalie Matosin, Francesca Fernandez-Enright, Xu-Feng Huang

174. *Stress, Cortisol and Pituitary Volume during Psychosis*

Dorte Nordholm, Merete Nordentoft, Lasse Randers, Valeria Mondelli, Mette Ø Nielsen, Sanne Wulff, Kristine Krakauer, Paola Dazzan, Henrik Nørbak-Emig, Egill Rostrup, Birte Glenthøj

175. *The Erythrocyte Membrane Lipid Abnormalities Observed in Schizophrenia Patients Support the Oxidative Stress Hypothesis in Schizophrenia*

Philippe Nuss, Cédric Tessier, Haifa Bergaoui, Ariel Fragerman, Antonin Lamaziere, Marc De Hert

176. *Uniquely Targeted Molecular Therapeutic for Schizophrenia: Characterization of ITI-007 in Vitro and in Vivo Animal Models*

Lawrence P. Wonnogle, Gretchen L. Snyder, Robert E. Davis, Kimberly Vanover, Joseph Hendrick, Peng Li

177. *Proteomic and Genomic Analyses Implicate the Postsynaptic Density in Schizophrenia*

Melanie Foecking, Lorna M. Lopez, Jane English, Patrick Dicker, Gerard Cagney, David Cotter

178. *Left Parietal Lobe Arachnoid Cyst in a Patient with Psychosis: Case Report*

Arnab K. Ghosh, Richard Cuthbert Mellor

179. *Gene Expression throughout Human Postnatal Development in Single Cell Populations in the Prefrontal Cortex*

Tsung-Ung W. Woo, Emily A. Kohlbrenner, Sarah A. Mauney

180. *Dynamic Causal Modelling of Abnormal Frontal Evoked Gamma Band Activity in Patients with Schizophrenia*

Alvaro Diez, Siri M. Ranlund, Harriet Brown, Rick A. Adams, Muriel Walshe, Robin M. Murray, Karl Friston, Dimitris Pinotsis, Elvira Bramon

181. *Greater Leftward Frontal Alpha Activation during Criticism is Associated with Schizotypal Traits and Anxiety*

Preethi Premkumar, Miguel Espirito-Santo, Juliana Onwumere, Veena Kumari, Maddie Groom, Elizabeth Kuipers

182. *The Effect of Reboxetine and Haloperidol on Sensory Gating in Healthy Humans and Rats*

Louise M. Witten, Birte Glenthøj, Jesper Bastlund, Arne Mørk, Björn Steiniger-Brach, Bob Oranje

183. *Chronic Social Defeat Stress Induces Increased Expression of D2-dimmer in the Prefrontal Cortex of Mice*

Tarique R. Bagalkot, Hong-Mei Jin, Yin Cui

184. *Meta-analysis of 'Learning Potential' on the Dynamic Wisconsin Card Sorting Test (D-WCST): Distinct Cognitive Subgroups with Divergent Functional Outcomes*


Joseph Bisogno, Josh Mervis, Jimmy Choi

185. *Attribution of Mental States during Conversation in Schizophrenia: Profile of Poor Mentalisers*

Maud Champagne-Lavau, Hélène Wilquin, Catherine Faget, Florence Vaillant, Stéphane Rauzy, Laurent Boyer, Christophe Lançon

186. *Cognitive Performances of Juvenile Offenders with Severe Psychiatric Disorders*

Stéphanie Charles, Gaëlle Grajek, Nelson Provost, Audrey Pauwels, Anu Raevuori, Laurent Servais



187. *At-risk States in Psychosis: Schizophrenia Proneness Instrument (SPI-A / SPI-CY) and its Neuropsychological Correlates*

Diane N. Dvorsky, Sibylle Metzler, Mario Müller, Christine Wyss, Karsten Heekeren, Susanne Walitza, Wulf Roessler, Anastasia Theodoridou

188. *The Role of Cognitive Reserve in Predicting Neuropsychological Outcome in Schizophrenia*

Wanping Huang, Jimmy Lee, Max Lam, Attilio Rapisarda, Michael Kraus, Richard S.E. Keefe

189. *Neurocognitive Functioning of Subjects with Putative Pre-psychotic States and Early Psychosis: Baseline Assessment and 1-year Follow-up*

Chen-Chung Liu, Mau-Sun Hua, Hai-Gwo Hwu

190. *Screening for Cognitive Impairment in Chronic Schizophrenia using the Cognigram Cognitive Assessment System*

Paul Maruff, Peter Snyder, Judy Jaeger

191. *The Chicken or the Egg? - An Investigation of Cognitive and Non-Cognitive Impairments in Schizophrenia in the Light of Goal-directed Behaviours' Implementation*

Rinaldi Romina, Lefebvre Laurent

192. *Examining the Impact of Neurocognitive and Language Impairments on Formal Thought Disorder in Schizophrenia*

Eric Tan, Gregory Yelland, Susan Rossell

193. *Social Cognition Training for People with Schizophrenia: A Randomised Study*

Matteo Cella, Rumina Taylor, Emese Csipke, Charles Heriot-Maitland, Til Wykes

194. *Roll-out and Impacts of DJ's Choices Workshops*

Marie-France Demers, Julie Bourbeau, Julie Bouchard, Claudia Lévesque, Lysanne Gauthier, Marc-André Roy

195. *Prevention of Weight Gain in Early Psychosis: A Randomized Controlled Clinical Trial of 16-Week Stepped Behavioral Intervention*

Rohan Ganguli, Sabrina Hassan, Mehreen Bhamani, Todd Jenking

196. *Community-based Skills Training Helps Psychotic Clients of Varying Ages, Educational Level, and Work Experience Make Functional Gains*

Alice Medalia, William Jock, Alicia Ventresca, Tiffany Herlands

197. *Enhancing Cognitive Training through Aerobic Exercise after a First Schizophrenia Episode: Theoretical Conception and Pilot Study*

Keith H. Nuechterlein, Joseph Ventura, Denise Gretchen-Doorly, Sarah C. McEwen, Sophia Vinogradov, Kenneth L. Subotnik

198. *Is Cortical Thickness Associated to Responsiveness to Cognitive Remediation Therapy in Schizophrenia?*

Rafael Penadés, Rosa Catalán, Núria Pujol, Clemente García-Rizo, Guillem Massana, Carme Junqué, Miquel Bernardo

199. *REFLEX: A Metacognitive Group Treatment to Improve Insight in Psychosis*

Gerdina Pijnenborg, Annerieke De Vos, Liset Van der Meer, Esther Sportel, Claudi Bockting, Mark van der Gaag, Andre Aleman

200. *A Three Month Follow Up Study Evaluating Clinical Change and Attitudes towards Involuntary Admission in Individuals Detained Under the Mental Health Act 2001*

Emma Bainbridge, Brian Hallahan, David McGuinness, Agnes Higgins, Kathy Murphy, Colm McDonald

201. *Stability of Retrospective Self-reports of Childhood Trauma in Early Psychosis*

Sarah Bendall, Samantha Simpson, Gennady Baksheev, Belinda Garner, Christina Phassoulitis, Lisa Phillips

202. *Characterization of a Number of Atypical Antipsychotics In-vitro*

Claus T. Christoffersen, K. Holm, A. Ruskov-Nielsen, J. Nielsen

203. *Increased Autonomic Arousal: Is it a Vulnerability Factor and Specific for Psychosis?*

Annika Clamor, Maike Hartmann, Ulf Köther, Christian Otte, Steffen Moritz, Tania Lincoln

204. *Non Psychotic Pregnancy Denial: A Case Report*

Ester di Giacomo, Tommaso Tabacchi, Fabrizia Colmegna, Susan Pawlby, Barbara Pucci, Patrizia Vergani

205. *Examining and Contrasting the Social Stereotype of Schizophrenia and Depression*

Ross G.M. Norman, Elizabeth Hampson, Richard Sorrentino, Yang Ye, Yxian Li

206. *Vitamin D Deficiency in Dutch Outpatients with Bipolar Disorder, Schizoaffective Disorder or Schizophrenia*

Peter F.J. Schulte, Remco Boerman, Dan Cohen

207. *Accumulated Environmental but not Genetic GWAS-derived Risk Determines Schizophrenia Onset*

Beata Stepniak, Sergi Papiol, Christian Hammer, Martin Begemann, Anna Ramin, Sarah Everts, Lena Hennig, Hannelore Ehrenreich

208. *Beliefs about the Concept of Schizophrenia in the Argentinian Population*

Laura N. Vanadia, Noelia Johanna Benschart, Raimundo Juan Muscellini



209. *Effects of Object Size and Distance on Reach-to-grasp Movement in Patients with Schizophrenia and Healthy Controls*

Shu-Mei Wang, Li-Chieh Kuo, Wen-Chen Ouyang, Hsiao-Man Hsu, Hui-Ing Ma

210. *Maori Patients with Schizophrenia: How to Improve their Rehabilitation and Recovery*

Nicoletta Clementi, Alison Brown, Ellen Norman

211. *Treatment Outcomes, Insight and Recovery in First-episode Schizophrenia*

Ofer Agid, Cynthia Siu, Philip D. Harvey, Robert Zipursky, Gagan Fervaha, George Foussias, Krysta McDonald, Gary Remington

212. *Sexual and Physical Trauma and the Social and Vocational Functioning in First-episode Psychosis Patients*

Luis Alameda, Carina Ferrari, Philipp Baumann, Margot Fournier, Hélène Moser, Mehdi Mohammad Gholam-Razaei, Kim Q. Do, Philippe Conus

213. *Perfectionism and Working Alliance in a Cognitive-behavioral Intervention for Weight Loss in Psychotic Illness*

Sabrina Hassan, Rohan Ganguli, Gordon Flett, Amanda Suleiman, Paul Hewitt

214. *Remission Criteria and Functional Outcome in Schizophrenia Patients, a Longitudinal Study*

Henriette Heering, Mayke Janssens, Lindy Boyette, Neeltje E.M. van Haren, GROUP authors

215. *Effects of Cannabis Use on Clinical and Psychosocial Outcomes in First-episode Psychosis*

Anna Kolliakou, Hannah Sallis, Antonella Trotta, Jennifer O'Connor, Marta Di Forti, Anthony S. David, Robin M. Murray

216. *Vitamin D as a Predictor of Illness Severity at One Year in First Episode Psychosis*

John Lally, Poonam Gardner-Sood, Oliver Howes, Stefania Bonaccorso, Shubulade Smith, Marta Di Forti, Robin M. Murray, Fiona Gaughran

217. *Comparison of Characteristics of Psychosis Patients with and without Hospitalization at First Episode*

Edwin Lee, Christy L.M. Hui, W.C. Chang, Sherry K.W. Chan, Eric Y.H. Chen

218. *Meta-analysis shows that the Level of Cannabis Use Determines the Risk of Psychosis*

Marta Di Forti, Arianna Marconi, Robin M. Murray, Cathryn Lewis, Evangelos Vassos

219. *The Relationship between Neurocognition and Real Life Functioning in First-episode Schizophrenia: Results from the 2-year Follow-up in the Oslo Longitudinal Recovery Study*

Anne-Kari Torgalsboen, Christine Mohn, Nikolai Czajkowski, Bjørn Rishovd Rund

220. *Premorbid Cannabis Use and Earlier Age at Onset of Psychosis: Findings from Two Studies in the U.S.*

Michael T. Compton, Mary Kelley, Beth Broussard, Claire Ramsay Wan

221. *Suicidality in Schizophrenia Spectrum Disorders: Relation to Hallucinations and Persecutory Delusions*

Eirik Kjelby, Igne Sinkeviciute, Rolf Gjestad, Rune Andreas Kroken, Else-Marie Løberg, Hugo A. Jørgensen, Erik Johnsen

222. *Disturbed Bodily Experiences in Patients with First-episode Schizophrenia*

Lene Nyboe, Poul Videbech

223. *Association between Subtle Dyskinesia and Schizotypy in Subjects with Auditory Verbal Hallucinations and Healthy Controls*

Anne E. Willems, Diederik Tenback, Jeroen Koning, Peter Van Harten

224. *Cortisol Levels in Early Psychosis: Systematic Review and Meta-analysis*

Boris Chaumette, Oussama Kebir, Thérèse Jay, Marie-Odile Krebs

225. *Predicting Psychosis in a General Adolescent Psychiatric Sample*

Maija Lindgren, Marko Manninen, Hely Kalska, Ulla Mustonen, Taina Laajasalo, Kari Moilanen, Matti Huttunen, Tyrone D. Cannon, Jaana Suvisaari, Sebastian Therman

226. *Neural Networks Involved in Self-referential Processing and Perspective Taking in Healthy People: Its Association with Theory of Mind Ability and Anomalous Self Experience*

Kyoungri Park, Hye Yoon Park, Minji Bang, Suk Kyoan An

227. *Remembering Daily Cognitive Functioning in Subjects at Ultra-high Risk for Psychosis: A Cross-Sectional Study on Everyday Manifestations of Cognitive Deficits in an Ultra-high Risk Cohort*

Lasse Randers, Birgitte Fagerlund, Jens R.M. Jepsen, Dorte Nordholm, Kristine Krakauer, Birte Y. Glenthoj, Merete Nordentoft

228. *The Association between Reported Childhood Trauma, Perceived Parenting and Psychopathological Risk*

Attilio Rapisarda, Guo Quan Ryan Nah, Vidhya Renjan, Max Lam, Jimmy Lee

229. *Dosing and Clinical Strategies of Paliperidone ER in Acutely Exacerbated Schizophrenia: An Expert Consensus in Taiwan*

Ya Mei Bai, Yao Hung, Chia Yi Liu, Y.C. Yen, M.W. Huang, S.W. Wu, C.C. Chiu, M.H. Hsieh, W.T. Kao, Y.S. Lee

230. *Natural Medicines in Schizophrenia: A Systematic Review*

Agna A. Bartels-Velthuis, Rogier Hoenders, Nina Vollbehre, Richard Bruggeman, Rikus Kneegtering, Joop de Jong

231. *Treatment of Violent Dissocial Personality Disorder Patients with Clozapine Requires Lower Dose and Therapeutic Levels than in Schizophrenia*

Darcy Brown, Fintan Larkin, Samrat Sengupta, Jose Romero, Callum Ross, Morris Vinestock, Mrigendra Das



232. *Efficacy of Second-versus First-generation Antipsychotic Drugs for Treatment-resistant Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials*
Markus Dold, Stefan Leucht

233. *All-cause Discontinuation and Safety of Aripiprazole Once-monthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials*
Anna Eramo, W. Wolfgang Fleischhacker, Raymond Sanchez, Lan-Feng Tsai, Timothy S. Peters-Strickland, Ross A. Baker, Dusan Kostic, John M. Kane

234. *Resting Cerebral Blood Flow (rCBF) in First Episode Psychosis and Changes Induced by Antipsychotic Medication*
Rhianna M. Goozee, Fernando Zelaya, Rocio Perez-Iglesias, Alice Egerton, Kyra Verena Sendt, Simone Reinders, Philip McGuire, Paola Dazzan

235. *Lifetime Use of Antipsychotic Medication and Change of Verbal Learning and Memory in Schizophrenia in 9-years Follow-up in a General Population Sample*
Anja Husa, Irina Rannikko, Jani Moilanen, Marianne Haapea, Graham Murray, Jennifer Barnett, Peter B. Jones, Matti Isohanni, Hannu Koponen, Jouko Miettunen, Erika Jääskeläinen

236. *Correlation between Expected and Effective Plasma Concentrations of Antipsychotics and Changes in Psychopathology in Patients with Schizophrenia*
Alexandra Kaufmann, M.A. Rettenbacher, N. Yalcin-Siedentopf, F. Biedermann, C.G. Widschwendter, M. Edlinger, G. Kemmler, S.W. Toennes, W.W. Fleischhacker, A. Hofer

237. *Simulation of Dopamine D2 Receptor Occupancy by Aripiprazole in Steady State: Based on PK-PD Modeling*
Euitae Kim, Bo-Hyung Kim, In-Jin Jang, Jae Min Jeong, Jun Soo Kwon

238. *Pharmacological Modulation of Kv3 Potassium Channels on Parvalbumin-positive Fast-spiking Interneurons – A Novel Approach to the Treatment of Schizophrenia*
Charles Large, Marcelo Rosato-Siri, Caterina Virginio, Erica Zambello, Chiara Mutinelli, Giuseppe Alvaro

239. *AZD8529, A Positive Allosteric Modulator at the mGluR2 Receptor, Does Not Improve Symptoms in Schizophrenia: A Proof of Principle Study*
Robert E. Litman, Mark A. Smith, Jim Doherty, Alan Cross, Shaine Raines, Stephen Zukin

240. *Oxytocin and Psychosis: Exploratory Meta Analysis of Randomized Controlled Trials*
Angus M. MacBeth, Andrew Gumley, Christine Braehler

241. *The Position of Blonanserin as a Treatment for Schizophrenia: Evidence from Meta-analysis of Randomized, Placebo-controlled Trials*
Yuki Matsuda, Taro Kishi

242. *The Subjective Treatment Satisfaction of Switching Antipsychotics in Japanese Patients with Schizophrenia; J-BETA (Japan-broad Effectiveness Trial of Aripiprazole)*
Masatsugu Moriwaki, Nakao Iwata

243. *Clozapine Treatment in Pediatric Onset Schizophrenia: Lessons from the NIMH Experience*
Anna E. Ordóñez, David I. Driver, Mark Orloff, Jerry Overman, Deanna Greenstein, Diane Dillard-Broadnax, Judith Rapoport, Nitin Gogtay

244. *Consultant Psychiatrists' Perspectives Regarding Antipsychotic Dose Choice and Plasma Concentration Therapeutic Drug Monitoring*
Maxine X. Patel, Suzanne Law, Lauren A. Best-Shaw, Maria Gudbrandsen, Nusrat Husain, Imran B. Chaudhry, Richard Drake, Anthony S. David, Peter M. Haddad

245. *Long-term Safety and Effectiveness of Lurasidone in Schizophrenia: Results of a 22 Month, Open-label Extension Study*
Andrei Pikalov, Christoph Correll, Josephine Cucchiaro, Robert Silva, Jay Hsu, Antony Loebel

246. *Effects of Duration of Illness on Therapeutic Response to Adjunctive Treatment with N-acetyl Cysteine in Schizophrenia*
Marta Rapado-Castro, Michael Berk, Kamallesh Venugopal, Ashley Ian Bush, Seetal Dood, Olivia M Dean


247. *A Randomized, Active-controlled Rater-blinded 2-year Study of Paliperidone Palmitate Versus Investigators' Choice of Oral Antipsychotic Monotherapy in Patients with Schizophrenia (PROSIPAL)*
Andreas Schreiner, Kaire Adamsoo, Carlo Altamura, Manuel Franco, Philip Gorwood, Nikolay G. Neznanov, Juan Schronen, Alp Üçok, Mathias Zink, Marjolein Lahaye, Ludger Hargarter

248. *Flexibly Dosed Paliperidone Palmitate in Non-acute Patients with Schizophrenia Previously Unsuccessfully Treated with Conventional Depot Antipsychotics*
Andreas Schreiner, Ludger Hargarter, Pierre-Michel Llorca, Behcet Cosar, Antonino Petralia, Paul Bergmans, Pierre Cherubin

249. *Is Once Daily Dosing of Perphenazine Clinically Feasible?*
Hiroyoshi Takeuchi, Gagan Fervaha, Hiroyuki Uchida, Takefumi Suzuki, Robert Bies, David Grönte, Gary Remington

250. *Prescription Patterns Prior to Clozapine Initiation in First-episode Psychosis*
Charmaine Tang, Swapna Verma, Mythily Subramaniam, Boon Tat Ng, Edimansyah Abidin, Lye Yin Poon

251. *Prognostic Factors for Treatment Resistance in Schizophrenia*
Theresa Wimberley, Henrik Støvring, James H. MacCabe, Holger Sørensen, Christiane Gasse



252. *Objective Measurement of Compliance and Attitude toward Treatment in Patients with Schizophrenia*

Nursen Yalcin-Siedentopf, Maria Rettenbacher, Alexandra Kaufmann, Susanne Baumgartner, Falko Biedermann, Monika Edlinger, Georg Kemmler, Christian G. Widschwendter, Wolfgang W. Fleischhacker, Alex Hofer

253. *Show Me the Money Revisited: Monetary Reinforcement versus Intrinsic Reward for Learning in Schizophrenia*

Jimmy Choi, Joanna Fiszdon, Steven Silverstein, Deanna M. Barch

254. *Infancy-to-adolescence Functional Deterioration in Early Onset Psychosis: Are There Differences Between Schizophrenia and Affective Psychosis?*

Angel Del Rey-Mejías, David Fraguas, Josefina Castro-Fornieles, Inmaculada Baeza, Elena De la Serna, Marta Rapado-Castro, Laura Pina-Camacho, Celso Arango, Mara Parellada

255. *Comparative Study of Schizophrenia Patients According to Their Functionality*

Irvin Garay, Raul Escamilla, Yehu Garfias, Ricardo Saracco-Alvarez, Tania Morales

256. *Longitudinal Follow-up of Criticism and Depression among Families of First Episode Psychosis Patients*

Yumiko Hamaie, Noriyuki Ohmuro, Masahiro Katsura, Chika Obara, Tatsuo Kikuchi, Emi Sunakawa, Fumiaki Ito, Tetsuo Miyakoshi, Hiroo Matsuoka, Kazunori Matsumoto

257. *Touching by Hand: How Psychotic Features Translate into Worse Life Conditions: The Relation of Key Psychosocial Issues with Clinical Variables in Non-psychotic, Psychotic Responder, and Psychotic Non-responder Patients*

Felice Iasevoli, Sara Giordano, Raffaele Balletta, Livia Avvisati, Gianmarco Latte, Valentina Gilardi, Elisabetta F. Buonaguro, Mariavittoria Formato, Emiliano Prinzivalli, Rodolfo Rossi, Andrea de Bartolomeis

258. *Teaching and Learning the Discourse of Schizophrenia: Development of a Standardized Patient Training Program*

Luka Lucić, Anzalee Khan, Christian Yavorsky, Brian Rothman

259. *FFM Personality Traits and Adult Attachment Styles in Patients with Psychosis, Their Siblings and Healthy Controls*

Carin Meijer, L.N. Boyette, N. Korver

260. *Addressing Defeatist Beliefs in Work Rehabilitation*

Josh Mervis, Paul Lysaker, Joanna Fiszdon, Joseph Bisoglio, Jimmy Choi

261. *Sleep Disorders and Schizophrenia*

Hannah Newall, Cherrie Galletly, Dennis Liu, Campbell Thompson

262. *Impact of Obesity on Quality of Life in Patients with Schizophrenia*

Milawaty Nurjono, Nan Luo, Natasha Mitter, Vidhya Renjan, Jimmy Lee

263. *Does Routine Outcome Monitoring in Schizophrenia Improve the Implementation of Evidence Based Care?*

Stynke Castelein, Marte Swart, Gert Wolters, Richard Bruggeman, Henderikus Knegtering

264. *Evaluation of a Community Case-management Program for Patients with Schizophrenia-Spectrum Disorder: A Prospective 1-year Case-control Study*

Chung W. Chang, Emily S.M. Chen, Tracey C.W. Chan, K.W. Chan, H.M. Lee, L.M. Hui, Eric Y.H. Chen

265. *The Association between Working Alliance and Clinical and Functional Outcome in a Cohort of 400 Patients with First Episode Psychosis: A Cross-sectional Study*

Marianne Melau, Susanne Harder, Pia Jeppesen, Carseten Hjorthøj, Jens Richart Jepsen, Anne A.E. Thorup, Merete Nordentoft

266. *Virtual Reality Job Interview Training*

Matthew J. Smith, Emily Ginger, Michael Wright, Katherine Wright, Morris Bell, Michael Fleming

267. *Improving Somatic Health of Outpatients with Severe Mental Illness*

Fenneke M. van Hasselt, Marian J.T. Oud, Paul F.M. Krabbe, Maarten J. Postma, Anton J.M. Loonen

268. *Decreased Brain Cannabinoid Receptor (CB1R) Availability in Cannabis Dependence Rapidly Normalizes with Abstinence*

Deepak Cyril D'Souza, Jose Cortes, Mohini Ranganathan, Halle Thurnauer, Beata Planeta, Rajiv Radhakrishnanst, Yiyung Huang, Richard Carson, Patrick Skosnik

269. *Dextromethorphan and Psychiatric Morbidity: A Singapore Perspective*


Rajesh Jacob, Hui Leng Khoo, Arnab Kumar Ghosh

270. *Does Substance Abuse Increase the Risk of Psychiatric Illness?*

Nanna G. Toftdahl, Carsten Rygaard Hjorthøj, Merete Nordentoft

271. *Schizophrenia and Disordered Gambling: Qualitative Features of Dual Diagnosis*

Igor Yakovenko, Cameron M. Clark, David C. Hodgins, Vina M. Goghari



POSTERS, MONDAY 07 APRIL

12:00 PM - 2:00 PM

Location: Cavaniglia

1. *Childhood Maltreatment, the BDNF-Val66Met Polymorphism and Hippocampal Volume: Further Evidences from a MRI-twin Study*

Silvia Alemany, Aldo Córdova-Palomera, Carles Falcón, Mar Fatjó-Vilas, Ximena Goldberg, Bárbara Arias, Núria Bargalló, Benedicto Crespo-Facorro, Igor Nenadic, Lourdes Fañanás

2. *Investigation of the Role of Allelic Variants of Multidrug Resistance Gene (MDR1) on Clozapine Related Leukopenia/Agranulocytosis*

A. Elif Anıl Yağcıoğlu, Gökhan Yoca, R. Özgür Karaca, Lokman Çevik, Melih O. Babaoğlu, Yavuz Ayhan, Nurhayat Eni, M. Kazım Yazıcı, Atilla Bozkurt, Clozapine Related Leukopenia/Agranulocytosis Study Group (CRLA-SG)

3. *Prediction of Suicidal Behaviours in Young People Presenting with First-episode Psychosis in Hong Kong: A 3-year Follow-up Study*

Sze Man Chen, W.C. Chang, L.M. Hui, K.W. Chan, H.M. Lee, Eric Y.H. Chen

4. *Treatment of Clozapine-induced Hypersalivation with Amisulpride: A Systematic Review*

Maria Cristina R. Grilli-Tissot, M.R. Louzã

5. *Clozapine-induced Seizures, EEG Abnormalities, and Clinical Response in Japanese Patients with Schizophrenia*

Yuka S. Kikuchi, Wataru Sato, Keiichiro Ataka, Kiwamu Yagisawa, Yuki Omori, Takashi Kanbayashi, Tetsuo Shimizu

6. *Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials*

Taro Kishi, Yuki Matsuda, Nakao Iwata

7. *Negative Self and Other Schemas and Insecure Attachment Mediate the Association between Childhood Interpersonal Adversity and the Nonclinical Psychosis Phenotype*

Tamara Sheinbaum, Thomas R. Kwapił, Sergi Ballespí, Neus Barrantes-Vidal

8. *Positive Allosteric Modulation of mGluR5 Reverses the Akt Signaling Deficits in Serine Racemase Knockout Mice, a Genetic Model of Schizophrenia Due to NMDA Receptor Hypofunction*

Darrick T. Balu, Shunsuke Takagi, Jose Bartolomé, Thomas Steckler, Carrie Jones, P. Jeffrey Conn, Joseph Coyle

9. *Disc1 Mutation Induced Alterations in Cerebral Metabolism and in the Response to Acute Subanaesthetic Ketamine: A Comparison of Three Different Disc1 Mutations*

Neil Dawson, Catherine Winchester, Allan McVie, David Thomsom, Zoe Hughes, John Dunlop, Nicholas Brandon, Brian Morris, Judith Pratt

10. *A New "Double Hit" Schizophrenia Model in Rat Shows Structural and Neurochemical Alterations of the Medial Prefrontal Cortex and the Hippocampus*

Javier Gilabert-Juan, Maria Belles, Hector Carceller, Ana Rosa Saez, Rocio Gonzalez-Martinez, Sara Zamarbide-Fores, Maria Dolores Moltó, Juan Nacher

11. *Long-term Effects of Neonatal MK-801 Treatment on Protein Translation Signal Pathway in the Rat Frontal Cortex*

Yong Sik Kim, Se Hyun Kim, Hong Geun Park

12. *Reward Deficits in the Maternal Immune Activation Model*

Marie A. Labouesse, Wolfgang Langhans, Urs Meyer

13. *Characterization of a 'Two-Hit' Mouse Model of Methamphetamine-induced Psychosis: Effects of Brain-derived Neurotrophic Factor (BDNF) Deficiency and Relevance to Schizophrenia*

Elizabeth E. Manning, Maarten van den Buuse

14. *Use of Folate to Prevent Schizophrenia in Animal Model of Ketamine Induce Schizophrenia in Rats*

Flavio Augusto Pereira, Felipe Damazio, Alexandra Yugno

15. *Pre-synaptic Localization of PDE2 Enzyme and Pharmacological Characterization of the PDE2 Inhibitor PF-999 in Models Related to Cognitive Symptoms of Schizophrenia*

Holger Rosenbrock, Katja S. Kroker, Barbara Bertani, Birgit Stierstorfer, Cornelia Dorner-Ciossek, Roberto Arban

16. *Effects of a Nitric Oxide Synthase Inhibitor on an Animal Model for the Study of Schizophrenia Based on the Neurodevelopmental Hypothesis*

Cristiane Salum, Michelle Brosco, Oderci Messias-Filho, Angela Rodrigues

17. *The Mechanism of Action of Antipsychotics and Intracortical Myelination in Schizophrenia*

George Bartzokis, Po Lu, Chandra Kirkpatrick, Meghan Pyle, Erika Raven, Jim Mintz, Joseph Ventura, Laurie Casaus, John Luo, Kenneth Subotnik, Keith H. Nuechterlein

18. *Olfactory Identification Deficits as a Marker of Impaired Brain Development? A Cross-sectional Study in Patients with Schizophrenia and Healthy Controls*

Jessica de Nijs, Julia Meijer

19. *Shared Brain Dysfunction in Subtypes of Schizophrenia and Bipolar Disorder Defined by Poor Working Memory*

Melissa J. Green, Yann Quide, Alana Shepherd, Jesseca Rowland, Philip Mitchell, Vaughan Carr

20. *Increased Glycogen Synthase Kinase-3B (GSK-3B) Expression in Platelets of First Onset Psychosis Non-affective Patients*

Helena P.G. Joaquim, Leda L. Talib, Marcus Zanetti, Martinus van de Bilt, Geraldo Busatto, Mauricio Serpa, Wagner Gattaz



21. *Predictive Validity of Combined Minor Physical Anomalies and Neurological Soft Signs in Patients with Schizophrenia and their Nonpsychotic First-degree Relatives*

Sheng-Hsiang Lin, Shu-Ting Gan, Ming-Kun Lu, Jin-Jia Lin

22. *Classification of People with Treatment-resistant and Ultra-treatment-resistant Schizophrenia using Personalised Computer Modelling and EEG Data*

Carolyn McNabb, Reggio Hartono, Meghan McIlwain, Valerie Anderson, Nikola Kasabov, Rob Kydd, Bruce Russell

23. *Antipsychotic Treatment Decreased iPLA2 Activity in First Episode Drug Naïve Patients with Schizophrenia*

Leda L. Talib, Helena Joaquim, Mauricio Serpa, Geraldo Busatto, Martinus van de Bilt, Marcus Zanetti, Wagner Gattaz

24. *Alterations in the Amplitude of Low Frequency Fluctuations in Refractory Schizophrenia Patients with Auditory Verbal Hallucinations*

Anna Alonso-Solís, Yolanda Vives-Gilabert, Eva M. Grasa, Rosa Blanca Sauras, Santiago Durán-Sindreu, Sara Vieira, Fidel Núñez-Marín, Beatriz Gómez- Ansón, Maria J. Portella, Enric Alvarez, Iluminada Corripio

25. *Spontaneous Brain Activity as a Biomarker for Schizophrenia*

Simon J. Anhoj, Kristen Ford, Peter Williamson, Birte Glenthøj, Egill Rostrup

26. *Association of Schizophrenia with Independent Components of Brain Connectivity During Attentional Control*

Linda A. Antonucci, Paolo Taurisano, Leonardo Fazio, Rosa Vitale, Tiziana Quarto, Raffaella Romano, Annabella Di Giorgio, Grazia Caforio, Antonio Rampino, Giuseppe Blasi, Alessandro Bertolino

27. *Serious Obstetric Complications Contribute to Risk for Hippocampal Dysfunction during Recognition Memory*

Aurora Bonvino, Maria Antonietta Nettis, Annamaria Porcelli, Raffaella Romano, Enrico D'ambrosio, Paolo Taurisano, Leonardo Fazio, Giuseppe Blasi, Annabella Di Giorgio, Alessandro Bertolino

28. *Brain Activation Induced by Mental Stress in Patients with Schizophrenia*

Mariana N. Castro, Mirta F. Villarreal, Natasha Bolotinsky, Eliana Papávero, Nicolás Deschle, Fernando Binder, Lucas Drucaroff, Elsa Y. Costanzo, Delfina de Achaval, Karl-Jürgen Bär, Salvador M. Guinjoan

29. *Brain Hardware and Software for Self-reflection Associated with Insight in Patients with Schizophrenia*

Branislava Ćurčić-Blake, Lisette van der Meer, Marieke G.H. Pijneborg, Anthony S. David, André Aleman

30. *Presynaptic Dopamine Modulates Goal-directed Behavior and Interacts with Prefrontal and Striatal Glutamate*

Lorenz Deserno, Andreas Heinz, Florian Schlagenhauf

31. *Relationship between Cortical Activation during Working Memory and Functional Outcomes in Individuals at High Risk for Psychosis*

Irina Falkenberg, Isabel Valli, Marie Raffin, Marco M. Picchioni, Philip McGuire

32. *Imaging Endophenotypic Biomarkers for Schizophrenic and Affective Psychoses in Key Neural Circuits*

Oliver Gruber, Henning Vieker, Sarah Trost, Anna Fanelli, Kathrin Jakob, David Zilles

33. *Salience Network in Young People with Familial Risk for Psychosis the Oulu Brain and Mind Study*

Tuomas Jukuri, Vesa Kiviniemi, Juha Nikkinen, Jouko Miettunen, Pirjo H. Mäki, Jenni Koivukangas, Tanja Nordström, Jennifer Barnett, Peter Jones, Graham Murray, Juha Veijola

34. *Functional Dysconnection in the First Episode of Schizophrenia and in Remission*

Tomas Kasperek, Jozef Zubor, Radovan Prikryl, Hana Prikrylova, Jiri Vanicek, Eva Ceskova

35. *Disruptions in Small-world Cortical Functional Connectivity Network during an Auditory Oddball Paradigm Task in Patients with Schizophrenia*

Seung-Hwan Lee, Miseon Lim, Jung Seo Yi, Dowon Kim, Chang-Hwan Im

36. *Decreased Activation in Superior Frontal Gyrus in Patients with Schizophrenia Exposed to Curse Words: fMRI Study*

Eun-jin Na, Jong-Il Park, Tarique Rajasaheb Bagalkot, Hong-Mei Jin, Yin Cui, Young-Chul Chung

37. *Working Memory and Brain Activation in Schizophrenia vs. Psychotic Bipolar I Disorder Assessed with Functional MRI*

Igor Nenadic, Kerstin Langbein, Maren Dietzek, Raka Maitra, Gianluca Mingoia, Stefan Smesny, Gerd Wagner, Ralf Schloesser, Christian Gaser, Heinrich Sauer

38. *Neural Correlates of Self-reference Processing and Aberrant Salience Attribution – Implications for Psychosis*

Anne Pankow, Teresa Katthagen, Sarah Diner, Henrik Walter, Andreas Heinz, Florian Schlagenhauf

39. *Semi-metric Analysis of the Functional Human Brain Network: Relationship with Familial Risk for Psychotic Disorder*

Sanne Peeters, Tiago Simas, John Suckling, Ed Gronenschild, Petra Habets, Jim van Os, Machteld Marcelis



40. *The Relation of Abnormal Brain Connectivity and Psychiatric Symptom Expression in Subjects at High-risk for Psychosis*

André Schmidt, Renata Smieskova, Paul Allen, Paolo Fusar-Poli, Philip McGuire, Undine Lang, Marc Walter, Ernst-Wilhelm Radue, Anita Riecher-Rössler, Stefan Borgwardt

41. *High Resolution Basal State Functional Imaging Reveals a Subcortical-cortical Spreading Pattern of Functional Abnormality in Clinical High-risk Patients Who Progress to Psychosis*

Scott Schobel, Ragy Gergis, Cheryl Corcoran, Jeffrey Lieberman, Scott Small

42. *A Functional Neuroimaging Family Study of Facial Emotion Perception in Schizophrenia*

Michael J. Spilka, Aiden E. Arnold, Vina M. Goghari

43. *Cerebral Blood Flow Changes in Late-onset Schizophrenia Using SPECT with the Easy Z-score Imaging System*

Naohisa Tsujino, Sunao Mizumura, Yoko Baba, Naoyuki Katagiri, Taijyu Yamaguchi, Takahiro Nemoto, Nobuyuki Shiraga, Masafumi Mizuno

44. *Interaction between Diagnosis of Schizophrenia and Drd2 Genetic Variation on Amygdala Activity during Explicit Emotion Processing*

Giovanna Viscanti, Tiziana Quarto, Paolo Taurisano, Leonardo Fazio, Barbara Gelao, Rita Masellis, Mariateresa Attrotto, Grazia Caforio, Annabella Di Giorgio, Giuseppe Blasi, Alessandro Bertolino

45. *GABA, Glutamate and Intellectual Ability*

Anouk Marsman, Rene Mandl, Dennis Klomp, Vincent Boer, Anna Andreychenko, Wiepke Cahn, Rene Kahn, Peter Luijten, Hilleke Hulshoff Pol

46. *Are the Glutamatergic Dysfunction and Membrane Lipid Hypothesis Linked? A Combined 1H/31P-MR-Spectroscopy Study in Never Treated Acute Onset Schizophrenia*

Stefan Smesny, Alexander Gussew, Igor Nenadic, Natalie Joan Biesel, Carl Christoph Schultz, Paul Amminger, Heinrich Sauer

47. *White Matter Integrity as a Candidate Endophenotype for Schizophrenia*

Marc Bohlen, René Mandl, Rachel Brouwer, René Kahn, Hilleke Hulshoff Pol

48. *Childhood Trauma Affects the Hypothalamic-pituitary-adrenal Axis Activity and Brain Structure in Individuals at First Episode Psychosis and Healthy Controls Differently*

Simone Ciufolini, Valeria Mondelli, Matthew Kempton, Tiago Reis-Marques, Craig Morgan, Simone Reinders, Anthony S. David, Robin M. Murray, Carmine Pariante, Paola Dazzan

49. *Functional and Gray Matter Asymmetries in Patients with Schizophrenia and Bipolar Disorders*

Sonia Dollfus, Nicolas Delcroix, Elise Leroux, Mathieu Alary, Annick Razafimandimby, Perrine Brazo, Pascal Delamillieure

50. *Structural Grey Matter and White Matter Differences in Individuals with Psychotic like Signs from an Epidemiological Cohort*

Mark Drakesmith, Anirban Dutt, Glyn Lewis, Anthony S. David, Derek K. Jones

51. *Temporal Lobe White Matter Alterations in Schizophrenia: A Diffusion Tensor Imaging Tractometry Family Study*

Vina Goghari, Thibo Billiet, Stefan Sunaert, Louise Emsell

52. *Neurological Soft Signs and Brain Morphology in Patients with Chronic Schizophrenia*

Christina J. Herold, Marc M. Lässer, Lena A. Schmid, Ulrich Seidl, Marco Essig, Philipp A. Thomann, Johannes Schröder

53. *Diagnosing Schizophrenia Using Neuroimaging: A Meta-analysis of Multivariate Pattern Recognition Studies*

Joseph Kambeitz, Lana Kambeitz-Illankovic, Leucht Stefan, Steven Wood, Christos Davatzikos, Berend Malchow, Peter Falkai, Nikolaos Koutsouleris

54. *The Role of a FOXP2 Variant on Brain Structure and Speech Production – a DTI Study*

Axel Krug, Davide Laneri, Bruno Dietsche, Heidelore Backes, Stephanie Witt, Marcella Rietschel, Jens Sommer, Tilo Kircher, Arne Nagels

55. *Duration of Illness Associated with Cortical Thickness Change in Schizophrenia: A Longitudinal MRI Study*

Manabu Kubota, Neeltje E.M. van Haren, Wiepke Cahn, René Kahn

56. *Shared White Matter Dysconnectivity in Schizophrenia and Bipolar Disorder with Psychosis*

Iyothika Kumar, Sarina Iwabuchi, Shamuz Oowise, Vijender Balain, Lena Palaniyappan, Peter Liddle

57. *Left Fronto-temporal Disconnectivity within the Language Network in Schizophrenia: An fMRI and DTI Study*

Elise Leroux, Sonia Dollfus, Nicolas Delcroix

58. *Brain Structure Changes in First-episode Psychosis Patients with Persistent Apathy*

Lynn Mørch-Johnsen, Ragnar Nesvåg, Ann Faerden, Unn Kristin Haukvik, Kjetil Nordbø Jørgensen, Elisabeth Heffermehl Lange, Ingrid Melle, Ole Andreas Andreassen, Ingrid Agartz

59. *The “Fibre” Path to Psychosis? Can Advanced Diffusion Imaging Capture White Matter Brain Anomalies in Adolescents Experiencing Psychotic Symptoms?*

Erik O’Hanlon, Alexander Leemans, Mary C. Clarke, Ian Kelleher, Francesco Amico, Thomas Frodl, Mary Cannon



60. *Modelling Genetic and Environmental Influences on Brain Volume in Twins with Schizophrenia*
Marco M. Picchioni, Timothea Touloupoulou, Christopher Chaddock, James Cole, Ulrich Ettinger, Robin M. Murray, Philip McGuire

61. *Auditory Hallucinations in First Episode Psychosis: A Longitudinal DTI Study of the Arcuate Fasciculus*
Tiago Reis Marques, Francisco Marques-Teixeira, Heather Taylor, Flavio Dell'Acqua, Aurora Falcone, Andy Simmons, Marta DiForti, Robin M. Murray, Anthony S. David, Paola Dazzan

62. *White Matter Volume Reductions in First Episode Psychosis Are Associated with Cortisol Levels*
Renate L. Reniers, Belinda Garner, Christina Phassoulotis, Lisa Phillips, Connie Markulev, Christos Pantelis, Sarah Bendall, Patrick McGorry, Stephen Wood

63. *Progressive Brain Structure Change Predicts Negative Symptoms in First Episode Psychosis at 3 Year Follow-up*
Cathy Scanlon, Shane McNerney, Stefani O'Donoghue, Liam Kilmartin, Heike Anderson-Schmidt, John McFarland, Mairead Waldron, Joanne Kenney, Srinath Ambati, Brian Hallahan, Dara Cannon, Colm McDonald

64. *Continuing Grey Matter Changes in First-episode Schizophrenia and Affective Psychosis*
Maristela S. Schaufelberger, Pedro Rosa, Marcus Zanetti, Fabio Duran, Luciana Santos, Paulo Menezes, Marcia Scazufca, Robin Murray, Geraldo Busatto

65. *ZNF804A and Cortical Structure in Schizophrenia – In vivo and Postmortem Studies*
Carl C. Schultz, Igor Nenadic, Brien Riley, Vladimir Vladimirov, Gerd Wagner, Thomas Mühleisen, Markus Nöthen, Sven Cichon, Kathrin Koch, Ralf Schlösser, Heinrich Sauer

66. *Reduced Regional Grey Matter Volumes in Offspring of Schizophrenia Patients Relative to Offspring of Bipolar Patients and Controls*
Gisela Sugranyes, Elena De la Serna, Soledad Romero, Vanessa Sanchez-Gistau, Anna Calvo, Inmaculada Baeza, Dolores Moreno, Josefina Castro-Fornieles

67. *Apathy in Schizophrenia: Are Structural Abnormalities in Primary Emotion Processing Areas Involved?*
Marie-José van Tol, Edith Liemburg, Lisette van der Meer, Marieke Pijnenborg, Esther Opmeer, Richard Bruggeman, Henrikus Knegtering, André Aleman

68. *Prevalence of SPEs in Child and Adolescents with Anxiety and Depressive Disorders and Correlation with General Functioning*
Marco Armando, Nella Lo Cascio, Elena Monducci, Maria Pontillo, Nicoletta Girardi, Claudia Battaglia, Martina Patanè, Giada Colafrancesco, Claudia Dario, Mauro Ferrara, Ignazio Ardizzzone, Paolo Girardi, Stefano Vicari, Paolo Fiori Nastro

69. *What Lies Beneath? A Thematic Content Analysis of Sub-clinical Psychotic Experiences among Children and Young Adolescents from the General Population in Ireland and the UK*
Helen Coughlan, Ian Kelleher, Mary C. Clarke, Niamh Higgins, Kristin R. Laurens, Mary Cannon

70. *Juvenile Offenders with Severe Psychiatric Disorders in a Forensic Unit: Risk Factors of Overt Aggressive Behaviors*
Gaëlle Grajek, Elsa Hoffmann, Nelson Provost, Gilles Vandekerckhove, Bruno Piccinin, Stephan De Smet, Anu Raevuori, Laurent Servais

71. *Subclinical Psychotic Experiences are Associated with Anxiety, Daily Stressors and Family Functioning in an Adolescent General Population Sample*
Ashleigh Lin, Tamara Woodall, Danielle Hallett, Renate Reniers, Stephen Wood

72. *Differential Development of the Reward Network in Adolescent Offspring of Schizophrenia Patients*
Matthijs Vink, Ruby Pouwels, Manon Hillegers, René Kahn

73. *Thought Disorder in First-episode Psychosis*
Ahmet Ayer, Esra Aydın, Şilay Sevilmiş, Berna Yalınçetin, Berna Binnur Akdede, Köksal Alptekin

74. *Problem-solving Based Bibliotherapy for First-time Primary Caregivers of Family Members with a First Episode of Psychosis: Randomized Controlled Trial*
Terence McCann, Susan Cotton, John Gleeson, Kingsley Crisp, Brendan Murphy, Dan Lubman

75. *The Effects of Modafinil on Cognitive Training: A Proof-of-concept Trial in Patients with Schizophrenia*
Panayiota Michalopoulou, Shon Lewis, Richard Drake, Abraham Reichenberg, Richard Emsley, Anastasia Kalpakidou, Jane Lees, Eve Applegate, Til Wykes, Shitij Kapur

76. *An Open-label, Flexible-dose Study of Paliperidone Extended Release in Chinese Patients with First-onset Psychosis*
Tianmei Si, Wang Yang, Rui Qing, Tan QingRong, Zhang KeRang

77. *How Does the NSA-4 Compare to the NSA-16?*
Janet B. W. Williams, Lori Garzio, Douglas Osman

78. *Effectiveness of Three Atypical Antipsychotic-initiated Treatments in Chinese First-episode Schizophrenia: An Open Randomized Clinical Trial*
Yanbo Yuan, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Xin Yu

79. *Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis*
Danijela Piskulic, Mariapaola Barbato, Lu Liu, Jean Addington



80. *Schizotypy is Associated with a 'Reversal Inference' Deficit but no 'Jumping to Conclusions'*
Rick A. Adams, Timothée Devaux, Christoph Mathys, Karl Friston

81. *How Framing of the Response and Metamemory Self-monitoring and Control Allow Patients with Schizophrenia to Improve their Memory Reporting for General Knowledge*
Elisabeth Bacon, Marie Izaute, Elçin Akdogan

82. *Link between Facial Emotion Perception and Schizophrenia towards a Clinical and Cognitive Study Among a Sample of 83 Schizophrenic Patients*
Marie-Cecile Bralet, Nordine Mebtoul, Christian Koegel, Trang Ton

83. *Do Patients with Schizophrenia Use Prosodic Focus Marking to Attribute Mental States in a Conversation Situation?*
Maud Champagne-Lavau, Amandine Michelas, Catherine Faget, Cristel Portes, Anne-Sophie Lienhart, Laurent Boyer, Christophe Lançon

84. *Reward Learning Impairment in Patients with First-episode Schizophrenia-spectrum Disorder*
Tracey Chi Wan Chan, W.C. Chang, J.M. Gold, J.A. Waltz, C.L.M. Hui, K.W. Chan, H.M. Lee, E.Y.H. Chen

85. *Verbal Episodic Memory Impairment along the Course of Schizophrenia and Bipolar Disorder*
Letícia S. Czepielewski, Raffael Massuda, Pedro Goi, Mireia Sulzbach, Mirela Vasconcelos-Moreno, Ramiro Reckziegel, Monise Costanzi, Paulo Belmonte-de-Abreu, Flavio Kapczinski, Clarissa Gama

86. *Decreasing Paranoia Levels through Classical Conditioning: An Exploratory ESM Non Clinical Study*
Filiberto Fuentenebro, Regina Espinosa, Carmen Valiente, Borja Paredes, Patricia Villavicencio, Jose Maria Prados, Filiberto Fuentenebro

87. *Folate Pharmacogenomics, Endothelial Functioning, and Neurocognition in Schizophrenia Spectrum Disorders*
Tyler Grove, Vicki Ellingrod, Stephan Taylor

88. *Spreading Depolarization Effect on Behavioral Test of Schizophrenic Rat*
Babak Khodaie, Ahmad Ali Lotfinia, Milad Ahmadi, Mahmoud Lotfinia

89. *Psychosis Proneness, Anxiety, Depression and Interpretation Bias: The Twins Scan China Study*
Phoebe Kar Yu Kong, Jenny Yiend, Shelly Leung, Cecilia Leung, Emma Li, Francesca A. Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothea Touloupoulou

90. *Calibration and Cross-validation of MCCB and CogState in Schizophrenia*
Jane Lees, Eve Applegate, Richard Drake, Shon Lewis

91. *The MATRICS Consensus Cognitive Battery (MCCB): Performance and Functional Correlates*
June U. Lystad, Erik Falkum, Christine Mohn, Helen Bull, Stig Evensen, Bjørn Rund, Torill Ueland

92. *Predicting Functional Capacity and Real-world Functioning in Schizophrenia: The Role of Cognition and Negative Symptoms*
Lucas M. Mantovani, Rodrigo Ferretjans, João Vinícius Salgado

93. *The Role of Cognition in Metabolic Disturbance in People with Psychotic Illness: Novel Data from a Large Population Prevalence Survey*
Vera A. Morgan, Johanna Badcock, Anna Waterreus, Cherrie Galletly, Sonal Shah, Andrew Mackinnon

94. *Are the Relationships of Cognitive Performance to Psychosocial Functioning at Five Year Outcome Mediated by Disorganization Symptoms?*
Ross M. G. Norman, Rahul Manchanda, Raj Harricharan, Sandra Northcott

95. *A Randomized Controlled Trial of Cognitive Remediation after a First Episode of Schizophrenia: Improving Cognition and Work/School Functioning*
Keith H. Nuechterlein, Joseph Ventura, Kenneth L. Subotnik, Denise Gretchen-Doorly, Luana Turner, Laurie Casaus, John Luo, Morris D. Bell, Alice Medalia

96. *Metacognitive Abilities in First Episode Psychosis: A Controlled Experimental Study*
Emma C. Palmer, Anthony S. David, Stephen M. Fleming

97. *Effects of Intimacy on the Social Decision in Patients with Schizophrenia*
Sunyoung Park, Jungeun Shin, Kiwan Han, Yu-Bin Shin, Jae-Jin Kim

98. *Optimising the Delivery of Cognitive Remediation for Schizophrenia – Results from a Feasibility Randomised Controlled Trial of a new Computerised Programme, CIRCuiTS*
Clare Reeder, Matteo Cella, Vyv Huddy, Sabine Landau, Til Wykes

99. *An Examination of Auditory Processing and Affective Prosody in Relatives of Patients with Auditory Hallucinations*
Susan Rossell, Rachel Tucker, John Farhall, Neil Thomas, Chris Groot

100. *Investigating Facial Affect Processing in Psychosis: A Study Using the Comprehensive Affective Testing System*
Susan Rossell, Tamsyn Van Rheenen, Nicki Joshua, Andrea Gogos, Alison O'Regan

101. *Cognition among Schizophrenia in Supported Employment Program in Hospital Permai Malaysia*
Marina Abd Rahman Sabri, Abdul Kadir Abu Bakar, Abdul Hamid Abd Rahman

102. *Transcriptome Analysis Reveals Down-regulated Signal Transduction Pathways in Peripheral Blood Mononuclear Cells from Schizophrenia Patients with Cognitive Impairment*
Jingqin Wu, Melissa J. Green, Erin Gardiner, Paul Tooney, Rodney Scott, Vaughan J. Carr, Murray J. Cairns



103. *A New Method of Assessment of Thought Disorders (Schizophrenia Spectrum) Using the Standard for Clinicians' Interview in Psychiatry (SCIP)*

Ahmed Aboraya

104. *Setting Psychopathology in Motion: A Network Perspective*

P.R. Bakker, Marieke Wichers, Peter N. van Harten, Inez Myin-Germeys, Philippe Delespaul, Jim van Os

105. *Schizotaxia Redux*

Vaughan J. Carr, Jessica Bowen, Melissa J. Green

106. *The Clinical Overlap between Autism and Psychosis*

Katie E. Chisholm, Stephen Wood, Renate L. Reniers, Matthew Broome, Ashleigh Lin

107. *Clinical Implications of Screening for NMDA Encephalitis in First Episode Psychosis*

Eric Kelleher, Colin Doherty, Aiden Corvin

108. *Measuring Stigma - An Overview of Available Instruments*

Esther Sportel, Gerdina Pijnenborg, Stynke Castelein

109. *Comparing Diagnostic Stability in Two First Episode Follow-up Studies Within a Single Geographical Area Between 1992-2007*

Katherine C. Williams, Benjamin Lomas, Gillian Doody

110. *P3 Abnormalities in Neuroleptic-naïve First-episode Schizophrenia Patients and in Their Healthy Siblings*

Müge Devrim-Üçok, Alp Üçok

111. *Adolescent VTA Neurons Retain Neuronal Correlates of Reward Opportunity after Extinction*

Nicholas Simon, YunBok Kim, Jesse Wood, Bitá Moghaddam

112. *Electrodermal Activity as Possible Neuropsychiatric Biomarker*

Sergey Yagoda, Igor Boev

113. *Threatening and Intrusive Life Events as Precursors to Psychotic Disorders*

Stephanie Beards, Helen L. Fisher, Charlotte Gayer-Anderson, Kathryn Hubbard, Tjasa Velikonja, Adanna N. Onyejiaka, Valeria Mondelli, Carmine Pariante, Paola Dazzan, Rowena Handley, Craig Morgan

114. *Shared Risk Factors between Schizophrenia and Other Neurodevelopmental Disorders*

Mary C. Clarke, Antti Tanskanen, Matti Huttunen, David Cotter, Mary Cannon

115. *Schizophrenia and Violence: A Comparison between Formerly and Never Violent Patients Living in Residential Facilities*

Giovanni De Girolamo, Valentina Candini, Chiara Buizza, Clarissa Ferrari, Gian Marco Giobbio, Paolo Maggi, Stefania Greppo, Maria Elena Boero, Anna Melegari, Laura Iozzino

116. *Social Inequality at Birth and Risk of First Episode Psychosis in Rural Ireland: A Case-control Study*

Martha A. Finnegan, Sami Omer, Anthony Kinsella, Dennis Pringle, Paul Fearon, John L. Waddington

117. *Evidence that Childhood Urban Environment is Associated with Blunted Stress Reactivity across Groups of Psychotic Patients, Relatives and Controls*

Aleida Frissen, Ritsaert Lieveer, Marjan Drukker, Tineke Lataster, Philippe Delespaul, Inez Myin-Germeys, Jim van Os

118. *A Population-based Longitudinal Study of Atopic Disorders and Inflammatory Markers in Childhood before Psychotic Experiences in Adolescence*

Golam Khandaker, Stanley Zammit, Glyn Lewis, Peter B. Jones

119. *Prenatal and Postnatal Exposures to Maximum Adversity among Holocaust Survivors and the Course of Schizophrenia: A Population-based Study*

Stephen Z. Levine, Itzhak Levav, Rinat Yoffee, Inna Pugachova

120. *Taxometric Analysis of Multilevel Multimodal Risk Data from Siblings of Proband with Non-affective Psychotic Disorders*

Richard J. Linscott, Inez Myin-Germeys, Jim van Os, G.R.O.U.P. Investigators

121. *Incidence, Illness Characteristics and Early Outcome in an Irish First Episode Psychosis Service*

John Paul Lyne, Laoise Renwick, Brian O'Donoghue, Kevin Madigan, Anthony Kinsella, Niall Turner, Eadbhard O'Callaghan, Mary Clarke

122. *Prevalence of Infections in Patients with Schizophrenia: A Pilot Study*

Monika E. Pankiewicz-Dulacz, Elsebeth Stenager, Egon Stenager, Ming Chen

123. *Do Persons with Schizophrenia Selectively Migrate Towards City Areas?*

Carsten B. Pedersen

124. *Formal Thought Disorder: A Systematic Epidemiological Review*

Eric Roche, Lisa Creed, Donagh MacMahon, Daria Brennan, Brendan Kelly, Kevin Malone, Mary Clarke

125. *The Effects of Cannabis on Relapse in Psychosis*

Tabea Schoeler, Anna Monk, Musa Sami, Giulia Camuri, Ruth Brown, Sagnik Bhattacharyya



126. *Attitudes towards Patients with Psychosis and Depression in the General Population: Effects of Labeling*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmenn

127. *Characteristics of a Catchment Area in the State of São Paulo, Brazil, for Conducting an Incidence Study of Schizophrenia and Other Psychotic Disorders*

Sílvia H. Tenan, Maristela S. Schaufelberger, Rosana Shuhama, Juliana Souza, Jair Santos, Geraldo Busatto, Craig Morgan, Jim van Os, Cristina Del Ben, Paulo Menezes

128. *Testing Ødegaard's Selective Migration Hypothesis: a Longitudinal Cohort Study of Risk Factors for Non-affective Psychotic Disorder among Prospective Emigrants*

Elsje van der Ven, Christina Dalman, Susanne Wicks, Peter Allebeck, Jim van Os, Jean-Paul Selten

129. *Genetic Variability in the FKBP5 and NTRK2 Genes and Clinical Response to Clozapine*

Rosa Catalan Campos, Marina Mitjans, Bárbara Arias, Mireia Vázquez, Alexandre González, Rafael Penadés, Alexandre Pons, Guillem Masana, Janet Munro, Ma Jesús Arranz

130. *Effects of Genetic Variations in NRG1 on Cognitive Domains in Patients with Schizophrenia and Healthy Subjects*

Youngah Cho, Seunghyong Ryu, Iksoo Huh, Eun Young Cho, Hyeji Oh, Yu-Sang Lee, Taesung Park, Kyung Sue Hong

131. *Epigenetic Signatures in IGF2 and Related Genes and their Link to Birth Weight, Working Memory and Psychotic Experiences: A Study Based on Informative MZ Twins*

Aldo Cordova-Palomera, Silvia Alemany, José Ignacio Martín-Subero, Mar Fatjó-Vilas, Ximena Goldberg, Igor Nenadic, Lourdes Fañanás

132. *Stress and Variation in the Glucocorticoid Regulating Enzyme 11-β-hydroxysteroid-dehydrogenase Type 2 in Children who later Develop Schizophrenia*

Jean-Christophe Debois, Liselotte Petersen, Jakob Grove, Mette Nyegaard, Anne Hedemand, Tine Henriksen, Preben Bo Mortensen

133. *Association between Rs2267641 in the A2RE Sequence of the DDR1 Gene with Cognitive Processing Speed in Patients with Schizophrenia Spectrum Disorders*

Maria Cinta Gas, Ana M. Gaviria, Marta Creus, Itziar Montalvo, Maria José Cortés, Lourdes Martorell, Alfonso Gutiérrez-Zotes, Joaquín Valero, Javier Labad, Elisabet Vilella

134. *Association of Immune Gene Polymorphisms with Schizophrenia in a North Indian Cohort*

Prachi Kukshal, Triptish Bhatia, K.V. Chowdari, A.M. Bhagwat, S.N. Deshpande, V.L. Nimgaonkar, B.K. Thelma

135. *A Genome-wide Analysis on Antipsychotic-induced Weight Gain Using Refined Criteria in the CATIE Sample*

Daniel J. Müller, Eva J. Brandl, Arun Tiwari, Clement Zai, Nabilah Chowdhury, James Kennedy

136. *Investigation of the Relationship between Schizophrenia and KREMEN1 Gene*

Dua Özsoylu, Banu Değirmencioğlu, Çiğdem Eresen Yazıcıoğlu, Köksal Alptekin

137. *Hypothesis-driven Genome-wide Association Study (GWAS) Analysis Highlights the Role of Immune Genes in the Extended Major Histocompatibility Complex in Schizophrenia*

Jennie Pouget, Vanessa Gonçalves, Virginia Misener, James Kennedy, Jo Knight

138. *P250GAP a New Candidate Gene for Schizophrenia and Psychosis-proneness?*

Araceli Rosa, Elionora Peña, Marta de Castro-Català, Thomas R. Kwapił, Paula Cristóbal-Narváez, Neus Barrantes-Vidal

139. *Investigation into an Association between Genetic Risk Factors for Schizophrenia and Bipolar Disorder and Dimension-specific Psychotic Experiences in Adolescence*

Dominika Sieradzka, Robert A. Power, Daniel Freeman, Alastair Cardno, Philip McGuire, Robert Plomin, Emma Meaburn, Frank Dudbridge, Angelica Ronald

140. *Cost Effectiveness of the Job Management Program (JUMP)*

Stig Evensen, Torill Ueland, June U. Lystad, Helen Bull, Erik Falkum

141. *Risk Reduction and Numbers Needed to Treat to Avoid Metabolic Syndrome: 12-month Cardiometabolic Parameters Changes among Schizophrenia Subjects Treated with Lurasidone or Quetiapine XR*

Krithika Rajagopalan, Timothy Niecko, Andrei Pikalov, Mariam Hassan, Andrei Loebel

142. *Depressive Disorders in Psychosis Risk Syndrome in a Child and Adolescent Sample*

Xavier Álvarez, Marta Rodríguez, Marta Carulla, Jordina Tor, Elena De la Serna, Gisela Sugranyes, Bernardo Sánchez, Marta Espadas, Vanessa Sánchez-Gistau, Inmaculada Baeza, Montse Dolz

143. *Psychosis Risk Syndrome in Children and Adolescents: Clinical Characteristics and Treatment in Help-seekers vs. Controls*

Inmaculada Baeza, Elena De la Serna, Gisela Sugranyes, Olga Puig, Vanessa Sánchez-Gistau, Jordina Tor, Marta Carulla, Clara Espelt, Daniel Ilzarbe, Marta Espadas, Montserrat Dolz

144. *Neuropsychological Characteristics of Child and Adolescent Offspring of Schizophrenia or Bipolar Disorder Patients*

Elena De la Serna, Montse Vila, Dolores Moreno, Soledad Romero, Vanessa Sánchez-Gistau, Gisela Sugranyes, Inmaculada Baeza, Teresa Sánchez, Elisa Rodríguez, Josefina Castro-Fornieles

145. *Focused Interventions in 258 Subjects at High Clinical Risk for Psychosis: Oasis 6-years Naturalistic Study*

Marianna Frascarelli, Lucia Valmaggia, Majella Byrne, Louisa Codjoe, Laura Weinberg, Stefania Tognin, Xenaki Lida, Philip McGuire, Paolo Fusar-Poli



146. *The Relationship between Positive Psychotic and Depressive Symptoms and Functioning in Young People with Mental Health Issues*

Kareen Heinze, Ashleigh Lin, Stephen Wood

147. *Gender Differences in Cognitive Functioning in At-risk Mental State for Psychosis, First-episode Psychosis and Healthy Control Subjects*

Sarah Ittig, Erich Studerus, Martina Pappmeyer, Martina Uttinger, Susan Koranyi, Avinash Ramyeed

148. *Social Cognitive Functioning in Prodromal Psychosis: A Meta-analysis*

Tae Young Lee, Na Young Shin, Sang Bin Hong, Jun Soo Kwon

149. *Are UHR Patients who Present with Hallucinations Alone at Lower Risk of Transition to Psychosis?*

Karen O'Connor, Barnaby Nelson, Ashliegh Lin, Stephen Wood, Alison Yung, Andrew Thompson

150. *Cannabis Use in a Sample of Subjects at Risk for Developing Psychosis*

Marta Pardo, Jordina Tor, Daniel Muñoz, Marta Rodríguez, Bernardo Sánchez, Elena De la Serna, Josep Lluís Matalí, Vanesa Sánchez-Gistau, Marta Carulla, Inmaculada Baeza, Montserrat Dolz

151. *A Multimodal Biomarker to Predict the Onset of Schizophrenia*

Diana Prata, Evangelos Vassos, Ceri Jones, Christopher Chaddock, Alice Egerton, Isabel Valli, James Stone, Lucia Valmaggia, Stefania Tognin, Andrea Marquand, Philip McGuire

152. *Clinical Depression Predicts Paranoia in High-risk Patients. Results of the EPOS Project*

Raimo K.R. Salokangas, Markus Heinimaa, Tiina From, Jarmo Hietala, Heinrich Graf von Reventlow, Don Linszen, Max Birchwood, Stephan Ruhrmann, Joachim Klosterkötter

153. *Environmental Risk Factors, Prodromal Psychotic Symptoms and Psychopathology of Child and Adolescent Offspring of Parents with Bipolar Disorder, Schizophrenia and Community Controls. The Bipolar and Schizophrenia Young Offspring Study (BASYS)*

Vanessa Sanchez-Gistau, Soledad Romero, Elena de la Serna, Gisela Sugranyes, Inmaculada Baeza, Dolores Moreno, Josefina Castro-Forneles

154. *Prevalence of Psychosis-risk Criteria and Symptoms in an Inpatient and General Population Sample of Children and Adolescents*

Benno G. Schimmelmänn, Chantal Michel, Alexandra Martz-Irtinger, Frauke Schultze-Lutter

155. *Mediation Models of the Relationship between Childhood Trauma and Depressiveness in Patients At-risk for Psychosis and in Help-Seeking Controls*

Stefanie J. Schmidt, Stephan Ruhrmann, Benno G. Schimmelmänn, Joachim Klosterkötter, Frauke Schultze-Lutter

156. *Understanding Social Functioning in "At-risk Mental State" Findings from the Zurich Early Recognition Program*

Anastasia Theodoridou, Karsten Heekeren, Nicolas Rüsch, Diane N. Dvorsky, Mario Müller, Sibylle Metzler, Susanne Walitzka, Wulf Rössler

157. *The Danish High Risk and Resilience Study - VIA 7-attachment Style, Home Environment and Emotional Climate among 7-year-old Children with Familiar High Risk of Developing Schizophrenia Spectrum Disorder or Bipolar Disorder*

Anne A.E. Thorup, Nicoline Hemager, Jens Richardt Jepsen, Camilla Jerlang Christiani, Anne Ranning, Ditte Lou Gantriis, Aja Greve, Mette Skærbæk, Niels Ole Mors, Merete Nordentoft, Kerstin Jessica Plessen

158. *Neural Correlates of Reward Processing in Unmedicated Persons At-risk for Psychosis*

Diana Wotruba, Karsten Heekeren, Lars Michels, Buechler Roman, Joe J Simon, Ana Theodoridou, Spyros Kollias, Wulf Roessler, Stefan Kaiser

159. *Symptomatic Outcome of Non-converters with At-risk Mental State Patients in Support for Wellness Programme, Institute of Mental Health, Singapore*

Spencer Yuen, Swapna Verma, Sujatha Rao, Lye Yin Poon, Helen Lee

160. *Improved Individualised Prediction of Schizophrenia in Subjects at Genetic High Risk, Based on Neuroanatomical and Clinical Data*

Eleni Zarogianni, Amos J. Storkey, Thomas W. J. Moorhead, Stephen M. Lawrie

161. *The Brief Negative Symptom Scale: Psychometric Properties and Factor Analysis of the German Translation*

Martin Bischof, Stefan Kaiser, Matthias N. Hartmann, Oliver Hager, Matthias Kirschner, Kluge Agne, Oliver Matthes, Gregory P. Strauss

162. *Which Negative Symptoms do Site Raters have the most Trouble Rating?*

David G. Daniel

163. *Negative Symptom Subgroups have Different Effects on Clinical Course after First Episode of Schizophrenia: A 24 Months Follow-Up Study*

Ceylan Ergul, Alp Uçok

164. *Improvement in Negative Symptoms in Patients Treated with Antipsychotics*

Diego Novick, William Montgomery, Tamas Treuer, Jordan Bertsch, Josep Maria Haro

165. *Negative Symptoms of Schizophrenia Correlate Specifically with Deficits in Social Functioning*

Cedric O'Gorman, Philip D. Harvey



166. *Evolution of Risk Factors for Late and Persistent Negative Symptoms over Time: Results from a 12-year Follow-up of First Episode Psychosis Patients*

Hugh Ramsay, John Lyne, Michele Hill, Niall Crumlish, Niall Turner, Mary Clarke

167. *Assessing Effort-based Decision-making in Schizophrenia with Two Novel Behavioral Paradigms*

Felice Reddy, William Horan, Jonathan Wynn, Patricia Corey-Lisle, Gregory Maglinte, Deanna Barch, Robert W. Buchanan, James Gold, Jared Young, Michael Green

168. *DNA Methylation of the 5-HT1A Receptor Gene Promoter is Associated with Negative Symptom Response to Antipsychotic Drug Treatment*

Gavin Reynolds, Caroline Dalton, Hao Tang

169. *Persistent Negative Symptoms after First-episode Schizophrenia; Results of 2 Years Follow-up*

Alp Uçok, Ceylan Ergül

170. *Negative Symptoms in the Early Course of Schizophrenia: Their Longitudinal Stability and Relationship to Early Cognitive Processes*

Joseph Ventura, Kenneth L. Subotnik, Denise Gretchen-Doorly, Micheal J. Gitlin, Gerhard S. Hellemann, Keith H. Nuechterlein

171. *Both Psychosis Patients and their Unaffected Siblings Show Increased Concentrations of Red Blood Cell Membrane Polyunsaturated Fatty Acids as Compared to Controls - for GROUP (Genetic Risk and Outcome of Psychosis)*

Suzanne Medema, Roel J.T. Mocking, Nico J.M. van Beveren

172. *Molecular Mechanisms Underlying Synaptic Pathology in Schizophrenia*

Peter Penzes

173. *Studying Heart Arrhythmias in Relation to Psychosis (SHARP). Increased Prevalence of Cardiac Arrhythmias in Recent Onset Schizophrenia*

Arjen Sutterland, Marieke Blom, Lieuwe de Haan, Hanno Tan

174. *Trauma may Induce Early Cognitive Deficits Antedating Schizophrenia in Children and Adolescents at High Genetic Risk*

Michel Maziade, Nicolas Berthelot, Elsa Gilbert, Thomas Paccalet, Isabel Moreau, Chantal Mérette, Joanne Lavoie, Valérie Beaulieu-Monfette, Marco Battaglia, Nancie Rouleau

175. *Gene Set Enrichment of Differential Expression and Splicing Analysis by RNA-Seq in Postmortem DLPFC and PBMcs in Schizophrenia*

Murray J. Cairns, Xi Wang, Joshua R. Atkins, Stu G. Fillman, Paul Tooney, Rodney Scott, Cynthia Weickert, Vaughan Carr

176. *Messenger RNA and MicroRNA Expression Profiling of Pyramidal Neurons, Parvalbumin-immunoreactive Neurons, Dopamine Neurons and Oligodendrocytes in Schizophrenia and Parkinson's Disease*

Tsung-Ung W. Woo, Sarah A. Mauney, Lindsey L. Wimberly, Kai-Christian Sonntag

177. *Lack of Habituation of Mirror Neuron Activity: Study Using Transcranial Magnetic Stimulation Paradigms*

Hulegar A. Abhishekh, Urvaksh M. Mehta, Rakshathi Basavaraju, Jagadisha Thirthalli, Bangalore Gangadhar

178. *Visual Habituation is Impaired in Schizophrenia: A Study with Pattern Reversal Visual Evoked Potentials*

Giorgio Di Lorenzo, Fabio Ciabattini, Andrea Daverio, Fabiola Ferrentino, Gianluca Coppola, Cherubino Di Lorenzo, Cinzia Niolu, Francesco Pierelli, Alberto Siracusano, Stefano Seri

179. *Reduced Theta Band Response to Relevance in Schizophrenia*

Alvaro Diez, Alejandro Bachiller, Manuel Martín-Loeches, Pilar Casado, Jesús Poza, Roberto Hornero, Vicente Molina

180. *Behavioral Monitoring Deficits in Schizotypal Personality Disorder: Decreased ERN as a Trait Marker of Schizophrenia-spectrum Disorders*

Eva M. Grasa, Mireia Rabella, Susanna Clos, Iluminada Corripio, Rosa M. Antonijoan, Victor Pérez, Jordi Riba

181. *Sex-related Differences of EEG Coherence Between Patients with Schizophrenia and Healthy Controls*

Yu Sang Lee, Hye Min Jung

182. *EEG Coherence in Schizophrenia and Schizoaffective Disorder*

Yulia Zaytseva, Zhanna Garakh

183. *Thought Disorders and Family Liability in First Episode Psychosis*

Esra Aydinli, Silay Sevilimis, Ahmet Ayer, Berna Yalincetin, Berna Binnur Akdede, Koksai Alptekin

184. *Self-esteem and Psychopathology among Chinese Teenagers and University Students*

Lu Hua Chen, Francesca A. Cotier, Winifred Mark, Kar Yu Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Touloupoulou

185. *Cognition, Self-esteem and Quality of Life in Schizophrenia; A 12 Month Follow-up Cognitive Remediation Clinical Trial*

Gemma Garrido, Maite Barrios, Rafael Penadés



186. *Neurocognitive Architecture of Schizophrenia*

Max Lam, Simon Collinson, Goi Khia Eng, Attilio Rapisarda, Michael Kraus, Jimmy Lee, Siow-Ann Chong, Richard S.E. Keefe

187. *Neurocognitive Impairments in Adolescents with and without At-risk States of Psychosis*

Chantal Michel, Benno G. Schimmelmann, Alexandra Martz-Irgartinger, Frauke Schultze-Lutter

188. *Implicit and Explicit Self-evaluation as Underlying Mechanisms of Impaired Insight in Patients with Schizophrenia*

L. van der Meer, Annerieke De Vos, Marieke Pijnenborg, André Aleman

189. *The Efficacy of Occupational Therapy in the Rehabilitation of Executive Functions in Patients with Treatment-resistant Schizophrenia: A Pilot Randomized Controlled Trial*

Adriana Dias Barbosa, Vizzotto, Diego Luis Celestino, Patricia Cardoso Buchain, Alexandra Martini de Oliveira, Graça Maria Ramos de Oliveira, Elaine Scapaticio Di Sarno, Isabel Cristina Napolitano, Helio Elkis

190. *Disorganization and Timing of Motor Behavior: Insight from Gesture Impairments and Movement Patterns in Schizophrenia*

Sebastian Walther, Fabian Ramseyer, Wolfgang Tschacher, Tim Vanbellinghen, Stephan Bohlhalter

191. *Keeping the Body in Mind for Young People with First Episode Psychosis*

Jackie Curtis, Andrew Watkins, Simon Rosenbaum, Scott Teasdale, Megan Kalucy, Katherine Samaras, Philip B. Ward

192. *The DJ's Choices Approach Adapted for Families*

Marie-France Demers, Claudia Lévesque, Julie Bouchard, Julie Bourbeau, Marc-André Roy

193. *The Impacts of Aerobic Exercise and Mind-body Exercise (Yoga) on Neuro-Cognition and Clinical Symptoms in Early Psychosis - A Single-blind Randomized Controlled Clinical Trial*

Jessie Jingxia Lin, H.M. Lee, K.W. Chan, W.C. Chang, Wayne Su, William Honer, Pek-Lan Khong, Michael Tze, C.L.W. Chan, K.F. So, E.Y.H. Chen

194. *The Effect of Motivational Interviewing on Medication Adherence and Hospitalization Rates in Nonadherent Patients with Multi-episode Schizophrenia*

Carin Meijer, Emile Barkhof, Leo de Sonnevill, Don Linszen, Lieuwe de Haan

195. *The Interaction between CNR1 Genetic Variation and Cannabis Exposure Predicts Prefrontal Functional Connectivity and Behavior During Working Memory*

Marco Colizzi, Leonardo Fazio, Laura Ferranti, Annamaria Porcelli, Rita Masellis, Gianluca Ursini, Giuseppe Blasi, Alessandro Bertolino

196. *Emotional Intelligence in Serious Mental Illness – Gender Differences in Patients with Schizophrenia and Bipolar I Disorder*

Beatrice Frajo-Apor, Moritz Mühlbacher, Georg Kemmler, Irene Lehner-Adam, Alex Hofer

197. *Non-linear Dynamics of Speech in Schizophrenia: A Machine-learning Approach*

Riccardo Fusaroli, Arndis Simonsen, Ethan Weed, Vibeke Bliksted

198. *Is the DINE Adequate for Capturing Dietary Patterns Among Patients with Severe Mental Illness?*

Poonam Gardner Sood, Fiona Gaughran, Zerrin Atakan, Khalida Ismail, John Lally

199. *Between Self-clarity and Recovery in Schizophrenia: Reducing the Self-stigma and Finding Meaning*

Ilanit Hasson-Ohayon, Michal Mashiach-Eizenberg, Phil Yanos, Paul Lysaker, David Roe

200. *Assessing Threat Responses towards the Symptoms and Diagnosis of Schizophrenia by Measuring Visual Perceptual Biases*

Adam Heenan, Michael Best, Sarah Ouellette, Erin Meiklejohn, Nikolaus Troje, Chris Bowie

201. *Experience Sampling Method through a Smartphone App: The Case of City Living & Psychosis*

Georgina M. Hosang

202. *Comparing Illness Presentation, Treatment and Functioning between Patients with Early- and Adult-onset Psychosis*

Christy L.M. Hui, W.C. Chang, Sherry K.W. Chan, Edwin H.M. Lee, Eric Y.H. Chen

203. *Schizophrenia “for Life” – A Registry and Interview Study Among Elderly with Lifelong Schizophrenia*

Maria Brink, Kjeld Andersen, Bent Nielsen, Anders Green

204. *Outcomes of Patients with First-episode Schizophrenia at One-year Follow-up: Findings from the National Mental Health Registry in Malaysia*

Kok Yoon Chee, Norsiatul Azma Muhammad Dain, Salina Abdul Aziz, Sharifah Suziah Syed Mokhtar, Mazni Mat Junus, Ruzanna Zam Zam, Badiyah Yahya, Yee Chuan Cheah

205. *Duration of Untreated Psychosis – Relation to Functional Outcome of Patients with Schizophrenia*

Roxana Ciungu, Anne-Marie Murgulescu, Victor Marinescu

206. *Performance on the UCSD Performance-based Skills Assessment (UPSA) and Real-world Outcomes in Severe Mental Illness: A Systematic Review of the Literature*

Amy Duhig, Julie Myers, Amber Pitts, Steven Hass, Robert Klein, Philip D. Harvey

207. *Use of Reliable Change Index to Evaluate Clinical Significance in the Positive and Negative Syndrome Scale (PANSS): A CATIE Analysis*

Linda Gao, Anzalee Khan, Luka Lucic, Brian Rothman



208. *Aging in Schizophrenia: A Systematic Review*

Matti Isohanni, David Cowling

209. *The Longitudinal Course of Schizophrenia: A Systematic Review*

Adrian Preda, Robert Bota, Steven Potkin

210. *The UCSD Performance-based Skills Assessment-brief Japanese Version (UPSA-B_J):*

Discriminative Validity for Schizophrenia

Chika Sumiyoshi, Manabu Takaki, Yuko Okahisa, Thomas Patterson, Philip D. Harvey, Tomiki Sumiyoshi

211. *The Three Faces of Schizophrenia: Sub-typing Schizophrenia Based on Response and Implications for Treatment*

Ofer Agid, Gagan Fervaha, George Foussias, Cynthia Siu, Krysta McDonald, Gary Remington

212. *Ecological Validity of the Schizotypy Dimensions and Stress-reactivity Model of Psychotic-like Experiences*

Neus Barrantes-Vidal, Tamara Sheinbaum, Sergi Ballespi, Charlotte Chun, Inez Myin-Germeys, Thomas R. Kwapil

213. *Prevalence and Predictors of Depressive Symptoms in Non-affective Psychosis Patients in Jockey Club Early Psychosis (JCEP) Project in Hong Kong*

Chung W. Chang, Rowan Chang, L.M. Hui, K.W. Chan, H.M. Lee, Eric Y.H. Chen

214. *Body-oriented Psychotherapy for Persons with Schizophrenia: Interpretative Phenomenological Analysis of Participants' Experience*

Laura Galbusera

215. *The Course of Obsessive-compulsive Symptoms in Patients with Non-affective Psychotic Disorders and in Un-affected Sibling: A 3 years Follow-up Study*

Frederike Schirmbeck, Marije Swets, GROUP Investigators

216. *Long-term Improvements in AVHs: Clinician vs. Patient Perspectives*

Yong Sik Kim, Sam Yi Shin, Samuel Suk-Hyun Hwang, Se Hyun Kim, Jae Seung Jang, Hee Yeon Jung, In Won Chung

217. *A Network Approach to the Psychopathology of Psychosis*

Johanna Wigman, Jim van Os, Dina Collip, Catherine Derom, Evert Thiery, Nele Jacobs, Tineke Lataster, Inez Myin-Germeys, Philippe Delespaul, Marieke Wichers

218. *Pathways to Care for Young Individuals with a First-episode Psychosis in South London: Use of Prodromal Services*

Olesya Ajnakina, Craig Morgan, Sherifat Oduola, François Bourque, Lucia Valmaggia, Paola Dazzan, Robin M. Murray, Anthony S. David

219. *The Association of Autistic Traits and Psychosis Proneness in Chinese Early Adults: The Twins Scan China Study*

Shelly Leung, Phoebe Kong, Cecilia Leung, Emma Li, Francesca A. Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothea Touloupoulou

220. *Frequency and Duration of an At-risk Mental State (DUI-ARMS) in First-episode Psychosis Inpatients: Results from a Retrospective Assessment*

Jonas Rahman, Stephan Ruhrmann, Wolfgang Maier, Joachim Klosterkötter, Frauke Schultze-Lutter

221. *Structural Brain Imaging Correlates of At-risk Mental State*

Ulrich Schall, Tim Ehlkes, Pat Michie, Rebekah Atkinson, Philip B. Ward, MinT Consortium

222. *Psychosis Early Detection: Helpful or Stigmatizing Experience? - A Qualitative Pilot Study*

Martina Uttinger, Susan Koranyi, Martina Papmeyer, Erich Studerus, Fabienne Fend, Andor Simon, Anita Riecher-Rössler

223. *A Follow-up of Functioning in At-risk Mental State*

Justine Xue, Lye Yin Poon, Helen Lee, Swapna Verma

224. *Duration of Antipsychotic Medication Treatment is a Modifier for Weight Gain*

Maarten Bak, Jim van Os

225. *Amisulpiride for Elderly Patients with Chronic Schizophrenia*

Yoram Barak, Shani Pridan, Yehuda Baruch, Marnina Swartz

226. *Compliance to Medicament Algorithm for First-episode Psychoses; Experiences from TIPS-2 Project*

Petros Drosos, Tor Ketil Larsen, Inge Joa

227. *Safety and Tolerability of Cariprazine in the Long-term Treatment of Schizophrenia*

Suresh Durgam, Andrew J. Cutler, Yao Wang, Raffaele Migliore, Kaifeng Lu, István Laszlovszky, Krisztián Nagy

228. *Flexibly Dosed Paliperidone Palmitate in Non-acute Patients with Schizophrenia Switched from Previously Unsuccessful Monotherapy with Oral Atypical Antipsychotics*

Ludger Hargarter, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernado Carpinello, Pierre Vidailhet, Andreas Schreiner

229. *Efficacy and Relevance of the Modulation of Kv3 Channels to Alleviate Cognitive Dysfunction in an Animal Model of Schizophrenia Symptomatology*

Michael K. Harte, Marianne Leger, Ben Grayson, Samuel Marsh, Charles Large, Jo Neill



230. *QTc Prolongation in Children and Adolescents in Second-generation Antipsychotics Treatment: A Review*

Karsten G. Jensen, Anne Katrine Pagsberg, Anders Fink-Jensen, Cristoph Correll

231. *Two Novel KV3 Ion Channel Modulators Alleviate Cognitive Dysfunction and Social Behaviour Deficits of Relevance to Schizophrenia in an Animal Model*

Marianne Leger, Mike Harte, Ben Grayson, Sam Marsh, Charles Large, Jo Neill

232. *Neuroplastic Alterations in Rats Exposed to Prenatal Stress: Preventive Effect of Lurasidone Treatment during Adolescence*

Alessia Luoni, Alessandra Berry, Francesca Calabrese, Francesca Cirulli, Marco A. Riva

233. *A Rater-blinded, Randomized, Comparative Study of Aripiprazole versus Blonanserin in Japanese Patients with Schizophrenia*

Tomohiko Mukai

234. *Ketamine as a Model for Schizophrenia Deficits*

Erica Neill, Susan L. Rossell, Celia J.A Morgan, Olivia Carter, Nicole Joshua

235. *The Effect of Blood Plasma Clozapine Levels on Specific Measures of Behavior in Childhood Onset Schizophrenia*

Anna E. Ordóñez, David I. Driver, Mark Orloff, Scott R. Penzank, Jerry Overman, Deanna Greenstein, Diane Dillard-Broadnax, Judith Rapoport, Nitin Gogtay

236. *The Potential Beneficial Effects of Celecoxib or Omega-3 as Adjuvant Therapy in Schizophrenia Induced in Experimental Animals*

Enass Y. Osman, Alaa ElDin Elsisy, Samia Sokar, Magda Elsayad, Ehab Ramadan

237. *Histamine H2 Blockers for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials*

Kazuto Oya, Taro Kishi, Nakao Iwata

238. *Effect of Lurasidone on Cognitive Impairment: From the Lab to the Clinic*

Andrei Pikalov, Philip D. Harvey, Cynthia Siu, Josephine Cucchiari, Antony Loebel

239. *Exploration of the Therapeutic Potential of Selective TAAR1 Agonists in Preclinical Paradigms*

Eric Prinssen, Anja Harmeyer, Roger Norcross, Tanya Wallace, Celine Risterucci, Patrick Mortas, Jean-Luc Moreau, Joseph Wettstein, Marius Hoener

240. *Behavioral Effects of the Novel Benzodiazepine Positive Allosteric Modulator SH-053-2'F-S-CH3 in an Immune-mediated Neurodevelopmental Disruption Model*

Juliet Richetto, Marie A. Labouesse, Michael M. Poe, James M. Cook, Anthony A. Grace, Marco A. Riva, Urs Meyer

241. *Description of the Impacts of Clozapine Use in an Early Stage Psychosis Population*

Marc-André Roy, Brigitte Pelletier, Annie Loiseau, Marie-Claude Harisson

242. *Obsessive-compulsive Symptoms in Patients with Schizophrenia Comparing Treatment with Clozapine, Olanzapine, Risperidone and No Antipsychotics: A Longitudinal Study of 550 Patients after 3 Years of Treatment*

Albertine Scheltema Beduin, Carin Meijer, Lieuwe de Haan

243. *Paliperidone Palmitate – Impact on Negative, Disorganized and Depressive Symptoms, Subjective Well-being and Patient Satisfaction in Patients with Schizophrenia Previously Unsuccessfully Treated with Oral Antipsychotics*

Andreas Schreiner, Ludger Hargarter, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernardo Carpiello, Pierre Vidailhet

244. *The Use of Mirtazapine as Add-on Therapy in the Treatment of Schizophrenia*

Gaurav Singh, Klara Sputova, Eric Hecht

245. *Positive Results with ITI-007 for the Treatment of Schizophrenia: A Randomized, Double-blind, Placebo- and Active-controlled Phase 2 Study*

Kimberly Vanover, Robert E. Davis, Larry Ereshefsky, Sharon Mates

246. *Social Anxiety as a Treatment Target to Improve Social Adjustment and Quality of Life in Schizophrenia*

Sayaka Aikawa, Takahiro Nemoto, Naohisa Tsujino, Yoko Baba, Yuko Yorozyu, Miki Tobe, Kiyoaki Takeshi, Taiju Yamaguchi, Naoyuki Katagiri, Masafumi Mizuno

247. *Can Work History at Baseline Predict Work Behavior Within the First Four Weeks of Vocational Rehabilitation?*

Helen Bull, Torill Ueland, June U. Lystad, Stig Evensen, Erik Falkum

248. *Improving Social Functioning in Schizophrenia through Social Cognitive Remediation*

Linda K. Byrne

249. *Helping People with Psychotic Disorders Back to Work – The JUMP Study*

Erik Falkum, June U. Lystad, Helen Bull, Stig Evensen, Torill Ueland

250. *The Role of Gender and Symptoms in Predicting Functioning in Early Episode Psychosis*

Maya Gupta, Michael Grossman, Michael Best, Emma Ayukawa, Christopher Bowie

251. *Methodological Considerations in the Implementation of the US MOSAIC Registry: A Large-Scale, Long Term Study of People with Schizophrenia*

Philip D. Harvey, Cedric O'Gorman



252. *Patients' Opinions on Key Issues of Psychosocial Functioning Among Non-psychotics, Psychotic Responders and Non-Responders: Correlation with Clinical Variables and Symptom Domains Relevant to Remission from Psychosis*

Felice Iasevoli, Sara Giordano, Raffaele Balletta, Elisabetta F. Buonaguro, Carmine Tomasetti, Rodolfo Rossi, Valentina Gilardi, Claudia Cucciniello, Cristiana Elce, Roberto Acampora, Andrea de Bartolomeis

253. *Vocational Recovery in First Episode Psychosis: Preliminary Results from a Large Randomised Controlled Trial of Individual Placement and Support*

Eoin Killackey, Henry Jackson, Kelly Allott, Susan Cotton

254. *Differential Effects of Antipsychotics on Quality of Life and Functioning in Chinese Patients with First-episode Psychosis*

Edwin Lee, Christy L.M. Hui, Wing Chung Chang, Sherry K.W. Chan, Elaine Ching, Eric Y.H. Chen

255. *Interpersonal Trauma and the Social Functioning of Adults with First Episode Psychosis*

Helen J. Stain, Kolbjorn Bronnick, Wenche ten velden Hegelstad, Inge Joa, Jan Olav Johannessen, Johannes Langeveld, Lauren Mawn, Tor Ketil Larsen

256. *The Effects of Self-stigma Content and Process on Subjective Quality of Life in People with Schizophrenia*

Kevin K.S. Chan, Winnie W.S. Mak

257. *Variables Influencing Subjective Well-being in Patients with Schizophrenia*

Seung-Hyun Kim, Changsu Han, Young-Hoon Ko, Jong-Woo Paik, Moon-Soo Lee, Hyun-Ghang Jeong, Jinseung Oh, Jung Jin Kim

258. *Quality of Life and Depression among Caregivers of Schizophrenics*

Priyanka Rawat

259. *Social Support, Quality of Life, Psychotic Symptoms, and Depression in Schizophrenia*

Sirijit Suttajit, Suttrak Pilakanta

260. *The Role of Consumer Feedback in Shaping Recovery Services for Agitated Psychotic People*

David Ash, Shuichi Suetani, Matt Halpin, Cassandra Burton

261. *Health Service and Resource Use at 12 Years in First Episode Psychosis*

Caragh L. Behan, David Moloney, Michele Hill, Anthony Kinsella, John Waddington, Mary Clarke

262. *Acute Medical Care Utilisation in Psychiatric Inpatients*

John Lally, Emma Wong, Hitesh Shetty, Anita Patel, Vivek Srivastava, Matthew TM Broadbent, Fiona Gaughran

263. *Clozapine Prescription to Treatment-resistant Schizophrenia Patients in Community Mental Health Services in São Paulo, Brazil*

Rodrigo Bressan, Deyvis Rocha, Ana Silveira, Cecilia Attux, Claudiane Daltio, Leticia Silva, Helio Elkis, John Kane

264. *Differences in Cannabis-related Experiences between Patients with a First Episode of Psychosis and Healthy Controls*

Matteo Bonomo, Francesca Bianconi, Marta Di Forti, Arianna Marconi, Anna Kolliakou, Simona A. Stilo, Valeria Mondelli, Pedro Gurillo Muñoz, Craig Morgan, Michael T. Lynskey, Robin M. Murray

265. *The Importance of Pharmacological and Non-pharmacological Factors for the Development of Organ Lesions and Occurrence of "Sudden Cardiac Death" in Patients with Schizophrenia. A PhD project as part of SURVIVE*

Anne Bugge, C.B. Høyer, L.W. Boel, G.L. Ottesen, J. Banner, J.L. Thomsen

266. *Clinical Characteristics in Early Onset First-episode Psychosis with Cannabis Use*

Radhika Patel, Maria-de-Gracia Dominguez, Helen Fisher, Sonia Johnson, Matthew Hodes

267. *Does Substance Abuse Increase the Risk of Schizophrenia?*

Nanna G. Toftdahl, Carsten Rygaard Hjorthoej



POSTERS, TUESDAY 08 APRIL

12:00 PM - 2:00 PM

Location: Cavaniglia

1. *Prevalence and Correlates of HIV Risk Behaviour among Persons with Schizophrenia in Southwestern Nigeria*
Olukayode Abayomi
2. *Perspective-taking Abilities in the Balance between Autism Tendencies and Psychosis Proneness*
Ahmad Abu-Akel, Stephen Wood, Peter Hansen, Ian Apperly
3. *Predictors of Theory of Mind and Social Functioning Impairments in Patients with Recent-onset of Psychosis*
Amelie M. Achim, Marc-André Roy, Marie-Audrey Lavoie, Philip Jackson
4. *Value Recalibration in First-episode Schizophrenia*
Ofer Agid, Gagan Fervaha, Krysta McDonald, Romie Littrell, Jessica Thoma, George Fousias, Eli Remington, Cynthia Siu, Gary Remington
5. *Escalated Social Aggression and Extracellular Synaptic Activity after Blockage of NMDA and mGluR1 Receptors in Central Nucleus of Amygdala in Developmental Schizophrenic Model*
Milad Ahmadi, Babak Khodaie, Ahmadali Lotfinia, Mahmoud Lotfinia, Ali Gorji
6. *Childhood Trauma, FKBP5 Gene and Psychotic Experiences in General Population*
Silvia Alemany, Bárbara Arias, Helena Villa, Jorge Moya, Manuel I. Ibáñez, Generós Ortet, Lourdes Fañanás
7. *Familial Liability, the BDNF-Val66Met Polymorphism and Psychotic-like Experiences*
Koksai Alptekin, Tolga Binbay, Hayriye Elbi, Nesli Zagli, Huseyin Onay, Ferda Ozkinay, Jim van Os
8. *Efficacy and Safety of Olanzapine Long-acting Injection in Patients with Schizophrenia: A Post-hoc Analysis of a 6-year, Multinational, Single-arm, Open-label Study*
Ernie Anand, Lovisa Berggren, Agoston Toth, David McDonnell
9. *The Gothenburg Research and Investigation in Psychosis – GRIP – An Interdisciplinary Naturalistic Study with the Major Aims to Improve Diagnostics and Predict Outcome in Patients Believed to be Suffering from a Psychotic Illness*
Kristina Annerbrink, Irma Rymo, Anneli Goulding, David Berg, Christian Öhrn, Mats Gustafsson, Mikael Landén
10. *Acceptability and Feasibility of Extended Use of Mobile Phone Technology to Assess Psychotic Symptoms in DSM-IV Schizophrenia Patients*
Eve Applegate, Jasper Palmier-Claus, Matthew Machin, Caroline Sanders, John Ainsworth, Shòn Lewis

11. *Reduction in the Use of Seclusion with the Introduction of Recovery Principles in an Acute Psychiatric Unit*
David Ash, Peter Metcalfe, Cassandra Burton
12. *Lifetime Symptom Dimensions and their Correlation with Cognitive Function, Functional Level, and Treatment Response in Chronic Schizophrenia Patients*
Moonoh Bae, Youngah Cho, Seunghyong Ryu, Hyeji Oh, Sohee Oh, Taesung Park, Kyung Sue Hong
13. *The Effect of Previous Dose or Oral Aripiprazole (10 or 30 mg/ day) on the Efficacy and Tolerability of Aripiprazole Once-monthly: Results from Post-hoc Analyses from Two Double-blind, Randomized, Controlled Trials*
Ross A. Baker, Anna Eramo, Anna-Greta Nylander, Lan-Feng Tsai, Timothy S. Peters-Strickland, Dusan Kostic, Raymond Sanchez
14. *Facial Emotion Identification in Early-onset and First-episode Psychosis: A Systematic Review with Meta-analysis*
Sophie J. Barkl, Suncica Lah, Anthony W. Harris, Leanne Williams
15. *Postnatal mGluR5 Ablation from Parvalbumin-positive Interneurons Alters the Responsivity to Psychotomimetic Drugs*
Samuel A. Barnes, Terrence J. Sejnowski, M. Margarita Behrens, Athina Markou
16. *Relatives' Expressed Emotion, Attributions and Emotional State in Clinical High-risk and Onset Stages of Psychosis*
Neus Barrantes-Vidal, Tecelli Domínguez-Martínez, Thomas R. Kwapił
17. *Prevalence of Disease Relevant NMDA Receptor Autoantibodies in Refractory Psychosis*
Katherine Beck, John Lally, Sukhwinder Shergill, James H. MacCabe, Fiona Gaughran, Oliver Howes
18. *Estimating the Cost and Effect of Early Intervention on In-patient Admission in First Episode Psychosis*
Caragh L. Behan, Niall Turner, Elizabeth Owens, Adam Lau, Anthony Kinsella, John Cullinan, Brendan Kennelly, Mary Clarke
19. *Animal Models of Schizophrenia Symptoms: Polydipsia Following Subchronic MK-801, Post-weaning Social Isolation or Amphetamine Sensitization in Rats*
Richard J. Beninger, Emily R. Hawken
20. *The Association between Infections and General Cognitive Ability in Young Men – A Danish Nationwide Study*
Michael E. Benros, Holger Sørensen, Philip Nielsen, Merete Nordentoft, Preben Bo Mortensen, Liselotte Petersen



21. *Maternal Smoking during Pregnancy and Symptom Severity among Offspring During Their First Episode of Psychosis*

Francesco Bernardini, Michael T. Compton

22. *Exploring the Impact of Family Interventions for Patients Presenting a First Episode Psychosis and their Families*

S  verine Bessero, Fabrice Chantaine, Manuel Tettamanti, Logos Curtis

23. *Affective Prosody in Remitted and Non-remitted Schizophrenia Patients Compared to Healthy Controls*

Falko Biedermann, Baumgartner Susanne, Alexandra Kaufmann, Georg Kemmler, Christine Hoertnagl, Christian Widschwendter, Nursen Yalcin, W.Wolfgang Fleischhacker, Alex Hofer

24. *The Impact of Consanguinity on Risk of Extended Psychosis Phenotype*

Tolga Binbay, K  ksal Alptekin, Hayriye Elbi, Halis Ula  , Marjan Drukker, Jim van Os

25. *Anomalies in the Fabric of the Perineuronal Net and Schizophrenia Pathophysiology*

Byron K.Y. Bitanirwe, Charmaine Pietersen, Tsung-Ung W.

26. *A Cross-sectional and Longitudinal Study of Global Cortical Morphology in the Edinburgh High Risk Study of Schizophrenia*

Catherine L. Bois, Liat Levita, Lisa Ronan, Stephen Lawrie

27. *Altered Hippocampal Glutamate Function in People at Ultra High Risk for Psychosis*

Matthijs G. Bossong, Paul Allen, Carly Samson, Haleema Rasheed, Beverly Quinn, Ilaria Bonoldi, Gemma Modinos, James Stone, Oliver Howes, Philip McGuire

28. *Obsessive Compulsive Symptoms and Premorbid Adjustment as Predictors of Transition to Psychosis in Ultra-high Risk Subjects*

Julie Bourgin, Emilie Magaud, Anne Gut, Mathilde Kazes, Marie-Odile Krebs

29. *How to Predict and Measure Medication Adherence in Schizophrenia: Twelve Months of Electronic Monitoring (MEMS*) in the Swedish COAST-study*

Cecilia Brain, Katarina Allerby, Birgitta Sameby, Patrick Quinlan, Erik Joas, Ulla Karilampi, Eva Lindstr  m, Jonas Eberhard, Tom Burns, Margda Waern

30. *Link between Neurological Soft Signs and Poor Outcome Schizophrenia (Krapelinian Sub-type): Preliminary Results*

Marie-Cecile Bralet, Nordine Mebtoul, Trang Ton, Christian Koegel, Isabelle Amado, Marie-Odile Krebs

31. *Proteomic Investigation and Characterisation of Post-translational Modifications of Histone Proteins Purified from Prenatally Stressed Mouse Brain Tissue*

Elizabeth Brindley, Melanie Foeking, Daniel van den Hove, Jos Prickaerts, Gerard Cagney, David Cotter

32. *"People with Schizophrenia Sometimes Talk to themselves, and that's Okay." Community-partnered Development of Anti-stigma Messages*

Beth Broussard, Michael T. Compton

33. *Criminal Justice Settings as a Potential Site for Early Detection of Psychotic Disorders and Reducing Treatment Delay*

Beth Broussard, Michael T. Compton

34. *Increased Stability of Microtubules in Cultured Olfactory Neuroepithelial Cells from Individuals with Schizophrenia*

Alan Brown, Karin Borgmann-Winter, Chang-Gyu Hahn, Lorna Role, David Talmage, Raquel Gur, Jacky Chow, Patric Prado, Thelma McCloskey, J. Chloe Bulinski, Andrew Dwork

35. *The Effect of Lifestyle Treatments on Bodyweight, Cardiometabolic Risk and Depression in People with Severe Mental Illness - A Meta-analysis*

Joanneke Bruins, Frederike J  rg, Richard Bruggeman, Cees Slooff, Eva Corpeleijn, Marieke Pijnenborg

36. *Global Methylation Levels of Schizophrenia Subjects Supplemented with Folate: A Pilot Study*

Kyle J. Burghardt, Vicki Ellingrod

37. *Facial Affect Recognition: The Impact of Culture and Schizotypal Traits*

Linda K. Byrne, Richard Zhang, Xiaoyan Xu, Renati Solomon, Eugenia Vinet, Jose Luis Saiz, David Mellor

38. *Prediction of Symptom Outcome in Clinical High Risk Subjects Using the Acoustic Startle Paradigm*

Kristin Cadenhead, Jean Addington, Carrie E. Bearden, Tyrone Cannon, Tom McGlashan, Daniel Mathalon, Diana Perkins, Larry J. Seidman, Ming Tsuang, Elaine Walker, Scott Woods

39. *An Association Study of RGS4 Polymorphisms with Clinical and Neurocognitive Profiles of Schizophrenia Patients*

G  ne   Can, Emre G  lsu, Banu De  girmencio  lu, Ahmet Topuzo  lu,     dem Eresen Yazıcıo  lu, Berna Binnur Akdede, K  ksal Alptekin

40. *Theory of Mind and Personality Pathology in Schizophrenia Patients and First-degree Relatives*

Briana D. Cassetta, Vina Goghari

41. *Do Reward-processing Deficits in Schizophrenia Promote Cannabis Use? An Investigation of Response to Natural Rewards and Drug Cues*

Clifford M. Cassidy, Mathieu Brodeur, Martin Lepage, Ashok Malla

42. *Durability of Reinforcement Learning Changes after Cognitive Remediation*

Matteo Cella, Anthony Bishara, Clare Reeder, Til Wykes



43. *Automatic Self-stigma-relevant Associations in People with Schizophrenia Experiencing Habitual Self-stigma: Evidence from the Brief Implicit Association Tests*
Kevin K.S. Chan, Winnie W.S. Mak

44. *Three-year Outcome Comparison between Patients Presenting with First-episode Psychotic Mania and Schizophrenia to EASY Program in Hong Kong*
Chung W. Chang, Emily S.K. Lau, L.M. Hui, K.W. Chan, H.M. Lee, Eric Y.H. Chen

45. *Changes in Body Mass and Metabolic Profiles over 12 Months in Patients with First-episode Schizophrenia with Assured Antipsychotic Adherence*
Bonginkosi Chiliza, Laila Asmal, Piet Oosthuizen, Yvette van Niekerk, Rajiv Erasmus, Martin Kidd, Anil K. Malhotra, Robin Emsley

46. *Comparison of the Rorschach Performance between Schizophrenia and Bipolar I Disorder with Psychotic Features*
Booyeol Choi, Minkyung Koh, Yeon Ho Joo, Eun Ah Noh

47. *Similar Age-related Decline in Cortical Activity over Frontotemporal Regions in Schizophrenia and Healthy Individuals: A Multi-channel Near-infrared Spectroscopy Study*
Po Han Chou, Koike Shinsuke, Yukika Nishimura, Yoshihiro Satomura, Akihide Kinoshita, Ryu Takizawa, Chin Hong Chan, Tsuo Hung Lan, Kiyoto Kasai

48. *Investigation of the Pro-melanin-concentrating Hormone Gene in Antipsychotic Induced Weight Gain*
Nabilah Chowdhury, Arun Tiwari, Eva Brandl, Jeffrey Lieberman, Herbert Y. Meltzer, James Kennedy

49. *Hyper-theory-of-mind in Children with Psychotic Experiences*
Lars Clemmensen, Jim van Os, Anne Mette Skovgaard, Mette Væver, Els M.A. Blijd-Hoogewys, Agna A. Bartels-Velthuis, Pia Jeppesen

50. *Is Cognitive Remediation Therapy an Effective Intervention in Enhancing Vocational Outcomes for People with Severe Mental Illness?*
Natalia Contreras, Susan Rossell, David J. Castle, Carol Harvey, Ellie Fossey, Caroline Crosse, Dea Morgain

51. *Birth Weight and IQ Are Associated with Adult Cortical Surface Area: Additional Evidences Based on a Twin Study*
Aldo Cordova-Palomera, Silvia Alemany, Carles Falcón, Nuria Bargalló, Ximena Goldberg, Benedicto Crespo-Facorro, Igor Nenadic, Lourdes Fañanás

52. *COMT Moderation of the Association between Momentary Stress and Psychotic-like Experiences in Daily Life*
Paula Cristóbal-Narváez, Araceli Rosa, Marta de Castro-Català, Tamara Sheinbaum, Thomas R. Kwapil, Neus Barrantes-Vidal

53. *The Kumon Method for Cognitive Remediation of Individuals with Schizophrenia: A Randomized, Placebo-controlled Trial*
Marisa M. Crivellaro, Paula Martins, Monia Musskopf, Suely Ayuso, Silvia Arcury, Paula Martins, Zilda Celidonio, Rosa Bertinho, Mario Louzã

54. *Increasing Therapeutic Activities on Acute Psychiatric Wards*
Emese Csipke, Diana Rose, Paul McCrone, Tom Craig, Til Wykes

55. *Effect of Lurasidone on Depressive Symptoms in Patients with Schizophrenia*
Josephine Cucchiaro, Jay Hsu, Antony Loebel

56. *Learn Before You Burn: THC Impairs Encoding but not Retrieval of Verbal Information*
Deepak Cyril D'Souza, Mohini Ranganathan, Peter Addy, Halle Thurnauer, Ashley Schnakenberg, Brian Pittman, Rajiv Radhakrishnan, Patrick Skosnik, Richard Andrew Sewell

57. *Characteristics of Cognitive Deficit in Schizophrenia and Major Depression (in Terms of Differential Diagnostic)*
Nataliy Andreevna Daeva, Elizaveta Fedotova

58. *Lower Anterior Cingulate Volume in Seriously Violent Men with Antisocial Personality Disorder or Schizophrenia and a History of Childhood Abuse*
Mrigendra Das, Veena Kumari

59. *Relationship between the BDNF Val66Met Polymorphism, Childhood Trauma, Schizotypy and Psychotic-like Experiences*
Marta de Castro-Català, Neus Barrantes-Vidal, Thomas R. Kwapil, Paula Cristóbal-Narváez, Araceli Rosa

60. *Service Satisfaction and Spiritual Well-being as Predictors of Quality of Life among Patients with Schizophrenia: A Longitudinal Study Using a Structural Equation Model Approach*
Giovanni De Girolamo, Mariangela Lanfredi, Valentina Candini, Chiara Buizza, Clarissa Ferrari, Maria Elena Boero, Gian Marco Giobbio, Laura Iozzino

61. *Patterns of Habituation to Novelty in First Episode Schizophrenia and Control Subjects*
Elisabetta C. del Re, Margaret Niznikiewicz, Tracey Petryshen, Robert McCarley, Kevin Spencer

62. *Distinct Effects of Lithium Chloride and Clozapine in Preventing Suicide-related Behaviors in a Two-hit Model of Schizophrenia*
Jessica Deslauriers, Karine Belleville, Nicolas Beaudet, Philippe Sarret, Sylvain Grignon



63. *The Impact of a NCAN Gene Polymorphism on Memory and White Matter Microstructure in Healthy Individuals: A Diffusion Tensor Imaging Study*

Bruno Dietsche, Thomas Weikert, Davide Laneri, Heidelore Backes, Stephanie Witt, Marcella Rietschel, Jens Sommer, Tilo Kircher, Axel Krug

64. *Spectral Entropy Modulation Decrease in Patients with Schizophrenia during P300 Evocation*

Alvaro Diez, Vanessa Suazo, Alejandro Bachiller, Marta Ayuso, Cristina Domínguez, Roberto Hornero, Jesús Poza, Vicente Molina

65. *Image-based Automated Detection of First-episode Schizophrenia: The Importance of Spatial Resolution of Morphological Features and Ensemble Learning*

Petr Dluhos, Daniel Schwarz, Tomas Kasperek

66. *Premorbid Impairments in Childhood-onset Schizophrenia*

David I. Driver, Deanna Greenstein, Madison Farmer, Judith Rapoport, Nitin Gogtay

67. *Are Patients with Schizophrenia Abnormally Sensitive to Pain?*

Céline Z. Duval, André Dufour, Pierre Vidailhet, Kemmel Véronique, Yannick Goumon, Guy Mensah-Nyagan, Catherine Schmidt-Mutter, André Muller, Anne Giersch

68. *Brain Systems Regulating Food-intake and Body Mass Changes during Acute Antipsychotic Treatment in First-episode Schizophrenia*

Robin Emsley, Laila Asmal, Bonginkosi Ciliza, Stefan du Plessis, Jonathan Carr, Martin Kidd, Matthijs Vink, René Kahn

69. *Negative Symptom Subgroups have Different Effects on Clinical Course after First Episode of Schizophrenia: A 24-month Follow-up Study*

Ceylan Ergul, Alp Üçok

70. *The Effects of Psychosocial Stress Induction on the Jumping to Conclusions Bias in People with Clinical Risk for Psychosis*

Anna O. Ermakova, Graham Murray, Ian Goodyer, Paul Fletcher, Veronika Dobler

71. *Oxidative Stress is Related to Neurocognition but not Social Cognition in Patients with Schizophrenia*

Aysen Esen-Danaci, Cristina Gonzalez-Liencre, Cumhur Tas, Elliot C. Brown, Soner Erdin, Ece Onur, Zeynep Cubukcoglu, Omerr Aydemir, Aysen Esen-Danaci, Martin Brüne

72. *DNA Methylation and GABAergic Pathology of Schizophrenia*

Helene Aparecida Fachim, Umarat Srisawat, Michael K. Harte, Caroline Dalton, Gavin Reynolds

73. *Jumping to Conclusions, Neuropsychological Functioning, and Delusional Beliefs in First Episode Psychosis*

M. Aurora Falcone, Benjamin Wiffen, Robin M. Murray, Marta Di Forti, Suzanne Jolley, Daniel Freeman

74. *Engagement with Psycho-social Interventions Within and an EI Psychosis Service*

Felicity Fanning, Roisin Doyle, Patrick Egan, Niall Turner, Elizabeth Lawlor, Mary Clarke

75. *Prenatal Exposure to Maternal Immune Stimulation Leads to Changes in Myelin Proteins in the Adult Rat Prefrontal Cortex Which can be Prevented by Risperidone in Adolescence*

Lorna Farrelly, Melanie Föcking, Yael Piontkewitz, Patrick Dicker, Jane English, Kieran Wynne, Mary Cannon, Ina Weiner, Gerard Cagney, David Cotter

76. *Behavioural Economics of Effort-based Reward-driven Choice in Schizophrenia*

Gagan Fervaha, Ofer Agid, George Foussias, Ariel Graff-Guerrero, Konstantine Zakzanis, Gary Remington

77. *Perceived Stress is Associated with the Risk of Hospitalization in Early Psychosis: 1-year Prospective Study*

Rosa Maria Gabernet Florensa, Rosa Monseny, Laura Ortega, Itziar Montalvo, Oscar Reátiga, Marta Creus, Javier Labad

78. *Determinants of Poor Diet among a Large Sample of People Living with a Psychotic Illness*

Cherrie Galletly, Lisa Hahn, Debra Foley, Andrew Mckinnon, Gerald Watts, David Castle, Dennis Liu, Anna Waterreus, Vera A. Morgan

79. *Cognitive Biases, Personality and Dimension of Psychotic-like Experiences in the General Population*

Łukasz Gawęda, Katarzyna Prochwicz, Matteo Cella

80. *Investigation of the Relationship between Cognition and Anatomical Networks in Schizophrenia*

Suzanne Geier, Nelson Brent, Kelvin O. Lim, S. Charles Schulz

81. *Frequency and Characteristics of the Attenuated Psychosis Syndrome and Delineation to Other Risk Profiles in a Sample of Help-seeking Individuals*

Miriam Gerstenberg, Anastasia Theodoridou, Nina Traber-Walker, Maurizia Franscini, Diana Wotruba, Sibylle Metzler, Diane Dvorsky, Christoph U. Correll, Susanne Walitza, Wulf Rössler, Karsten Heekeren

82. *Social Stress and Psychotic Symptoms in the Daily Life of Young Adults with Hearing Impairment*

Martin Gevonden, Inez Myin-Germeyns, Jan Booij, Wim van den Brink, Jim van Os, Jean-Paul Selten

83. *Genetic Variation in Arrb2 Is Associated with B-arrestin2 Expression and Striatal Activity during Working Memory*

Giulia M. Giordano, Antonio Rampino, Gianluca Ursini, Leonardo Fazio, Laura Ferranti, Rita Masellis, Mariateresa Attrotto, Ilaria Bitetti, Pasquale Di Carlo, Giuseppe Blasi, Alessandro Bertolino



84. *Semaphorins and Plexins Gene Expression is Altered in the Prefrontal Cortex of Schizophrenia Patients with and without Auditory Hallucinations*

Rocío González-Martínez, Javier Gilabert-Juan, Ana Rosa Saez, Guillermo Lopez-Campos, Noelia Sebastián, Juan Nacher, Julio Sanjuán, María Dolores Moltó

85. *The Effects of Motivational Incentives on Cognition in Patients with Schizophrenia and Negative Symptoms – A Functional Magnetic Resonance Imaging Study*

Oliver M. Hager, Matthias Kirschner, Matthias N. Hartmann, Agne Kluge, Martin Bischof, Philippe N. Tobler, Stefan Kaiser

86. *Structural MRI in First Episode Psychosis: An International Collaborative Mega-analysis of Individual Adult Patient Data*

Brian Hallahan, Colm McDonald, Anne Gallagher, Cathy Scanlon, Aengus O'Conghaile

87. *Once Monthly Paliperidone Palmitate – Tolerability and Treatment Response in Recently Diagnosed versus Chronic Non-acute Schizophrenia Patients Switched from Previously Unsuccessful Treatment with Oral Antipsychotics*

Ludger Hargarter, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernardo Carpiello, Pierre Vidailhet, Andreas Schreiner

88. *The Effects of Maternal Immune Activation and MK-801 on Mismatch Responses in Awake, Freely Moving Rats*

Lauren R. Harms, Deborah Hodgson, William Fulham, Michael Hunter, Markku Penttonen, Ulrich Schall, Juanita Todd, Cyndi Shannon-Weickert, Katerina Zavitsanos, Patricia Michie

89. *Do Community Treatment Orders Keep People Out of Hospital? The Influence of the Level of Community Care*

Anthony W. Harris, Joe Garside, Grant Sara

90. *Effect of Lifetime Stress on Resistance to Antipsychotic Treatment*

Ahmed Hassan, Vincenzo De Luca

91. *Childhood Abuse and Brief Life Events in Postpartum Psychosis*

Katie M. Hazelgrove, Carmine M. Pariente, Astrid M. Pauls, Susan Pawlby, Costanza Vecchio, Paola Dazzan

92. *N-acetylcysteine Prevents Increased Sensitivity to Amphetamine in Social Isolation-reared Mice*

Ana P. Herrmann, Radharani Benvenuti, Luisa Pilz, Elaine Elisabethsky

93. *Concordance Rates and Heritability in Schizophrenia, Data from a Danish Twin Study*

Rikke Hilker, Dorte Helenius, Birgitte Fagerlund, Axel Skytthe, Merete Nordentoft, Birte Glenthøj

94. *Optimizing Treatment and Signal Detection with EVP-6124 in a CIAS Phase 2b Study*

Dana Hilt, Ilise Lombardo, Maria Gawryl, Nancy Dgetluck, Richard Keefe

95. *Excess Mortality in Mental Disorders Attributable to Substance Use Disorders*

Carsten R. Hjorthøj, Jon Andersen, Michael Benros, Nanna G. Toftdahl, Carsten B. Pedersen, Merete Nordentoft

96. *Measuring the Gap between Cognition and Functioning: Evaluating Awareness of the Bridge between Cognition and Everyday Behaviour via the Assessment of Bridging Strategies of Thinking to Real-world ACTIVITIES (ABSTRACT)*

Katherine Holshausen, Kasley Killam, Emma Ayukawa, Christopher R. Bowie

97. *TREC-SAVE: A Randomised Trial Comparing Mechanical Restraints with Seclusion for Aggressive Patients in Psychiatric Hospitals*

Clive Adams, Gisele Huf, Evandro Coutinho

98. *Using Progressive Ratio Responding in Mice to Demonstrate Pharmacological Attenuation of Deficits in Motivation*

Zoe A. Hughes, Alexander I. More, Ashley Hanks

99. *The Relation between Lifetime Antipsychotic Medication and Cognitive Performance in Schizophrenia at Age 43 Years - The Northern Finland Birth Cohort 1966*

Anja Husa, Jani Moilanen, Graham Murray, Marianne Haapea, Irina Rannikko, Jennifer Barnett, Matti Isohanni, Hannu Koponen, Jouko Miettunen, Erika Jääskeläinen

100. *Minocycline Add-on to Haloperidol Blunts Haloperidol-mediated Expression of Early Genes Implicated in Glutamatergic Neurotransmission in Both Vehicle and Ketamine-treated Rats*

Felice Iasevoli, Carmine Tomasetti, Elisabetta F. Buonaguro, Gianmarco Latte, Rodolfo Rossi, Livia Avvisati, Camilla Avagliano, Giovanna Fico, Giuliana Mazzola, Federica Marmo, Andrea de Bartolomeis

101. *Postnatal Development of the Islands of Calleja: Achilles' Heel in the Onset of Psychosis?*

Dragos Inta, Andreas Meyer-Lindenberg, Peter Gass

102. *Identification of a Susceptibility Locus in a Consanguineous Family with Multiple Schizophrenia-affected Members*


Jose L. Ivorra, Manir Ali, Clare Logan, Tariq Mahmood, Shabana Khan, Alastair G Cardno, Colin Johnson, Chris F. Inglehearn, Steven Clapcote

103. *Stress-reactivity as Possible Predictor for Social Functioning in a Sample of Psychotic Patients, Unaffected Siblings and Healthy Controls*

Mayke Janssens, Tineke Lataster, Claudia Simons, Margreet Oorschot, Mariëlle Lardinois, Jim van Os, Inez Myin-Germeys

104. *Brain Imaging in Patients with Schizophrenic Spectrum Disorder*

Arvid Jensen, Pål Wiktor, Morten Jacobsen



105. *Prevalence and Profile of Cognitive Deficits in a Cohort of First-episode Antipsychotic-naïve Schizophrenia Patients*

Maria H. Jensen, Birte Glenthøj, Mette Ødegaard Nielsen, Sanne Wulff, Birgitte Fagerlund

106. *Psychopathology, Level of Functioning and Socioeconomic Status: A Descriptive Study of 42 Subjects from an Ultra High-risk Cohort*

Helle K. Jessen, Dorte Nordholm, Lasse Randers, Kristine Krakauer, Merete Nordentoft

107. *Cigarette Smoking is Associated with Reduced Cingulate and Insular Thickness among Patients with Psychosis and Bipolar Spectrum Disorders*

Kjetil N. Jørgensen, Ingeborg Skjærvø, Mørch-Johnsen Lynn, Unn Kristin Haukvik, Elisabeth Heffermehl Lange, Melle Ingrid, Ole Andreas Andreassen, Ingrid Agartz

108. *The Relationship between Language Ability and Cognitive Function in People with Schizophrenia*

Do Un Jung, Sung Jin Kim, Joo Cheol Shim, Bo Geum Kong, Jung Joon Moon

109. *Association of Family History of Psychosis to Social, Occupational and Global Outcome in Schizophrenia: Systematic Review and Meta-analysis*

Juha P. Käkälä, Joni Panula, Eetu Oinas, Noora Hirvonen, Erika Jääskeläinen, Jouko Miettunen

110. *Classifying Schizophrenia Using Joint Multivariate Pattern Recognition Analysis of Brain Function and Structure*

Lana Marija Kambeitz-Ilankovic, Nikolaos Koutsouleris, Sebastian von Saldern, Peter Falkai, Carlos Cabral

111. *Association Study Between Antipsychotics-induced Restless Legs Syndrome and Polymorphisms of MEIS1 Genes in Schizophrenia*

Seung-Gul Kang, Ho-Kyoung Yoon, Young-Min Park, Heon-Jeong Lee, Leen Kim

112. *Identical Pattern of Hedonic and Affective Reactivity to Daily-life Social Stress among Patients with Psychotic Disorder and Healthy Individuals*

Zuzana Kasanova, Dina Collip, Johan Lataster, Jim van Os, Inez Myin-Germeys

113. *Saliency Attribution in Schizophrenia Patients and Delusion-prone Subjects*

Teresa Katthagen, Anne Pankow, Sarah Diner, Stefan Koch, Andreas Heinz, Florian Schlagenhaut

114. *Early Detection and Intervention Project for Young People at Risk for Developing Psychosis in Uchinada*

Yasuhiro Kawasaki, Reiko Hashimoto, Sachiko Ono, Takamitsu Shimada, Hiromasa Kihara, Masahiko Tunoda

115. *Kanizsa Shape Perception and Contour Integration in Schizophrenia: What Is the Role of Spatial Frequency?*

Brian P. Keane, Danielle Paterno, Genna Erlikhman, Sabine Kastner, Steven Silverstein

116. *Interaction between Parental Psychosis and Delays on Early Motor Developmental Milestones in Schizophrenia - The Northern Finland 1966 Birth Cohort Study*

Emmi S.J. Keskinen, Anna Marttila, Merja Kyllönen, P.B. Jones, G.K. Murray, Kristiina Moilanen, Heli Koivumaa-Honkanen, Pirjo H. Mäki, Matti Isohanni, Erika Jaaskelainen, Jouko Miettunen

117. *Childhood Neurodevelopmental Disorders, IQ and Subsequent Risk of Psychotic Experiences in Adolescence: A Population-based Longitudinal Study*

Golam Khandaker, Jan Stochl, Stanley Zammit, Glyn Lewis, Peter B. Jones

118. *Histological Response on Different Model of Schizophrenia*

Babak Khodaie, Ahmad Ali Lotfinia, Milad Ahmadi, Mahmoud Lotfinia

119. *Reward System Dysfunction and Negative Symptom Dimensions in Schizophrenia*

Matthias Kirschner, Oliver Hager, Matthias Hartmann, Agne Kluge, Martin Bischof, Erich Seifritz, Philippe Tobler, Stefan Kaiser

120. *Does rTMS Help to Improve Negative Symptoms in Schizophrenia? Results from a Randomized Controlled Trial in the Netherlands*

H. Kneegting, Jozarni Dlabac-de Lange, Leonie Bais, Bert Visser, Frank Van Es, Els Reinink, Bertil Bakker, Edwin van den Heuvel, André Aleman

121. *Social Cognition Dysfunction and Abnormality of the Brain Structure*

Minkyung Koh, Yangsik Kim, Jung-Sun Lee, Yeon Ho Joo, Changyoon Kim

122. *White Matter Structure in Subjects with Familial Risk for Psychosis - The Oulu Brain and Mind Study*

Jenni Koivukangas, Lassi Björnholm, Jouko Miettunen, Tanja Nordström, Pirjo H. Mäki, Erika Jääskeläinen, Jennifer Barnett, Vesa Kiviniemi, Osmo Tervonen, Juha Nikkinen, Juha Veijola

123. *A Transgenic Rat Model of DISC1opathies: Brain Disorders Characterized by DISC1 Aggregates and Aberrant Dopamine Homeostasis*

Carsten Korth, Svenja Trossbach, Verian Bader, Ingrid Prikulis, Sandra Schäble, Angelica de Souza Silva, Zoe A. Hughes, Nick Brandon, Joseph Huston

124. *Clinical and Brain Structural Predictors of 'Transition to Psychosis' or 'Risk Remission' in Individuals at Ultra High-risk for Schizophrenia*

Kristine Krakauer, Egill Rostrup, Bjørn H. Ebdrup, Lasse Randers, Dorte Nordholm, Louise Birkedal Glenthøj, Christina Wenneberg, Birte Y. Glenthøj, Merete Nordentoft

125. *Effects of Urban Upbringing on Brain Structure and Neuropsychological Functioning - A Multimodal DTI and VBM Study*

Axel Krug, Bruno Dietsche, Heide Lore Backes, Davide Laneri, Henriette Schneider-Haßloff, Tilo Kircher



126. *Head Movement Synchrony in Social Interactions of Patients with Schizophrenia Indicates Symptoms, Cognition and Social Functioning*

Zeno Kupper, Fabian Ramseyer, Holger Hoffmann, Wolfgang Tschacher

127. *Cardiovascular Risk Factors and Metabolic Syndrome in People with Severe Mental Illness – A UK Cross-sectional Study*

John Lally, Poonam Gardner-Sood, Khalida Ismail, Zerrin Atakan, Anthony S. David, David Hopkins, Daniel Stahl, Robin M. Murray, Kathryn E. Greenwood, Shubulade Smith, Fiona Gaughran

128. *Multitasking Capacities in Persons Diagnosed with Schizophrenia: A Preliminary Examination of their Neurocognitive Underpinnings and Ability to Predict Real World Functioning*

Julien Laloyaux, Martial Van der Linden, Marie-Noëlle Levaux, Haitham Mourad, Anthony Pirri, Hervé Bertrand, Marc-André Domken, Stéphane Adam, Frank Larøi

129. *Neurocognitive Architecture of Schizotypy in an Asian population*

Max Lam, Amy Yuning See, Jimmy Lee, Sim Kang, Attilio Rapisarda, Michael Kraus, Richard S. E. Keefe, Simon Collinson

130. *Neural Mediator of Schizotypy-antisocial Behaviors Relationship: Prefrontal and Orbitofrontal Gray*

Yin Hung Lam, Adrian Raine, Tatia M.C. Lee

131. *Autobiographical Memory Deficits in Patients with Chronic Schizophrenia*

Marc M. Lässer, Christina J. Herold, Lena Schmid, Johannes Schröder

132. *Differences in Insight between Schizophrenic and Schizoaffective Patients: Is Affectivity the Key?*

Santiago Latorre, Jesus Vicente Cobo, Esther Pousa, Lourdes Nieto, Susana Ochoa, Judith Usall, Iris Baños, Beatriz González, Carles García-Ribera, Insight Barcelona Research Group, Ada Ruiz

133. *Understanding the Physical Activity Behavior among Patients with Psychosis*

Jenny Tsui Man Lee, Edwin H.M. Lee, Sherry K.W. Chan, W.C. Chang, Eric Y.H. Chen, Christy L.M. Hui

134. *Persistence of Psychotic-like Experiences (PLEs) in the General Population of Hong Kong*

Kit Wai Lee, Sherry Chan, WC Chang, Edwin Lee, Christy Hui, Eric Chen

135. *Reduction in Hospital Stay of Patients with Schizophrenia after the Long-term Psychosocial Intervention*

Kyuyoung Lee, Heejin Oh, Minjeong Kang, Minyoung Kwon, Eunjeong Joo

136. *Positive and Negative Symptom Scores Correlated with Different Brain Regional Activation during Face Emotional Perception in Schizophrenia Patients: A Voxel-based sLORETA Source Activity Study*

Seung-Hwan Lee, Inki Sohn, Dowon Kim

137. *“Johyeonbyung (Attunement Disorder):” Renaming Mind Splitting Disorder as a Way to Reduce Stigma of Patients with Schizophrenia in Korea*

Yu Sang Lee, Jun Soo Kwon, Il Ho Park, Seon-Cheol Park, Jae-Jin Kim

138. *Capacities for Theory of Mind, Metacognition, and Neurocognitive Function as Independently Related to Performance on a Test of Emotional Recognition*

Bethany L. Leonhardt, Paul Lysaker, Martin Brune, Kelly Buck, Jamie Ringer, Jen Vohs, Michael Francis, Jay Hamm, Giampaolo Salvatore, Giancarlo Dimaggio

139. *Genotypic Variation, Childhood Literacy Skills and Risk of Psychotic Experiences in Early Adolescence: Findings from the ALSPAC Study*

Andrew J. Lewis, Mohajer Abbass Hameed, Sarah Sullivan, Stanley Zammit

140. *The Roles of Victimization Experiences, Paranoia and Salience Misattribution in Predicting Psychosis Proneness: The TwinsScan China Study*

Emma K. Li, Cecilia Leung, Francesca A. Cotier, Winifred Mark, Pearl Chen, Jim van Os, Timothea Touloupoulou

141. *Sensitivity to Minor Stressors Mediates the Relationship between Environmental Risk Exposures and Psychometric Risk for Schizophrenia*

Richard J. Linscott, Rebecca Grattan

142. *Social Cognition and Interaction Training - Tablet for Outpatients with Schizophrenia: A Preliminary Study*

Philip Y.T. Liu, David Roberts, Heather Carr

143. *Inflammatory Response in First Episodes of Psychosis. Markers of Cognitive Impairment*

Bibiana C. Llorca, Miquel Bioque, Ana Meseguer, Cristina Oliveira, Clemente Garcia-Rizo, Gisela Mezquida, Miquel Bernardo

144. *Integrated Genomic and Proteomic Evidence for the Postsynaptic Density in Schizophrenia*

Lorna M. Lopez, Jane English, Melanie Focking, David Cotter

145. *“I Am Here Because the Voices Came Back...” Narrative Exploration of the Function of Concept Formation in Adults Hospitalized Due to Symptoms of Schizophrenia*

Luka Lucic, Anzalee Khan, Daiute Colette



146. Delays to Treatment Predict Persistent Negative Symptom Domains

John Paul Lyne, Laoise Renwick, Brian O'Donoghue, Kevin Madigan, Tim Grant, Anthony Kinsella, Patricia McCarthy, Kevin Malone, Niall Turner, Eadbhard O'Callaghan, Mary Clarke

147. Deconstructing Negative Symptom Prevalence in First Episode Psychosis

John Paul Lyne, Laoise Renwick, Brian O'Donoghue, Kevin Madigan, Tim Grant, Anthony Kinsella, Patricia McCarthy, Kevin Malone, Niall Turner, Eadbhard O'Callaghan, Mary Clarke

148. Risk of Psychotic Disorder in Offspring of Parents with Schizophrenia: A Meta-analysis

Angus M. MacBeth, Andrew Gumley, Susanne Harder, Helen Beaumont

149. LINE1 Polymorphic Retrotranspositions in Schizophrenia

Fabio Macciardi, Guia Guffanti, James Fallon, Theo G.M. Van Erp, Michele Pato, Steven G. Potkin, James A. Knowles, Steven A. McCarroll, Carlos N. Pato, Simona Gaudi

150. Depersonalization in the Schizophrenia Spectrum: Lack of Sense of Agency at the Current Time of Action Due to Impaired Prediction

Takaki Maeda, Keisuke Takahata, Tsukasa Okimura, Akihiro Koreki, Sho Moriguchi, Masaru Mimura, Motoichiro Kato

151. Childhood and Adolescence Symptoms Preceding First Episode Psychosis in a General Population Based Northern Finland 1986 Birth Cohort

Pirjo H. Mäki, Tatu-Pekka Laakso, Marika Kaakinen, Jouko Miettunen, Graham Murray, Irma Moilanen, Tuula Hurtig, Matti Joukamaa, Markus Heinimaa, Sebastian Therman, Juha M. Veijola

152. Phenotypic Features of Patients with Schizophrenia Carrying De Novo Gene Mutations

Pierre J. Malherbe, J. Louis Roos, J. Louw Roos, Maria Karayiorgou, René Ehlers

153. Aberrant Affective Salience Attribution as a Risk Factor for Psychosis-proneness: Insights from the Twinsscan China Study

Winifred Mark, Francesca Alice Cotier, Lu Hua Chen, Kar Yu Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Touloupoulou

154. The Independent Effects of Two Novel Social-cognitive Remediation Programs for Schizophrenia: Emotion Recognition Training and Complex Mental-state Reasoning Training

Pamela Marsh, Robyn Langdon, Anthony W. Harris

155. Factors Related to Employability of Outpatients with Schizophrenia and Schizoaffective Disorders

Larissa C. Martini, Beatriz Petreche, Fernanda Vieira Lima, Patrícia Barbosa, Ana Olívia Silva, Gisela Moraes, Carlos Antônio Ferreira, Cecília Attux, Rodrigo Bressan

156. Decreased Cortical and Right Prefrontal Cortex Volumes Are Correlated with an Inflammatory Marker (IL-6) in Patients with Schizophrenia

Raffael Massuda, Mariana Pedrini, Bruna Panizzutti, Juliana Duarte, Sandra Polita, Leonardo Sodre, Pedro Goi, Mireia Vianna-Sulzbach, Leticia Czepielewski, Antonio L. Teixeira, Clarissa S. Gama

157. Progressive Reduction of Visual P300 Amplitude in Patients with First Episode Schizophrenia

Robert McCarley, Naoya Oribe, Yoji Hirano, Elisabetta C. del Re, Kevin Spencer, Margaret Niznikiewicz

158. A Comparison of Long-acting Injected Medications for Schizophrenia

Joseph P. McEvoy, Matt Byerly, Robert M. Hamer, Scott Stroup, Rosalie Dominik

159. "It Is Hard Work to Become Educated in One's Vulnerability." Patients' Conceptualization of Treatment for First Episode Psychosis: A Qualitative Study

Marianne Melau, Charlotte Bredahl Jacobsen, Anne A. E. Thorup, Merete Nordentoft

160. A Stratified Model for Psychosis Prediction in Clinical Practice

Chantal Michel, Stephan Ruhrmann, Benno G. Schimmelmann, Joachim Klosterkötter, Frauke Schultze-Lutter

161. An Open-label Trial of Adjunctive Tocilizumab in Schizophrenia

Brian J. Miller, James Dias, Peter Buckley

162. CAARMS in the Community: Assessing the Prevalence of Ultra-high Risk Symptoms in the General Population

John G. Mills, Craig Morgan, Philip McGuire

163. Altered Connectivity in the Hippocampal Network and Heightened Coupling with the Salience Network in People at Ultra-high Risk for Psychosis

Iun Miyata, Toby Winton-Brown, Nicolas Crossley, Shitij Kapur, Philip McGuire

164. Emotion Processing in Schizophrenia is State-dependent

Simone van Montfort, Arija Maat

165. Ethnicity, Social Disadvantage and the Long-term Course and Outcome of Psychosis


Craig Morgan, Julia Lappin, Margaret Heslin, Tim Croudace, Gillian Doody, Kim Donoghue, Peter B. Jones, Robin M. Murray, Paul Fearon, Paola Dazzan

166. Can the Motor Threshold Be Predictive to Response to rTMS Treatment in Schizophrenic Patients with Auditory Hallucinations?

Clément Nathou, Olivier Etard, Grégory Simon, Sonia Dollfus

167. Ketamine as a Model for Schizophrenia Deficits

Erica Neill, Celia J.A Morgan, Nicole Joshua, Olivia Carter, Susan L. Rossell



168. *Brain Structure in Subgroups of Persons at Ultra High-risk (UHR) Compared to First-episode Schizophrenia and Healthy Persons*

Igor Nenadic, Raka Maitra, Soumyajit Basu, Maren Dietzek, Nils Schoenfeld, Carsten Lorenz, Heinrich Sauer, Christian Gaser, Stefan Smesny

169. *Effect of Long-term Treatment with Lurasidone or Risperidone on Metabolic Syndrome Status in Patients with Schizophrenia*

John W. Newcomer, Andrei Pikalov, Kei Watabe, Josephine Cucchiaro, Krithika Rajagopalan, Antony Loebel

170. *Could Reward-disturbances Caused by Antipsychotic Medication Lead to Weight Gain?*

Mette Ødegaard Nielsen, Egill Rostrup, Henrik Nørbaek-Emig, Sanne Wulff, Birte Glenthøj

171. *Pierre Rivière vs. Anders Breivik: Is History Repeating Itself? Rationality, Madness, and Psychopathology in the 19th and 21st Century*

Lars Siersbæk Nilsson, Kristina Milting, Igor Petrov, René Sjølland, Annick Urfer Parnas

172. *Project CHANGE: It is about Life. A Randomised Clinical Trial Investigating the Effect of a Systematic Intervention for Improving the Physical Health of Patients with Schizophrenia*

Merete Nordentoft, Helene Speyer, Ole Mors, Hans Christian Noergaard

173. *The Prognostic Significance of Early Remission of Positive Symptoms in First Episode Psychosis*

Ross M.G. Norman, Rahul Manchanda, Raj Harricharan, Sandra Northcott

174. *Gender Differences in the Course of Schizophrenia across Diverse Regions of the World*

Diego Novick, William Montgomery, Tamas Treuer, Maria Victoria Moneta, Magdy Gado, Josep Maria Haro

175. *NPAS3: New Genetic and Biological Findings with Implications for Protein Aggregation and Schizophrenia*

Frederick Nucifora Jr., Leslie Nucifora, Nicolas Arbez, Elaine Roby, Lan Yu, Dong Wei, Lynn DeLisi, Akira Sawa, Christopher Ross, Russell Margolis

176. *The Increased Number of Phospholipid Abnormalities Observed in the Erythrocyte Membrane of Schizophrenia Patients is Associated with Increased Psychopathology*

Philippe Nuss, Haifa Bergaoui, Cédric Tessier, Ariel Fragman, Antonin Lamaziere, Kim Sweers, Marc De Hert

177. *Relationship between Psychotic Symptoms and Jumping to Conclusions: Are there Differences by Gender?*

Susana Ochoa, Christian Stephan-Otto, Judith Usall, Jorge Cuevas, Elena Huerta-Ramos, Josep Maria Haro

178. *Lifetime Exposure to Severe Trauma, Stress Sensitivity and Psychosis in a UK Sample*

Adanna N. Onyejiaka, Charlotte Gayer-Anderson, Stephanie Beards, Kathryn Hubbard, Inez Myin-Germeys, Robin M. Murray, Carmine Pariante, Paola Dazzan, Til Wykes, Craig Morgan, Ulrich Reininghaus

179. *Atypical Antipsychotics Normalize Gamma Evoked Oscillations in Patients with Schizophrenia*

Felipe Ortuño, Patricio Molero, Manuel Alegre

180. *The Course of Cognitive Functioning in Clinical High Risk and First-episode Psychosis Individuals*

Martina Papmeyer, Erich Studerus, Marlon Pflüger, Sarah Ittig, Avinash Ramyeed, Martina Uttinger, Susan Koranyi, Fabienne Fend, Anita Riecher-Rössler

181. *Neurocognitive Characteristics of Pchosis Risk Syndrome in Help-seekers and Healthy Control Children and Adolescents*

Marta Pardo, Montserrat Dolz, Anna Sintes, Olga Puig, Clara Espelt, Marta Pardo, Daniel Muñoz, Xavier Alvarez, Elena De la Serna, Luis San, Inmaculada Baeza

182. *Clinical Predictors of the Diagnostic Stability of Brief Psychotic Disorder*

Soyeon Park, Saejeong Lee, Jung Sun Lee, Yeon Ho Joo

183. *Quality of Prescribing for Schizophrenia: Evidence from a National Audit for Antipsychotics - Oral and Long-acting Injections (n=5055)*

Maxine X. Patel, Delia Bishara, Simone Jayakumar, Krysia Zalewska, David Shiers, Mike Crawford, Stephen Cooper

184. *Vagal Nerve Stimulation as a Novel Therapy for the Treatment of Schizophrenia*

Stephanie M. Perez, Flavia Carreno, Alan Frazer, Daniel Lodge

185. *REFLEX: Results of a Metacognitive Group Treatment to Improve Insight in Psychosis*

Gerdina Pijnenborg, Annerieke De Vos, Liset Van der Meer, Esther Sportel, Claudi Bockting, Mark van der Gaag, Andre Aleman

186. *Effect of 12 Months of Treatment on Weight in Patients with Schizophrenia Treated with Lurasidone, Risperidone, or Quetiapine XR*

Andrei Pikalov, Jonathan Meyer, Yongcai Mao, Josephine Cucchiaro, Antony Loebel

187. *Efficacy of Lurasidone in the Treatment of Schizophrenia with Prominent Negative Symptoms: A Post-hoc Analysis of Short-term Trials*

Andrei Pikalov, Nina Schooler, Jay Hsu, Josephine Cucchiaro, Robert Goldman, Antony Loebel

188. *Comparing Changes in Functional Activation and Neural Connectivity from Cognitive Remediation in Schizophrenia*

Ian S. Ramsay, Angus MacDonald, Matthew Marggraf, Tasha Nienow



189. *Deviant Neural Oscillations and Lagged Phase Synchronicity in Patients with an At-risk Mental State for Psychosis*

Avinash Ramyeed, Michael Kometer, Erich Studerus, Martina Papmeyer, Sarah Ittig, Ute Gschwandtner, Peter Fuhr, Anita Riecher-Rössler

190. *Effective Connectivity in Schizophrenia – Dynamic Causal Modelling of the Mismatch Negativity*

Siri M. Ranlund, Alvaro Diez, Rick A. Adams, Harriet Brown, Muriel Walshe, Robin M. Murray, Karl Friston, Dimitris Pinotsis, Elvira Bramon

191. *Sources of Clinical Distress in Young People at Ultra High Risk of Psychosis*

Marta Rapado-Castro, Ana Calvo, Patrick McGorry, Alison Yung, Barnaby Nelson

192. *Functional Neuroanatomy of the 'Jumping to Conclusions'-task in Patients with Schizophrenia, Anorexia, Depression and in Healthy Subjects*

Alexander M. Rapp, Larissa Wolkenstein, Katrin E. Giel, Andreas Wittorf, Michael Erb, Karin Langohr, Phöbe Schmierer, Dorothee E. Mutschler, Martin Hautzinger, Stephan Zipfel, Stefan Klingberg

193. *Sex-differences in the Relationship between Cannabis Use and Risk of Admission in Young Subjects with an Early Psychosis: A 1-year Follow-up Study*

Oscar Reatiga, Rosa Monseny, Laura Ortega, Rosa Gabernet, Itziar Montalvo, Marta Creus, Javier Labad

194. *Improving Functional Outcomes for Schizophrenia Patients in the Netherlands using Cognitive Adaptation Training as a Nursing Intervention – A Pilot Study*

Jeroen Redmeijer, Piotr Quee, Annemarie Stiekema, Johanna Wigman, Harald Schneider, Lisette van der Meer, Natalie Maples, Durk Wiersma, Edwin Van den Heuvel, Dawn Velligan, Richard Bruggeman

195. *Psychological Mechanisms Underlying the Association between Childhood Adversity and Psychosis: An Experience Sampling Study*

Ulrich Reininghaus, Matthew Kempton, Tom Craig, Lucia Valmaggia, Adanna N. Onyejiaka, Charlotte Geyer-Anderson, Jim van Os, Til Wykes, Robin Murray, Inez Myin-Germeys, Craig Morgan

196. *Impact of Psychiatric Comorbidity in Individuals at Ultra High Risk (UHR) of Psychosis*

Gurpreet Rekhi, Jimmy Lee, Jeanette Lim, Max Lam, Attilio Rapisarda

197. *Antipsychotics and Antidepressants and their Associations with Suicidal Ideation – The Northern Finland Birth Cohort 1966*

Ina Rissanen, Erika Jääskeläinen, Matti Isohanni, Hannu Koponen, Matti Joukamaa, Antti Alaräisänen, Jouko Miettunen

198. *The Factor Structure and Associated Clinical Variables of Formal Thought Disorder in First Episode Psychosis*

Eric Roche, John Lyne, Laoise Renwick, Lisa Creed, Anthony Kinsella, Mary Clarke

199. *Working Memory and Visual Memory Deficit in Children Offspring of Schizophrenia Patients*

Elisa Rodríguez-Toscano, Teresa Sánchez-Gutiérrez, Ángel Del rey-Mejías, Laura Roldán, David Fraguas, Mara Parellada, Celso Arango, Dolores Moreno

200. *Subgroup Analysis in a Randomized Clinical Trial of Long-acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia*

Robert Rosenheck, Sarah Leatherman, John Krystal, Matthew Liang

201. *Behavioural and fMRI Evidence of Semantic Categorisation Deficits in Schizophrenia*

Susan Rossell, Matthew Hughes

202. *Social Cognition in Neurocognitive Subtypes of Psychotic Disorders*

Jessica E. Rowland, Nicole O'Reilly, Leah Girshkin, Philip B. Mitchell, Vaughan J. Carr, Melissa J. Green

203. *Using Personalised Computer Modelling to Classify People with Treatment-resistant or Ultra-treatment-resistant Schizophrenia Based on Cognitive Measures*

Bruce Russell, Reggio Hartono, Meghan McIlwain, Valerie Anderson, Nikola Kasabov, Rob Kydd, Carolyn McNabb

204. *Studying Relationship between Schizophrenia and PAI-1 4G/5G Polymorphism in Iranian Patients*

Vida Sadeghifard, Seyed Mehdi Sadat, Ahmad Ebrahimi, Mohammad Reza Aghasadeghi, Abas Gharagouzloo, Elham Sadeghi, Foozieh Javadi

205. *Trajectories of Neurocognitive Functioning According to Cannabis Use Pattern in Children and Adolescents with First Episode Psychosis: A 2-year Follow-up Study*

Teresa Sanchez-Gutierrez, Celso Arango, Ana Calvo, Jessica Merchán-Naranjo, Dolores Moreno, Mara Parellada, Laura Roldan, Elisa Rodríguez, Marta Rapado-Castro

206. *Possible Association between ITIH3 Gene Polymorphism and Schizophrenia in a Japanese Population*

Daimei Sasayama, Hiroaki Hori, Toshiya Teraishi, Masahiko Tatsumi, Kotaro Hattori, Miho Ota, Teruhiko Higuchi, Hiroshi Kunugi

207. *A Novel Digital Health Approach to Treating Negative Symptoms Using a Personalized Real-time Intervention for Motivational Enhancement (PRIME)*

Danielle Schlosser, Silvia Vergani, Daniel Kim, Tim Campellone, Charlie Ward, Sophia Vinogradov



208. *PROACTIVE: Exploring Longitudinal Symptom Course to Understand Outcomes in LAI-oral Comparisons*

Nina Schooler, Peter Buckley, Jim Mintz

209. *Flexibly Dosed Paliperidone Palmitate in Non-acute but Symptomatic Patients with Schizophrenia Previously Unsuccessfully Treated with Long-acting Injectable Risperidone*

Andreas Schreiner, Paul Bergmans, Pierre-Michel Llorca, Giulio Corrivetti, Behcet Cosar, Pierre Cherubin, Ludger Hargarter

210. *Paliperidone Palmitate in Acute Patients with Schizophrenia – Treatment Response, Safety and Tolerability: A Prospective Flexible Dose Study in Patients Previously Unsuccessfully Treated with Oral Antipsychotics*

Andreas Schreiner, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernado Carpiello, Pierre Vidailhet, Ludger Hargarter

211. *Glutamatergic Dysfunction Associated with Focal Brain Cortical Thickness in Antipsychotic – Naïve Patients with Schizophrenia*

Carl C. Schultz, Alexander Gussew, Igor Nenadic, Natalie Biesel, Christian Gaser, Bianca Besteher, Jürgen Reichenbach, Heinrich Sauer, Stefan Smesny

212. *Mental Health Literacy on Psychosis and Depression: Do Labeling and Causal Attribution Affect Treatment Recommendations?*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

213. *The Course of At-risk Symptoms for Psychosis in the General Population: 2-year Follow-up of the Bern Epidemiological At-risk (BEAR) Study*

Frauke Schultze-Lutter, Chantal Michel, Caroline Linder, Benno G. Schimmelmann

214. *A Systematic Review of Factors influencing Antipsychotic Medication Adherence in Schizophrenia*

Kyra-Verena Sendt, Derek Kenneth Tracy, Sagnik Bhattacharyya

215. *Association between Stressful Life Events and Psychotic Experiences in Adolescence: Evidence for Gene-Environment Correlations*

Sania Shakoor, Helena Zavos, Claire. M.A Haworth, Philip McGuire, Alastair. G Cardno, Daniel Freeman, Angelica Ronald

216. *Association of Vitamin-D with Hippocampal Gray Matter Volume in Antipsychotic - Naive Schizophrenia Patients*

Venkataram Shivakumar, Sunil V. Kalmady, Amaresha C. Anekal, Janardhanan C. Narayanaswamy, Dania Jose, Boban Joseph, Ganesan Venkatasubramanian, Vasanthapuram Ravi, Bangalore N. Gangadhar

217. *Preliminary Sample Description of First Episode Psychosis in a Brazilian Large Catchment Area*
Rosana Shuhama, Silvia Tenan, Juliana Souza, Maristela S. Schaufelberger, Paulo Louzada-Junior, Antonio Santos, Craig Morgan, Jim van Os, Paulo Menezes, Cristina Del-Ben

218. *The Third National Survey about Prescription Patterns of Psychotropic Drug for Three Mental Disorders in China*

Tianmei Si, Nan Li

219. *Pitfall of Using Absolute Risk Score for Risk Assessment and Prevention*

Cynthia Siu, Carla Brambilla

220. *Transition and Psychosis Related Hemodynamic Correlates of Motivational Salience Processing*

Renata Smieskova, Jonathan Roiser, Christopher Chaddock, André Schmidt, Andor Simon, Anna Walter, Paolo Fusar-Poli, Undine Lang, Anita Riecher-Rössler, Stefan Borgwardt

221. *Mechanism of Action of ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses*

Gretchen L. Snyder, Kimberly Vanover, Joseph Hendick, Wei Yao, Peng Li, Robert E. Davis, Lawrence P. Wennogle, Sharon Mates

222. *Abnormal Hyperactive Self-awareness Processing in Schizophrenia*

Injung Sohn, Jung Suk Lee, Sang Woo Cho, Jae Jin Kim

223. *Axis I and Axis II Disorders in Young People at Ultra-high Risk of Developing a Psychotic Disorder: A Long-term Follow-up Study*

Anneliese E. Spiteri-Staines, Alison R. Yung, Paul G. Amminger, Stephen J. Wood, Ashleigh Lin, Emily Li, Barnaby Nelson

224. *Tackling Stigma: Developing Neighbourhood Interventions by Means of Focus Groups*

Esther Sportel, Gerdina Pijnenborg, Johan Arends

225. *Failure to Find Additive Interaction between Social Adversity in Childhood and Family Risk of Psychosis*


Simona A. Stilo, Matteo Bonomo, Francesca Bianconi, Conrad Iyegbe, Charlotte Gayer-Anderson, Kathryn Hubbard, Stephanie Beards, Helen Fisher, Marta Di Forti, Robin M. Murray, Craig Morgan

226. *Social Anxiety Disorder in Recent-onset Schizophrenia Spectrum Disorders: The Relation with Symptomology, Anxiety, and Social Rank*

Stephanie A. Sutliff, Marc-André Roy, Amélie Achim

227. *Transdiagnostic Exploration of the Association of Toxoplasma Gondii with Psychiatric Disorders: A Systematic Review and Meta-analysis*

Arjen Sutterland, Guillaume Fond, Anne Kuin, René Lutter, Tom van Gool, Andrei Szoke, Marion Leboyer, Lieuwe de Haan



228. *Reduced Anterior Cingulate Gray Matter Volume and Thickness in Subjects with Deficit Schizophrenia*

Michio Suzuki, Mizuho Takayanagi, Jacqueline Wentz, Yoichiro Takayanagi, David Schretlen, Elvan Ceyhan, Akira Sawa, Patrick Barta, Tilak Ratnanather, Nicola Cascella

229. *Sexual Side Effects in Patients Using Long-acting Depot Antipsychotics*

Marte Swart, Marrit de Boer, Durk Wiersma, Robert Schoevers, Henderikus Knegtering

230. *Effects on Cognition of Clozapine in Treatment-naïve First-episode Schizophrenia (FES): Preliminary Results*

Diana Taboada Denia, Javier Sanz-Fuentenebro, Tomás Palomo Álvarez, Vicente Molina Rodríguez

231. *Anti-psychotic Treatment Decreased iPLA2 Activity in First Episode Drug Naïve Patients*

Leda L. Talib, Helena P.G. Joaquim, Mauricio Serpa, Geraldo Busatto, Martinus van de Bilt, Marcus Zanetti, Wagner Gattaz

232. *Assessing Theories of Semantic Memory Function in Schizophrenia Thought Disorder at Two Levels*

Eric Tan, Susan Rossell

233. *A Double-blind, Placebo-Controlled, Randomized Withdrawal Study of Lurasidone for the Maintenance of Efficacy in Patients with Schizophrenia*

Rajiv Tandon, Antony Loebe, Debra Phillips, Andrei Pikalov, David Hernandez, Yongcai Mao, Josephine Cucchiaro

234. *Sleep Disruption in Children and Adolescents At-risk for Psychosis: A Preliminary Study*

Leila Tarokh, Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

235. *Deficient Cortical Activity during Motor Inhibition in Schizophrenia*

Maxime Térémetz, Caroline Malherbe, Marie-Odile Krebs, Catherine Oppenheim, Pavel Lindberg, Isabelle Amado

236. *Environmental Influences on Symptomatology of a First Episode Psychosis*

Manuel Tettamanti, Paolo Ghisletta, Adriano Zanello, Panteleimon Giannakopoulos, Marco C.G. Merlo, Logos Curtis

237. *Using Structural Neuroimaging to Make Quantitative Predictions of Symptom Progression in Individuals at Ultra-high Risk for Psychosis*

Stefania Tognin, William Petterson-Yeo, Isabel Valli, Chloe Hutton, James Woolley, Paul Allen, Philip McGuire, Andrea Mechelli

238. *Relation Between Psychotic-like Experiences and Major Depression in the Community Based Sample*

Ahmet Topuzoğlu, Tolga Binbay, Hayriye Elbi, Nesli Zağlı, Huseyin Onay, Feriştah Ferda Özkanay, Jim Van Os, Köksal Alptekin

239. *Dimensional Exploration of Personality Disorders in Schizophrenic Patients and their First-degree Relatives Using the Shedler-Westen Assessment Procedure*

Maria Chiara Torti, Antonino Buzzanca, Fabio Di Fabio, Marianna Frascarelli, Alessia Mirigliani, Chiara Squarcione, Massimo Biondi

240. *Can Childhood Adversity Predict Onset and Clinical Outcomes of Psychotic Disorders?*

Antonella Trotta, Jennifer O'Connor, Anna Kolliakou, Marta Di Forti, Paola Dazzan, Carmine Pariante, Anthony S. David, Robin M. Murray, Helen Fisher

241. *Dose and Dosing Frequency of Long-acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications*

Hirofumi Uchida, Takefumi Suzuki

242. *Exceptional Experiences in Healthy People - Early Warning Signals of Psychosis?*

Lui Unterrassner, Thomas A. Wyss, Peter Krummenacher, Diana Wotruba, Peter Brugger, Helene Haker Rössler, Gerd Folkers, Wulf Rössler

243. *[11C]GMOM as New Potential PET Radiotracer to Image the NMDA Receptor in Vivo*

Thalia F. van der Doef, Sandeep (SVS) Golla, Pieter (PJ) Klein, Robert (RC) Schuit, Bert (AD) Windhorst, Adriaan (AA) Lammertsma, Bart (BNM) van Berckel, Ronald (R) Boellaard

244. *Testing the Estrogen Hypothesis of Schizophrenia: Associations between Cumulative Estrogen Exposure and Cerebral Structural Measures*

Christine van der Leeuw, Petra Habets, Ed Gronenschild, Patrick A.E. Domen, Stijn Michielse, Martinus van Kroonenburgh, Jim van Os, Machteld Marcelis

245. *Cognitive Functioning Associated with Stimulant Use in Patients with Non-affective Psychosis, their Unaffected Siblings and Healthy Controls*

Floor J. van der Meer, Julia Meijer, Carin Meijer, Wim van den Brink, Eva Velthorst

246. *Plasma Oxytocin and Testosterone Levels in Patients with Psychotic Disorder, Their Unaffected Siblings and Healthy Controls: Results from the EU-GEI Project*

Elsje van der Ven, Daniella S. van Dam, Floor J. van der Meer, Elles Messchaert, Eva Velthorst, Lieuwe de Haan, Jean-Paul Selten

247. *Subtle Movement Disorders in Individuals at Risk of Schizophrenia*

Peter van Harten, Thierry Q. Mentzel, Ritsaert Lieve, Jeroen P. Koning, P. Roberto Bakker, Diederik E. Tenback

248. *Negative Symptoms, Social Self-efficacy and Social Function in Schizophrenia: What Is the Pathway?*

Anja Vaskinn, Ole A. Andreassen, Ingrid Melle, Kjetil Sundet



249. *Psychosis Liability, Paranoia and Distress in Experimental Virtual Reality Social Environments*
Wim Veling, Roos Pot-Kolder, Jacqueline Counotte, Mark van der Gaag

250. *Theory of Mind in First Episode Schizophrenia: Clinical and Neurocognitive Correlates, State vs Trait, Relationship to Daily Functioning*
Joseph Ventura, Kenneth L. Subotnik, Arielle Ered, Denise Gretchen-Doorly, Gerhard S. Hellemann, Keith H. Nuechterlein

251. *Interaction between GSK-3 β rs12630592 and HTR2A rs6314 Polymorphisms on Cerebral Activity and Behavior during Attention*
Rosa Vitale, Paolo Taurisano, Linda A. Antonucci, Barbara Gelao, Rita Masellis, Raffaella Romano, Apostolos Papazacharias, Annabella Di Giorgio, Grazia Caforio, Giuseppe Blasi, Alessandro Bertolino

252. *Is Aerobic Exercise Effective in Improving Negative Symptoms in Patients with Schizophrenia? The Results of a Meta-analysis*
Sjoerd J. Vogel, Mark van der Gaag, Henderikus Knegtering, Stynke Castelein

253. *Differential Diagnosis of Schizophrenia vs. Borderline Personality Disorder Using Pattern Classification Methods in Structural MRI Images*
Sebastian von Saldern, Eva Meisenzahl-Lechner, Lana Kambeitz-Ilankovic, Carlos Cabral, Nikolaos Koutsouleris

254. *Dynamic Causal Modeling of fMRI Data Reveals Disordered Frontal-hippocampal-striatal Interactions during Associative Learning in Schizophrenia Patients*
Sunali Wadehra, Patrick Pruitt, Eric Murphy, Vaibhav Diwadkar

255. *Tissue-specific DNA Methylation across Blood and Brain and its Application to Schizophrenia*
Esther Walton, Johanna Hass, Jingyu Liu, Matthias Kirsch, Gabriele Schackert, Veit Roessner, Randy L. Gollub, Vince Calhoun, Stefan Ehrlich

256. *Age of Onset and Prevalence of Substance Use in Help-seeking Ultra-high Risk Youth are Linked to Current Psychopathology*
Philip B. Ward, Shanna Logan, Alana Scully, Danielle Mathersul, Celia Loneragan, Jackie Curtis, Helen Stain, Patricia Michie, Juanita Todd, Ulrich Schall, Robyn Landon, Rebekah Atkinson

257. *Perceptions of Participating in a Lifestyle Intervention From the Perspective of Patients with Psychosis*
Rikard E. Wärdig, Margareta Bachrach-Lindström, Sally Hultsjö, Torbjörn Lindström, Anniqa Foldemo

258. *Metabolic Syndrome in People with Psychosis: Is Cannabis Protective?*
Anna Waterreus, Patsy Di Prinzio, Cherrie Galletly, David J. Castle, Gerald Watts, Vera A. Morgan

259. *High False Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia*
Cheryl Wehler, Sheldon H. Preskorn

260. *Object Pattern Separation Performance in Schizophrenics Is Consistent with Disrupted Hippocampal Dentate Gyrus Activity and Compromised Neurogenesis*
Keith Wesnes, Lawrence Brownstein, Howard Hassman

261. *Schizophrenia: Bilirubin Levels Correlate with Positive Symptoms*
Christian G. Widschwendter, Maria Rettenbacher, Georg Kemmler, Monika Edlinger, Susanne Baumgartner, W. Wolfgang Fleischhacker, Alex Hofer

262. *The Effects of Dopaminergic Manipulation in Healthy Controls Compared to Patients with Schizophrenia during Social Decision-making*
Rebekah Wigton, Thomas White, Sukhi Shergill

263. *OTX2 Expression in Human Prefrontal Cortex Development and in Subjects with Schizophrenia*
Tsung-Ung W. Woo, Katina M. Athanas, Sarah A. Mauney

264. *Increased Pattern Detection in Meaningless Noise of Healthy People with Exceptional Experiences*
Thomas A. Wyss, Lui Unterrassner, Peter Krummenacher, Diana Wotruba, Peter Brugger, Helene Haker, Gerd Folkers, Wulf Rössler

265. *A Treatable Cause of Catatonia: Anti-NMDA Receptor Encephalitis in a Young Woman*
Woon Yoon, Saejeong Lee, Jungsun Lee, Yeonho Joo, Changyoon Kim

266. *Tardive Dyskinesia in Relation to Estimated Dopamine D2 Receptor Occupancy in Patients with Schizophrenia: Analysis of the CATIE data*
Kazunari Yoshida, Robert Bies, Takefumi Suzuki, Gary Remington, Bruce Pollock, Yuya Mizuno, Masaru Mimura, Hiroyuki Uchida

267. *Prefrontal Cortex Thickness in PTSD and Schizophrenia and the Role of Childhood Trauma*
Andre Zugman, Elson Asevedo, Rodrigo Mansur, Gracielle Asevedo, Ary Araripe, Lara Faria, Vitor Tardelli, Rodrigo Bressan, Andrea Jackowski, Elisa Brietzke




INDEX OF PRESENTERS AND AUTHORS*

Aas M. 51
Abayomi O. 4, 122
Abhishekh H. 113
Abi-Dargham A. 16, 44, 66
Aboraya A. 106
Abu-Akel A. 122
Achim A. 122
Adams C. 131
Adams R.A. 104
Adcock R.A. 46
Agid O. 45, 90, 116, 122
Ahmadi M. 122
Aikawa S. 119
Ajnakina O. 116
Akbarian S. 42
Akil H. 13, 26
Alameda L. 90
Alberati D. 56
Aleman A. 5, 84
Alemany S. 70, 96, 122
Allen P. 54, 58
Alonso-Solís A. 98
Alptekin K. 122
Álvarez X. 109
Amato D. 4, 60, 71
Amminger P. 67
Anand E. 122
Anderson K. 52
Anhøj S. J. 98
Anil Yağcıoğlu A. 96
Annerbrink K. 122
Anticevic A. 54, 69
Antonucci L.A. 98
Appelbaum P. 35
Applegate E. 122
Arango C. 3, 5, 31, 37
Armando M. 102, 70
Ash D. 120, 123
Atkins J. 82
Aydinli E. 113
Ayer A. 103
Bacon E. 104
Bae M. 123
Baeza I. 109
Bagalkot T. 87
Bahn S. 36
Bai Y.M. 91
Bailey C. 4
Bainbridge E. 89
Bais L. 73
Bak M. 117
Baker R.A. 123
Bakker P. R. 70, 106
Bales K. 14, 39
Balu D.T. 96
Barak Y. 117
Barch D.M. 14, 30, 35, 46
Barkl S. 123
Barnes S.A. 123
Barrantes-Vidal N. 70, 116, 123
Bartels-Velthuis A. 91
Bartzokis G. 97
Barzilay R. 72
Bassett A. 62
Bearden C. 62
Beards S. 106
Beck K. 123
Behan C.L. 120, 123
Ben-Mabrouk F. 80
Bendall S. 89
Beninger R. 123
Benros M. 123
Berg A. 70
Bergen S. 57
Bernardini E. 124
Bessero S. 124
Besteher B. 74
Biagianti B. 73
Biedermann F. 124
Binbay T. 124

Birchwood M. 52, 62
Birnbaum M. 52
Bischof M. 111
Bisoglio J. 87
Bitanirwe B.K.Y. 4, 124
Blomström A. 41
Blumberg D. 61
Bohlken M. 100
Bois C.L. 124
Boks M. 32
Bonomo M. 121
Bonvino A. 98
Boonstra N. 85
Bosch S. 84
Bossong M.G. 124
Bourgin J. 124
Brain C. 124
Bralet M.C. 104, 124
Brennand K. 51
Bressan R. 121
Brindley E. 124
Brink M. 115
Broussard B. 125
Brown A. 41, 125
Brown D. 91
Bruins J. 125
Brunelin J. 61
Bryant E. 78
Buchanan R. 31, 68
Buckley P. 12, 26, 67
Bugarski-Kirola D. 34
Bugge A. 121
Bull H. 119
Bullmore E. 14, 30, 36
Burdick K. 32
Burghardt K.J. 125
Burshtein S. 77
Byrne L.K. 119, 125
Cadenhead K. 125
Cahn W. 78
Cairns M.J. 112
Calem M. 70
Calhoun V. 35
Callaghan R. 16, 66
Campos R.C. 108
Can G. 125
Cannon M. 4, 12, 16, 65
Cannon T. 36
Cantillon M. 34
Carpenter W.T. 4, 12, 35, 40, 69
Carr V. 106
Cassetta B.D. 125
Cassidy C.M. 82
Castelein S. 95
Castle D. 4, 40
Castro M. 98
Cella M. 88, 125
Champagne-Lavau M. 87, 104
Chan R.C.K. 78
Chan K.K.S. 78, 120, 126
Chan T.C.W. 104
Chang C.W. 95, 116, 126
Charles S. 87
Chaumette B. 91
Chee K. Y. 115
Chen E.Y.H. 41
Chen L.H. 113
Chen S.M. 96
Chiliza B. 126
Chisholm K.E. 106
Cho Y. 108
Choi B. 126
Choi J. 94
Chou P.H. 126
Chowdhury N. 108, 126
Christiani C.A.J. 84
Christoffersen C.T. 89
Ciufolini S. 100
Ciungu R. 115
Clamor A. 89
Clarke M.C. 106
Clementi N. 90
Clemmensen L. 126
Colibazzi T. 44
Colizzi M. 114
Compton M.T. 52, 90
Conley R. 35
Contreras G.N. 126
Cordova-Palomera A. 75, 108, 126
Correll C. 16, 37, 66

* "The Index of Authors and Presenters includes only First Authors of Posters, Speakers of Plenary Sessions, Symposia, and Workshops."



Corvin A. 57, 61
Cotier F. 84
Cotter D. 51
Coughlan H. 103
Craig T. 62
Cristóbal-Narváez P. 127
Crivellaro M. 127
Csipke E. 127
Cucchiario J. 127
Cullen A. 4, 84
Ćurčić-Blake B. 98
Curtis J. 114
Curtis L. 78
Czepielewski L. 104
D'Souza D.C. 44, 54, 95, 127
Daeva N.A. 127
Dalman C. 4, 41
Daniel D.G. 77, 111
Das M. 127
David A. 5, 12, 35
Davidson M. 5, 53
Davis R.E. 77
Dawson N. 96
Dazzan P. 4, 5, 51
de Castro-Català M. 82, 127
De Girolamo G. 43, 107, 127
de la Fuente-Sandoval C. 44
De la Serna E. 109
de Leeuw M. 58
de Nijs J. 78, 97
de Vos A. 73
Debost J.C. 108
Değirmencioglu B. 78
del Re E.C. 127
Del Rey-Mejías A. 94
DeLisi L. 2, 3, 12, 14, 26, 29
deLuca V. 81
Demers M.F. 88, 114
Demjaha A. 58
Deserno L. 99
Deslauriers J. 127
Devrim-Üçok M. 106
Di Forti M. 32, 44, 90
di Giacomo E. 89
Di Lorenzo G. 113

Dias Barbosa A. 114
Dickerson F. 36
Dietsche B. 128
Diez A. 87, 113, 128
Dionisio B. 73
Dluhos P. 128
Dodd S. 67
Dold M. 92
Dollfus S. 100
Domen P.A.E. 55
Dorph-Petersen K.A. 69
Drakesmith M. 55, 101
Driver D.I. 128
Drosos P. 117
Duhig A. 115
Durgam S. 117
During S.W. 81
Dutta R. 33
Duval C.Z. 128
Dvorsky D. 88
Earls L. 62
Ebdrup B. 70
Edwards C. 57
Egerton A. 36
Ehrenreich H. 45
Ellingrod V. 67
Emsley R. 4, 5, 45, 80, 103, 128
English J. 51
Englund A. 44
Eramo A. 92
Ergul C. 111, 128
Ermakova A.O. 128
Esen-Danaci A. 128
Etain B. 51
Evensen S. 109
Fachim H.A. 71, 128
Falcone M.A. 128
Falkai P. 4, 41
Falkenberg I. 99
Falkum E. 119
Fanning F. 129
Farrelly L. 129
Fatjó-Vilas M. 82
Fazel S. 43
Fervaha G. 129

Fillman S. 72
Finnegan M.A. 107
Fleischhacker W.W. 35
Foecking M. 87
Foussias G. 78
Frajo-Apor B. 114
Frangou S. 60
Frascarelli M. 75, 109
Frissen A. 107
Fuentenebro F. 104
Fusar-Poli P. 40
Fusaroli R. 115
Fusté M. 4, 75
Gabernet Florensa R.M. 129
Gadelha A. 56
Gaebel W. 45, 60
Gage S. 32
Galbusera L. 116
Galderisi S. 26
Galletly C. 37, 79, 129
Gama C. 75
Ganguli R. 5, 88
Gao L. 115
Garay I. 94
Gardner Sood P. 115
Gardner R.M. 72
Gardner Sood R. 3
Garrido G. 113
Gas M.C. 108
Gass P. 131
Gaughran F. 16, 66
Gawęda L. 129
Gayer-Anderson C. 59
Geerts H. 79
Geier S. 129
Gerstenberg M. 129
Gevonden M. 42, 129
Geyer M.A. 46
Ghosh A.K. 87
Gilabert-Juan J. 97
Gillis J. 61
Giordano A. 72
Giordano G.M. 129
Giovannoli S. 71
Girgis R. 34

Giuffrida A. 52
Glenthøj B. 45, 69
Goghari V. 101
Gold J. 14, 39
González-Martínez R. 97, 130
Goozee R. 92
Gotfredsen D. 59
Grace A. 3, 14, 39
Grajek G. 103
Grasa E. 113
Green M. 4, 5, 9, 14, 31, 39, 46
Green M.J. 97
Grilli-Tissot M.C. 96
Grove T. 104
Gruber O. 99
Gulsu E. 83
Gupta M. 119
Gur R. 62
Gurillo Muñoz P. 32
Gurvich C. 83
Hager O. 130
Hahn L. 129
Hahn M. 60
Hallahan B. 130
Hallak J. 67
Hamaie Y. 94
Hargarter L. 117, 130
Harms L.R. 130
Haroutunian V. 33
Harris A.W. 130
Harrisberger F. 75
Harrison P. 51
Harte M.K. 117
Hartmann M. N. 86
Harvey P.D. 12, 86, 119
Hassan A. 130
Hassan S. 90
Hasson-Ohayon I. 115
Hattori K. 72
Hazelgrove K.M. 130
Hecher L. 72
Heenan A. 115
Heering H. 90
Heinze K. 110
Hemager N. 84




Hernaus D. 54
Herold C.J. 101
Herrmann A.P. 130
Hilker R. 130
Hilt D. 130
Hirnsstein M. 58
Hjorthøj C. 131
Hollins S. 57
Holshausen K. 131
Homan P. 61
Honer W. 41
Hosang G. 115
Hosford D. 34
Howes O. 10, 36, 42, 44
Huang W. 88
Hughes M. 141
Hughes Z.A. 71, 131
Hui C.L.M. 115
Humpston C. 73
Husa A. 92, 131
Hwang T.J. 73
Iakoucheva L.M. 83
Iasevoli F. 94, 120, 131
Ihalainen J. 71
Ilzarbe D. 84
Inta D. 42, 131
Isohanni M. 53, 116
Ittig S. 110
Ivorra J.L. 131
Iwata K. 86
Jacob R. 95
Janssens M. 131
Jardri R. 54
Jensen A. 131
Jensen K.G. 118
Jensen M.H. 132
Jessen H.K. 132
Ji E. 73
Joaquim H. 97
Johnsen E. 79
Jones P.B. 53
Jørgensen K.N. 132
Joyce E. 68
Jukuri T. 99
Jung D.U. 132

Kahn R. 3, 14, 29, 32, 46, 53, 62, 69
Käkelä J. 132
Kambeitz J. 101
Kambeitz-Ilankovic L.M. 132
Kanbayashi T. 45
Kane J. 3, 15, 26, 34, 49
Kane J. M. 52, 69
Kang S.G. 132
Kapur S. 60, 68
Kasanova Z. 132
Kasperek T. 99
Katsura M. 84
Katthagen T. 132
Kaufmann A. 92
Kawasaki Y. 132
Keane B. 132
Keefe R. 4, 15, 49
Keefe R. S. E. 46
Kegeles L. 69
Kelleher E. 106
Kelleher I. 33, 59
Kellendonk C. 60
Kelly D. 67
Kerr D. 83
Keshavan M. 69
Keskinen E.S.J. 133
Khandaker G. 41, 57, 107, 133
Khodaie B. 4, 104, 133
Kikuchi Y.S. 96
Kilian S. 4, 80
Killackey E. 120
Kim E. 92
Kim J.J. 83, 143
Kim N. 84
Kim S.H. 83, 120
Kim Y. S. 97, 116
Kinon B. 15, 49
Kircher T. 12, 60
Kirschner M. 133
Kishi T. 96
Kiss B. 71
Kjelby E. 91
Klaasen N. 73
Knegtering H. 133
Koenig J. 31, 68

Koh M. 133
Koivukangas J. 133
Kolliakou A. 90
Kondrup R.E. 56
Kong P.K.Y. 104
Koops S. 55
Korth C. 133
Koutsouleris N. 55
Krakauer K. 133
Krug A. 71, 101, 133
Kubota M. 101
Kukshal P. 108
Kumar J. 101
Kupper Z. 134
Kwapil T.R. 85
Labouesse M.A. 71, 97
Lally J. 90, 120, 134
Laloyaux J. 134
Lam M. 114, 134
Lam Y.H. 134
Lammers Vernal D. 77
Large C. 92
Larsen J.T. 81
Laruelle M. 59
Lässer M.M. 134
Latorre S. 134
Laurens K. 58
Lavin A. 81
Lawrie S. 36
Lee E. 90, 120
Lee K. 134
Lee K.W. 134
Lee S.H. 99, 135
Lee T.Y. 110
Lee Y. 113, 135
Lee J.T.M. 134
Lees J. 104
Leger M. 118
Legge S. 59
Lennox B. 45
Leonhardt B. 135
Leroux E. 100, 101
Leung C.N.W. 85, 117
Leung S. 117
Levine S.Z. 107

Leweke F.M. 46, 52
Lewis A. 135
Li E.K. 135
Liemburg E. 55, 81
Lim K. 35
Lin A. 103
Lin J.J. 114
Lin S.H. 98
Lindgren M. 91
Linscott R.J. 79, 107, 135
Litman R.E. 92
Liu C.C. 88
Liu P.Y.T. 135
Llorca B.C. 135
Lodge D. 52
Lopez L. 135
Lotfinia M. 72
Louzada-Junior P. 73
Lucić L. 94, 135
Luoni A. 118
Lyne J.P. 86, 107, 136
Lystad J.U. 104
Maat A. 75
MacBeth A.M. 92, 136
MacCabe J. 5, 32, 68
Macciardi F. 136
Mackay-Sim A. 51
Maeda T. 136
Maibing C. 77
Mailman R. 32
Mäki P.H. 136
Malherbe P.J. 136
Malhotra A. 5, 31
Mane Santacana A. 86
Manning E.E. 97
Mantovani L.M. 105
Mäntylä T. 75
Marcelis M. 75
Marder S. 3, 5, 68
Mark W. 136
Markou A. 46
Marsh P. 136
Marsman A. 55, 100
Martinez G. 79
Martini L.C. 136




Martins-de-Souza D. 86
Maruff P. 88
Marvulli D. 74
Massuda R. 4, 137
Matsuda Y. 92
Maziade M. 56, 112
McCann T. 103
McCarley R. 5, 12, 26, 137
McCombie D. 61
McEvoy J.P.M. 137
McGorry P. 3, 50, 67
McGrath J. 3, 5, 16, 25, 32, 43, 65
McGuire P. 4, 36, 46
McMahon F. 14, 30
McNabb C. 98
Medalia A. 88
Medema S. 112
Meijer C. 94, 114
Melau M. 95, 137
Melle I. 51
Mentzel T. 70
Merritt K.S. 74
Mervis J. 94
Metzler S. 85
Meyer U. 31
Meyer-Lindenberg A. 42, 68
Mezquida G. 86
Michalopoulou P. 103
Michel C. 81, 114, 137
Miettunen J. 81
Miller B.J. 137
Mills J.G. 137
Mitta Raghava J. 75
Miyata J. 137
Mizrahi R. 42
Mizuno Y. 4, 71
Moghaddam B. 42, 44, 46
Mondelli V. 51
Montfort S. 137
Moore H. 14, 30, 39
Mørch-Johnsen L. 101
Morgan C. 137
Morgan V.A. 5, 105
Morilak D. 52
Moriwaki M. 93

Morrison A. 50, 62
Mortensen P. 4, 16, 31, 66
Mouchlianitis E. 55
Mukai T. 118
Müller B.W. 81
Müller D.R. 77
Müller D. J. 108
Murray G. 14, 39, 68
Murray R. 16, 25, 26, 32, 40, 44, 53, 65, 66
Na E.J. 99
Najjar S. 45
Nathou C. 137
Neill E. 118, 137
Nelson B. 51
Nelson B. G. 74
Nenadic I. 5, 75, 76, 99 138
Nesvåg R. 81, 101
Newall H. 94
Newcomer J.N. 37, 138
Newell K. 86
Nicodemus K.K. 61
Nielsen J. 72
Nielsen M.Ø. 54, 138
Nielsen J. 72
Nielssen O. 43
Nieman D. 50
Nilsson L.S. 138
Nordentoft M. 5, 81, 138
Nordholm D. 86
Norman R.G.M. 89, 105, 138
Novick D. 111, 138
Nucifora Jr. F. 138
Nuechterlein K. 88, 105
Nurjono M. 4, 95
Nuss P. 86, 138
Nyboe L. 91
O'Connor K. 110
O'Donnell P. 5, 32, 42
O'Donoghue B. 82
O'Gorman C. 111
O'Hanlon E. 101
Ochoa S. 138
Onyejiaka A. 139
Ordóñez A.E. 93, 118
Ortuño F. 79, 139

Osman E. 118
Oya K. 118
Özsoylu D. 109
Padmanabhan J. 83
Palmer E. 105
Pani L. 35
Pankiewicz-Dulacz M. 107
Pankow A. 99
Pantelis C. 4, 67
Papmeyer M. 139
Pardo M. 85, 110, 139
Parente F. 74
Park K. 91
Park S. 105, 139
Patel M.X. 5, 12, 93, 139
Patel Rash 86
Patel Rad 121
Patterson P. 41
Paunio T. 14, 30
Pearlson G. 35
Pedersen C.B. 107
Peeters S. 99
Penadés R. 89
Penzes P. 112
Pereira F. A. 97
Perez S.M. 139
Peters E. 62
Petryshen T. 83
Picchioni M.M. 5, 54, 102
Pijnenborg G. 89, 139
Pijnenborg M. 73, 102, 114, 125
Pikalov A. 93, 118, 139
Piskulic D. 103
Porteous D. 61
Posporelis S. 74
Potkin S. 57
Pouget J. 109
Prata D. 110
Preda A. 116
Premkumar P. 87
Prinssen E. 118
Pruessner M. 76
Puig O. 85
Rabiner I. 69
Rabinowitz J. 5, 15, 34, 49

Rahman J. 117
Rajagopalan K. 83, 109
Ramsay H. 112
Ramsay I.S. 139
Ramyeed A. 140
Randers L. 91
Ranlund S. 140
Rao S. 85
Rapado-Castro M. 67, 93, 140
Rapisarda A. 91
Rapp A.M. 140
Raudino A. 56, 83
Rawat P. 120
Reatiga O. 140
Reddy F. 112
Redmeijer J. 140
Reeder C. 105
Reichenberg A. 5
Reichenberg Ab. 68
Reininghaus U. 140
Reis Marques T. 102
Rekhi G. 140
Reniers R. 76, 102
Reynolds G. 112
Richetto J. 118
Reicher-Rössler A. 25, 52, 80
Rinaldi R. 88
Rissanen I. 140
Riva M. 31, 72
Roberts D.L. 77
Robinson J. 33
Roche E. 107, 141
Rodríguez-Toscano E. 141
Roffman J. 67
Rosa A. 109
Rosenbrock H. 97
Rosenheck R. 141
Rossel S. 79, 105, 141, 144
Rowland J.E. 141
Roy M.A. 119
Rubino T. 44
Ruggeri M. 26
Ruhmann S. 50
Rujescu D. 18, 57
Rund B. 68



Russell B. 141
Sabri M.A.R. 105
Sadeghifard V. 141
Sahakian B. 14, 39
Salokangas R.K.R. 110
Salum C. 97
Sanchez-Gistau V. 110
Sanchez-Gutierrez T. 141
Santoro M.L. 83
Sanz-Fuentenebro F.I. 77
Saracco-Alvarez R. 78
Sasayama D. 141
Sawa A. 9, 31, 51
Sawada K. 41
Scanlon C. 102
Schall U. 117
Schaufelberger M.S. 102
Scheltema Beduin A. 119
Schimmelmänn B.G. 37, 110
Schirmbeck F. 116
Schlosser D. 141
Schmidt A. 33, 75, 100, 143
Schmidt C. 15, 49
Schmidt S.J. 85
Schnack H.G. 76
Schobel S. 100
Schoeler T. 107
Schooler N. 5, 12, 18, 58, 142
Schreiner A. 93, 119, 142
Schulte P.F.J. 89
Schultz C.C. 102, 142
Schultze-Lutter F. 82, 108, 142
Schulz S.C. 35, 45
Sebat J. 14, 29, 30
Seidman L. 5, 68
Selten J. 26, 42
Selvaggi P. 74
Sendt K.V. 142
Sevilmiş Demir Ş. 79
Shah S. 59
Shakoor S. 142
Shannon-Weickert C. 3, 4, 5, 18, 36, 42, 56
Sheinbaum T. 4, 70, 96
Shi C. 78
Shivakumar V. 4, 142


Shuhama R. 143
Si T. 4, 103, 143
Sieradzka D. 109
Siever L. 32,
Silberberg C. 82
Simon N. 4, 106
Simons C. 79
Simonsen A. 79
Simpson E. 46, 72
Singh G. 119
Siu C. 79, 143
Smesny S. 74, 100
Smieskova R. 143
Smith M.J. 95
So S.H. 80
Soguel-dit-Piquard F. 85
Sohn I. 143
Sommer I. 4, 5, 36
Sommer J. 61
Spilka M.J. 100
Spiteri-Staines A.E. 4, 143
Squarcina L. 54
Stain H. 120
Stefanis N. 16, 65
Steiner J. 33, 45
Stepniak B. 89
Stewart R. 16, 66
Stiekema A.P.M. 78
Stilo S.A. 71, 143
Strauss G. 68
Strik W. 60
Sugranyes G. 102
Sullivan P. 14, 30
Sumiyoshi C. 116
Sutliff S.A. 143
Suttajit S. 4, 120
Sutherland A. 112, 143
Suvisaari J. 56
Suzuki M. 76, 144
Swaminathan V. 56
Swanson J. 43
Swart M. 144
Taboada Denia D. 144
Takayanagi Y. 82
Takeuchi H. 93

Talib L.L. 97, 144
Tamagnan G.D. 76
Tan E. 88, 144
Tan G.C. 80
Tandon R. 144
Tang C. 93
Tarokh L. 144
Tenan S.H. 108
Térémets M. 144
Tettamanti M. 144
Theodoridou A. 111
Thibaut B. 80
Thompson A. 58
Thomson P. 61
Thorup A.A.E. 111
Toftdahl N.G. 95, 121
Tognin S. 144
Topuzoğlu A. 144
Torgalsboen A.K. 90
Torti M.C. 145
Trifileff P. 14, 39
Trizio S. 76
Trotta A. 145
Truong W. 76
Tseng K. 52
Tsujiro N. 100
Uchida H. 145
Ucok A. 112
Uhlhaas P. 69
Umbricht D. 5, 15, 49
Unterrassner L. 145
Upthegrove R. 33
Uranova N. 33
Uttinger M. 117
van Berckel B. 36
Van Dael F. 82
van den Heuvel M. 55
van der Doef T. 145
van der Gaag M. 50, 62
van der Leeuw C. 145
van der Meer F. 145
van der Meer L. 114
van der Velde J. 76
van der Ven E. 108, 145
van Haren N.E.M. 5, 76

van Harten P. 145
van Hasselt F.M. 95
van Lutterveld R. 61
van Nierop M. 59
van Os J. 4, 12, 16, 25, 26, 40, 60, 66
van Tol M.J. 102
Vanadia L.N. 89
Vanover K. 34, 119
Vaskinn A. 145
Veijola J. 58
Veling W. 146
Velthorst E. 80
Ventura J. 80, 105, 112, 146
Vernon A. 60
Vialou V. 42
Vink M. 103
Vinogradov S. 5, 18, 31, 41
Viscanti G. 100
Vitale R. 146
Vogel S.J. 146
Voineskos A. 31
von Saldern S. 146
Vorstman J. 62
Vreeker A. 80
Waddington J. 4, 12, 32
Wadehra S. 4, 146
Walters J. 57
Walther S. 114
Walton E. 146
Wang S.M. 90
Wang Y. 4, 77
Ward M.K. 74
Ward P.B. 146
Wärdig R.E. 146
Waterreus A. 146
Webster M. 56
Wehler C. 147
Weickert C.S. 3, 5, 18, 36, 42, 56
Weickert T. 5, 58, 73
Weiser M. 4, 5, 53, 67
Wennogle L.P. 87
Werbelloff N. 57, 82
Wesnes K. 147
Widschwendter C. 147
Wigman J. 77, 116



FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



NOTES



FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



NOTES

160

161



FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



NOTES

Notes

NOTES

Notes



FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014



NOTES

Notes

NOTES

Notes



NOTES

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.



**Schizophrenia
International Research
Society Conference**